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3-Abstract
Prostaglandins increase urine production, electrolytes excretion, detrusor 
contraction, micturition pressure, lower urethral pressure and inhibit antidiuretic 
hormone. We hypothesized that high production of prostaglandins or their dominant 
action on the urinary system may play a role in the pathogenesis of primary enuresis and 
nocturnal frequency of micturition. To test this, inhibition of prostaglandin synthesis by 
nonsteroidal anti-inflammatory drugs (NSAIDs), indomethacin suppositories or 
diclofenac sodium, or by carbamazepine, were used in their management. Measurement 
of urine volume and urinary and serum electrolytes and osmolality were performed 
before and after treatment with indomethacin. Similar to prostaglandins, nitric oxide 
(NO) causes natriuresis and diuresis, decreases antidiuretic hormone and relaxes trigone 
and urethra. We hypothesized that NO may play a role in the primary enuresis. Urinary 
nitrite, the end product of NO, was measured in enuretics before and after treatment 
with indomethacin and compared with normal control.
Prostaglandins are increased in urinary obstruction and implicated in the 
urinary calculus formation. The other aspect of the thesis is to determine whether 
inhibition of prostaglandin synthesis by short acting NS AID (eg: indomethacin 
suppository), long acting NSAIDs (eg: tenoxicam i.m or i.v, or piroxicam i.m), selective 
cyclooxygenase inhibitor (eg: sublingual meloxicam), and by calcium antagonist (eg: 
sublingual nifedipine), could relieve acute or resistant renal colic and facilitate urinary 
calculus expulsion. The other aims of the thesis are to demonstrate the efficacy and 
safety of different methods of drug delivery as i.v, i.m, sublingual, oral or rectal routs 
and their effects on renal function tests and their importance in emergency situations.
Results showed that indomethacin, diclofenac sodium or carbamazepine 
significantly reduced frequency of bedwetting in most of the patients with enuresis. 
Urinary nitrite excretion is elevated in enuretics and was decreased significantly when 
bedwetting episodes decreased by indomethacin. Indomethacin suppository decreased 
urine volume, urine electrolytes, clearance of free water, filtered sodium, fractional 
sodium excretion and reduced significantly bedwetting in patients with small as well as 
normal functioning bladder capacity. Regarding renal colic, indomethacin, tenoxicam, 
piroxicam, nifedipine and meloxicam alleviated pain of acute renal colic. Long acting 
NSAIDs had lower incidence of pain relapse and fewer drug administrations when 
compared to short acting NSAIDs and spasmolytic/analgesic. Indomethacin or 
nifedipine facilitated passage of urinary calculus and prevented or reduced pain 
recurrence.
It could be concluded for the first time that prostaglandin and NO might play 
a role in the pathogenesis of primary enuresis and frequency of micturition, and 
inhibition of their production might represent a new line for the management. The 
mechanism of action of indomethacin might be attributed to the significant reduction of 
urine volume and sodium excretion in addition to its possible effects on bladder and 
urethral contraction through inhibition of prostaglandin and NO. Short and long acting 
NSAIDs, COX-2 inhibitor and calcium antagonist, are safe and effective to alleviate 
pain of acute renal colic and could facilitate passage of urinary calculus. The different 
methods of drug administration, including rectal or sublingual which could be self- 
administered, are effective and safe in the treatment of the diseases. No significant 
deterioration in renal functions was encountered after treatment with the drugs. The 
mode of actions of the drugs in respect to prostaglandin inhibition, NO and calcium 
influx are discussed.
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5. List of Abbreviation
Nonsteroidal anti-inflammatory drugs NSAIDs
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6. INTRODUCTION
6.1. Morphogenesis of the urinary system
The primary excretory duct begins to develop in 23 to 24 days (Figure 
1). Three different systems are formed: the pronephrons, the mesonephrons 
and the metanephrons. The first system disappears at the end of the 4th week. 
By the end of second month the majority of the mesonephrons have 
disappeared (Williams & Warwick 1985d). The metanephrons appears in the 
5th week to form permanent kidney. The ureteric bud, an outgrowth of the 
mesonephric duct, gives rise to the ureter, the renal pelvis, the major and 
minor calyces and collecting tubule. The distal end of the collecting tubule is 
covered by a metanephric tissue cap, forming the renal vesicle, which gives 
rise to small tubules. These tubules together with tufts of capillaries known as 
glomeruli. The proximal end of the nephron forms the Bowman’s capsule.
The urorectal septum divides the cloaca into the anorectal canal and 
primitive urogenital sinus. The latter give rise to: (1) the urinary bladder, 
from the upper part, (2) the prostatic and membranous parts of the urethra 
from the pelvic part of the urogenital sinus and (3) the phallic part of the 
urogenital sinus.
The genital system consists: (1) the primitive sex glands (eg: testes 
and ovaries), (2) the genital duct, and (3) the external genitalia. The prostate 
arises from the proximal part of the urethra. In female, the urethra is derived 
from vesico-urethral portion of the cloaca. In the male, the prostatic urethra is 
derived from vesico-urethral part of the cloaca. The remainder part of the 
urethra is derived from the urogenital sinus.
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Figure 1: Schematic drawing to show urogenital organs developments 
(A; From Joltson,I(. (1988) Human Developmental Anatomy. Jhon 
Wiley & Sons,Inc., USA, pp.269, B; Front; Sadler, T.(1993) Longman 
Medical Embryology, 6th edition, Williams & Wilkins, pp. 263).
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6.2. Anatomy of the Urinary System
The urinary system comprises; (1) the paired kidneys, (2) the paired 
ureters, (3) the urinary bladder, and (4) the urethra (Figure 2). The female 
urethra is a purely urinary duct while the male urethra serves two functions, 
urinary and reproductive (William & Warwick, 1985a).
6.2.1. The Kidneys
The kidneys are two reddish-brown organs and approximately 10 cm 
long, 5 cm wide and 2.5 cm thick. In adult male the weight of the kidney 
averages about 150g, in adult female 135g.
Each kidney has a concave medial border. The hilum, where blood 
and lymph vessels enter and exit, nerves enter and the ureter exits. The lateral 
border is convex. The renal pelvis, the upper part of the ureter, is divided into 
2 or 3 major calyces. Several small, minor calyces arise from each major 
calyx. The kidney has an internal medulla and an external cortex. The renal 
medulla consists of 10 to 18 pale conical or pyramidal masses termed the 
renal pyramids.
The kidney is composed of very large number of tortuous uniferous 
tubules; each consists of two parts (1) nephron and (2) collecting tubules. 
Each kidney contains 1 to 4 million nephrons (Romanes 1985a).
The nephron comprises a dilated portion, the renal corpuscle, the proximal 
convoluted tubule; the thin and thick limbs of loop of Henle (LOH); and the 
distal convoluted tubule. The collecting tubule carries the fluid from a 
number of renal tubules to a terminal papillary duct, which opens into a 
minor calyx (Figure 3).
Renal corpuscle consists of a tuft of capillaries, the glomerulus, 
surrounded by a double-walled epithelial capsule, called Bowman’s capsule.
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The internal visceral layer envelops the capillaries of the glomerulus. The 
external parietal layer forms the outer limits of the corpuscle. Urinary space 
presents between the two layers of Bowman’s capsule which receive the fluid 
filtered through the capillary wall and the visceral layer. The afferent arteriole 
enters and the efferent arteriole leaves the renal corpuscle through a vascular 
pole. Proximal convoluted tubule begins at another pole, a urinary pole 
(Williams & Warwick 1985b).
A thick basement membrane presents between the fenestrated 
endothelial cells of the glomerular capillaries and the podocytes. The 
glomerular basement membrane acts as a selective filter, allowing the passage 
from blood of water and small molecule. The proximal convoluted tubule is 
second part of the renal tubule, just after glomerular capsule. It runs toward 
medulla to become the descending of LOH. The later is a U-shaped structure 
consisting of a thick descending limb, becoming a thin descending limb; 
which in turn becomes the thin ascending limb and the thick ascending limb 
(Junqueir et al. 1998a).
Distal convoluted tubule is the last segment of the nephron, which is 
lined with simple cuboidal epithelium. It establishes contact with afferent 
arteriole at which the distal tubule is modified, as is the afferent arteriole. The 
modified segment of the wall of distal tubule is called the macula densa. 
Adjacent to the renal corpuscle the tunica media of the afferent arteriole has 
modified smooth muscle cells called juxtaglomerular cells. This portion of 
arteriole and the macula densa form the juxtaglomerular apparatus. Macula 
densa produces signals that promote constriction of the afferent arteriole. 
Juxtaglomerular cells play a role in the regulation of blood pressure.
6.2.2.The Ureters
The ureters are the two muscular tubes, each measures from 25 to 30 cm 
in length and 3 to 5 mm in width (Williams & Warwick 1985b). The 
abdominal part of ureter descends almost vertically along the line of the tips 
of the lumbar transverse processes and it enters the pelvis. The pelvic part of 
ureter is the same length as the abdominal part. In the pelvis, opposite the
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ischial spine, it turns anteromedially to reach the base of the bladder. The 
ureter has fibrous, muscular and mucous coats. The muscular coats in the 
pelvis, calyces, and upper two-thirds of the ureter consist of inner 
longitudinal and outer circular layers of non-striated myocytes. In the lower 
third of the ureter a longitudinal muscular layer is added. The ureter is lined 
by the transitional epithelium. Blood supply of the ureter consists of small 
branches passing to the ureter from the renal, testicular or ovarian aorta, 
common and internal iliac, and vesical or uterine arteries. The nerves are 
derived from the renal, aortic, and superior and interior hypo-gastric plexuses. 
The ureteric plexuses contain sympathetic and parasympathetic fibres, which 
are sensory in nature (Snell 1992).
The pain is referred to cutaneous areas innervated from the same 
segments of the spinal cord as supply the ureter, mainly Li to L2, the front of 
the thigh through genitofemoral nerve (LI, 2), and cremaster may under go 
reflex contraction and retract the testis.
6.2.3.The Urinary Bladder and Urethra
The bladder has the shape of a three-sided pyramid that has a base, 
neck, apex, superior surface and two interio-lateral surfaces (Romanes 
1985b).
The bladder and the urinary passages are covered externally by an 
adventitial membrane except for the upper part of the bladder, which is 
covered by peritoneum. The bladder wall has three layers: adventitia, 
muscular and mucous. The muscular layer constitutes the detrusor muscles 
that consist of three layers of nonstriated myocytes: an external and internal 
longitudinal layers and a middle layer of circular fibers. There is no 
muscularis mucosa in the urinary bladder wall. The internal sphincter 
composed of nonstriated muscle and the external sphincter composed of 
striated muscle (Fawcett & Jendh 1997a).
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The ureters pass through the wall of the bladder obliquely, forming a 
valve that prevents the backflow of the urine to the ureter.
The mucosa of the urinary bladder and other urinary passages consist 
of transitional epithelium. The mucous membrane is urine-proof and 
stretchable. The blood supply of the urinary bladder comes from three 
branches of each internal iliac artery. Veins drain to the internal iliac vein and 
external iliac. The lymph vessels drain to the external and internal iliac nodes. 
The nerves supplying the bladder consist of both sympathetic and 
parasympathetic components; each contains motor and sensory fibers. The 
motor parasympathetic fibers arise from the second to the fourth sacral 
segments of spinal nerves, supplying the detrusor muscle. They are inhibitory 
fibres to the internal sphincter. The efferent sympathetic fibers arise from the 
lower two thoracic and upper two lumber segments of the spinal cord to 
supply inhibitory fibers to the detrusor muscle and motor fibers to the internal 
sphincter. The pudendal nerve supplies the external sphincter. The sensory 
nerves supplying the bladder are: (1) pain fibres run in sympathetic and 
parasympathetic nerves and (2) fibres concerned with conscious awareness of 
bladder distension run in the posterior columns of the spinal cord (fasciculus 
gracilis).
The male urethra extends from an internal orifice in the urinary 
bladder to an external opening at the end of the penis (Figure 2). The male 
urethra consists of prostatic, membranous, bulbous and pendulous parts. The 
urethra is composed of a mucous membrane, submucous tissues, and muscle. 
The female urethra is about 4 cm long and 6 mm in diameter, the female 
urethra begins at the internal urethral orifice of the bladder and is embedded 
in the anterior wall of the vagina. The external urethral orifice is situated 
anterior to the opening of the vagina and about 2 to 5 cm behind the clitoris 
(Junqueira et al. 1998b).
The muscular layer consists of internal longitudinal and external 
circular fibers. The circular fibres of the bladder form the internal sphincter at 
the vesical end of the urethra. The urethra is also surrounded by external 
sphincter just above the perineal membrane. The mucous membrane near the
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bladder consists of transitional epithelium, which becomes non-keratating 
stratified squamous epithelium distally (Fawcett & Jesh 1997a).
6.2.4. Innervations of the Kidney, Lower Urinary Tract and 
Micturition
The sympathetic preganglionic innervation comes primarily from the 
lower thoracic and upper lumber segments of the spinal cord. They supply 
afferent and efferent arterioles, the proximal and distal tubules, and the 
juxtraglomerular cells.
Pain in the kidney is mediated by nociceptive afferent that enter the 
spinal cord in the thoracic and upper lumber dorsal roots. The storage and 
periodic release of urine are controlled by the activity of the bladder 
(reservoir) and an outlet (bladder neck, urethra, and striated muscles of the 
pelvic floor). Their functions are regulated by neural circuitry in the brain and 
spinal cord (de Groat 1993; Lincoln & Burstock 1993). The innervations of 
the lower urinary tract are derived from sacral parasympathetic, 
thoracolumbar sympathetic and sacral somatic (de Groat 1992 & 1993). The 
sacral parasympathetic nerves, originated from the S2 to S4 segments of the 
spinal cord, provide the excitatory input to the bladder. Transmission in 
bladder ganglia is mediated by a nicotinic cholinergic mechanism. The 
ganglionic cells excite the bladder smooth muscle. The thoracolumbar 
sympathetic includes preganglionic pathways that arise from the T il to L2 
spinal cord segments. These pathways pass to the sympathetic chain ganglia 
and then to prevertebral ganglia in the superior hypogastric and pelvic 
plexuses and also to short adrenergic neurones in the bladder and urethra (de 
Groat & Booth 1993).
Sympathetic postganglionic nerves (releasing norepinephrine) provide 
an excitatory input to smooth muscle of the bladder base and the urethra, an 
inhibitory input to smooth muscle in the body of the bladder, and inhibitory 
and facilitory input to vesical parasympathetic ganglia (de Groat & Theobald 
1976; de Groat 1987). The sacral somatic efferent pathways to the external 
urethral sphincter are carried in the pudendal nerve from anterior horn cells in
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the 3rd and 4th sacral segment. Autonomic nerves transmit afferent activity 
arising in the bladder to the central nervous system (CNS) (de Groat 1986). 
The sympathetic nerve afferents carry nociceptive information from the lower 
urinary tract. Pudendal nerve carries afferents pathways from urethra, which 
induce the sensation of temperature, passage of urine and pain to the 
lumbosacral spinal segment. CNS controls the peripheral and autonomic 
nervous systems innervating the lower urinary tract (Figure 4). The control 
occurs at the sacral reflex micturition centre, the pontine micturition centre, 
the corpus collosum and the supramedial portion of the frontal lobe (Mallory 
et al. 1991). The afferent and efferent pathways and nervous system 
controlling bladder function and micturition are (Chai & Steers 1996):
1- The Afferent Pathways
(1) Parasympathetic afferent pathways are conveyed from the bladder to the 
CNS by the pelvic nerve and the dorsal root ganglia.
(2) Somatic afferent signals are conveyed from the urethral sphincter, by the 
pudendal nerve and overlap with the parasympathetic pathway.
2- The Efferent Pathways
(1) The parasympathetic efferent nerves convey efferent signals by 
cholinergic preganglionic neurones from 2, 3 and 4th ventral nerve roots.
(2) The sympathetic efferent conveys signals from Tn to L2 spinal nerve root.
(3) Somatic motor neurones originate at the 2nd, 3rd and 4th sacral segments, in 
Onufs nucleus, and travel by pudendal nerve to the striated urogenital 
sphincter muscle and pelvic floor.
3- CNS and reflexes
Included storage reflexes, voiding reflexes, primary micturition centre, frontal 
cortex, hypothalamus and brain stem.
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Figure 4 : A; Peripheral innervations of the lower urinary tract (From Benson, 
T., Walkers, D.(1993) Neurophysiology o f lower urinary tract, In; Walkers, D., 
Karram, M.(eds), Clinical Urogynecology, St. Louis: Mosby- Yearbook,Inc. 
pp.19). B; Urinary bladder innervations (From Guyton, A.,(1991) renal 
diseases, diuresis and micturition, In: Textbook o f Medical Physiology, 8th 
edition, W. B. Saunders, p. 352.
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6.3. Physiology of the Urinary System
6.3.1.The Kidney
The main functions of kidney are;
(1) Excretion of metabolic waste products and foreign chemicals. Waste products 
include urea, uric acid, creatinine, and products of haemoglobin breakdown, 
metabolites of hormones.
(2) Regulation of blood pressur.
(3) Regulation of acid-base balances.
(4) Regulation of vitamin D3 and erythrocyte production. The kidneys secrete 
erthropoietin which stimulates the production of red blood cells from bone 
marrow. Hydroxylation of vitamin D to active form occurs in the kidneys.
(5) Glucose synthesis during prolong fasting, the kidneys synthesise glucose from 
amino acid.
Three processes occur in the functional unit of the kidney, the nephron, which 
determine the rates at which different substance are excreted in the urine. These 
processes are;
(1) Glomerular filtration.
(2) Reabsorption from the renal tubules.
(3) Secretion of substances from the blood into the renal tubules.
Renal Blood Flow
The kidneys receive 1.2 to 1.3 litres of blood per minute (25% of the 
cardiac output) (Figure 5). Prostaglandins increase blood flow in the renal cortex 
and decrease renal blood flow in renal medulla.
Glomerular Filtration Rate
The glomerular filtration rate is approximated 125 ml min'1. This is about 180 1 
d'1. 99% of the filtrate is normally reabsorbed. The factor governing filtration across 
the glomerular capillaries the size of the capillary bed, the hydrostatic and osmotic 
pressure gradient and the permeability of the capillaries. Natural substances with
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molecular diameter of less than 4 nm are freely filtered. 20 percent of the plasma 
flowing through the kidneys filtered by the glomerular capillaries. The filtered fluid 
is essentially protein free and devoid of cells. Water, Na+ ions and glucose are freely 
filtered. Positively charged molecules are filtered much more easily than negatively 
charged molecules. Negative charges of the basement membrane cause restricting 
charged molecules. A greater rate of blood flow into the glomerulus tends to increase 
glomerular filtration rate and a lower rate tends to decrease glomerular filtration rate.
Increase in glomerular hydrostatic pressure raise glomerular filtration rate, 
and decrease in glomerular hydrostatic pressure reduces glomerular filtration rate. 
Dilatation of the afferent arterioles increase both the glomerular hydrostatic pressure 
and glomerular filtration rate (Ganong & Hall 1997a).
Tubular Functions
Some peptide hormones and small protein are reabsorbed in the proximal 
convoluted tubule by endocytosis. Other substances are secreted or reabsorbed by 
passive diffusion and facilitated diffusion down chemical or electrical gradient or 
active transport against such gradient.
Sodium moves by co-transport or exchange from tubular lumen into the 
tubular epithelial cells down its concentration and electrical gradient (Figure 6).
It is actively pumped from epithelial cells into interstitial space by Na+/K+ ATPase. 
Sodium actively transported out of all parts of the renal tubule except the thin portion 
of the LOH. Negative ions such as Cf ions are transported along with the Na+ 
because of electrical potentials.
Glucose, bicarbonate and amino acids are reabsorbed along with sodium in 
the early portion of the proximal convoluted tubule. All the glucose is absorbed by 
secondary active transport. Glucose and sodium bind to the common carrier. Amino 
acids leave epithelial cells by passive or facilitated diffusion to the interstitial fluid. 
Some chloride is reabsorbed with Na+ and K+ in the thick ascending limb of the 
LOH. About 25% of Na+, CL‘ and K+ are reabsorbed in the LOH.
In the proximal convoluted tubule, water moves passively through the tubule 
along the osmotic gradients set up by active transport of solutes. The movement is
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Figure 5 : A; The nephron ( From Smith (1951) The kidney: Structure & 
Functions in Health and Diseases. New York, Oxford University Press). B; 
Differences between a cortical and juxtramedullary nephron ( From Pitts 
(1974): Physiology o f kidney and Body Fluids, Chicago, Year Book Medical 
Publishers), C; The functional nephron ( From Guyton, A.(1991) Formation o f 
urine by kidney: 1. Renal blood flow, glomerular filtration and their control, In; 
Textbook o f Medical Physiology, 8th edition, JV.B. Saunders, pp. 288).
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facilitated by water channels, which facilitate the movement by the action of a 
protein called aquaporien-1. The descending limb of the LOH is permeable to water, 
but the ascending limb is impermeable. Approximately 20% of the filtered water 
enters the distal tubules. Na+, K+ and CL’ ions are co-transported out of the thick 
segment of the ascending limb. 5% of the filtered water is removed in the distal 
convoluted tubule. Collecting tubule has a cortical and a medullary portion (Figure 
5). In presence of vasopressin, water moves out of cortical collecting duct into the 
interstium of the cortex. 10% of the filtered water is removed and 4.7% or more of 
the filtrate is reabsorbed into interstitium of the medulla (Guyton 1996a).
The first part of distal tubule forms part of the juxtaglomerular complex that 
control glomerular filtration rate and renal blood flow. The convoluted part of distal 
tubule reabsorbs most of Na+, K+ and Cl ions, but is impermeable to water. The 
second half of the distal tubule and cortical collecting tubule has similar action. They 
are composed of principal cells (reabsorb Na+ and water from lumen and secrete K+) 
and intercalated cells (reabsorb K+ and secrete H+) (Figure 6). The rate of 
reabsorption of Na+ is controlled by aldosterone and the permeability to water is 
controlled by vasopressin. The medullar collecting tubule reabsorbs less than 10% of 
water and Na+. When vasopressin is absent the collecting duct is relatively 
impermeable to water and 13% of the filtered water may be excreted.
Urea moves passively out of the proximal convoluted tubule. The rest of 
the tubular epithelium is impermeable to urea except the inner portion of the 
collecting tubule. About one and half of the filtered urea is passively reabsorbed and 
the remainder pass into urine. Creatinine is impermeable to the tubular membrane. 
Almost none of the creatinine is reabsorbed. Hydrogen ion is secreted by proximal 
and distal tubules. In the proximal tubule the reaction that is responsible for proton 
secretion is Na /H exchange. For each H+ ion secreted one Na+ and one bicarbonate 
ion enter the interstitial fluid. When the plasma bicarbonate concentration is low all 
the filleted bicarbonate is reabsorbed.
Regulation of Tubule Functions: -
(1) Arterial blood pressure: Small increase in blood pressure causes a large increase 
in Na+ and water excretion
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(2) Hormones: Aldosterone is secreted by the zona glomerulosa cells of the adrenal 
gland. The primary site of action is the principle cell of the cortical collecting tubule. 
Aldosterone stimulates the Na+/K+ ATPase pump. Angiotensin 11 stimulates 
aldosterone secretion and increases Na+ reabsorption. Angiotenisn 11 constricts the 
efferent arterioles which cause increases of Na+ and water reabsorption in the 
proximal convoluted tubule. Antidiuretic hormone increases water permeability of 
the distal tubule, collecting tubule and collecting duct. Aterial natriuretic peptide is 
secreted from cardiac atria and inhibits the reabsorption of Na+ and water by 
collecting tubule.
(3) Sympathetic nervous system: Activation of sympathetic nerves increases Na+ 
reabsorption in the proximal convoluted tubule and the thick ascending limb of 
LOH. Na+ excretion can be decreased by constricting both the afferent and the 
efferent arterioles. In addition, sympathetic activation increases renin release and 
angiotensin 11 formation.
Regulation of Na+ion and Chloride Excretion
Factors affecting Na+ and Cl" reabsorption and excretion are factors affecting 
glomerular filtration rate, oncotic pressure in the peritubular capillaries, aldosterone, 
arterial natriuretic peptide, angiotensine and PGE2. Aldosterone increases Na+ 
reabsorption and increases K+ and H+ secretion. PGE2 inhibit Na+/K+ ATPase and 
increase intracellular calcium. Endothelin and interleukin-1 (IL-1) cause natriuresis 
by increasing PGE2.
Antidiuretic hormone is synthesised in supraoptic and paraventricular nuclei 
of the hypothalamus and it is released from the posterior pituitary gland. Increased 
osmolarity decreases arterial blood pressure and decreased blood volume increase 
antidiuretic hormone secretion. The osmoreceptor-antiduretic hormone and thirst 
regulate extracellular fluid osmolarity and sodium concentration. Aldosterone causes 
Na+ and water retention.
K+ secretion is stimulated by increased aldosterone, increased tubular flow 
rate, and increased extracellular fluid K+ concentration. Acute acidosis decreases K+ 
secretion. Kidney filters and reabsorbs calcium. 50% of calcium is filtered at the
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Figure 6: A, Active transport of sodium through tubular epithelial cell. B, 
Mechanism for active transport of sodium from tubular lumen all the way 
into the peritubular capillary. C, Mechanism of sodium and potassium 
transport through the distal tubular epithelium. {From Guyton, A. (1991) 
Formation o f urine by the kidney 11. Processing o f the filtrate in the tubules. In; 
Textbook o f Medical Physiology, 8th edition, IV. B. Saunders)
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glomerulus and 99% of the filtered calcium is reabsorbed by the renal tubules.
2d*Increased Mg excretion is caused by increased extra-cellular calcium.
6.3.2. Renal Pelvis and Ureter
The main function of the pyeloureteral complex is unidirectional transport of 
urine from the kidney to the urinary bladder. This is achieved with ureteral 
peristalsis, which is myogenic, and initiated by spontaneously active pacemaker cells 
in the renal pelvis. Urine flowing from the collecting tubule into the renal calices 
stretches these calyces and triggers pacemaker activity in renal pelvis. This, in turn, 
initiates peristaltic contractions that spread to the renal pelvis and ureter. Peristaltic 
contractions in ureter are evoked by parasympathetic stimulation and inhibited by 
sympathetic stimulation.
Removal of extracellular calcium totally eliminates the action potential 
(Brading et al. 1983). Prostaglandins regulate the pacemaker potentials of the renal 
pelvis and ureter (Thulesius et al. 1986). Substance P and Neurokin A are stimulants 
of pyeloureteral motility (Maggi et al. 1993).
Distension of the kidney, pelvis, or ureter and electrical stimulation of renal 
pelvis or ureter causes severe pain (Cervero 1994).
6.3.3. The Urinary bladder and Micturition
Control of bladder storage and micturition is mediated by co-ordination of the 
peripheral somatic, autonomic and CNS (Guyton & Hall 1996b). Detrusor muscle 
can increase the pressure in the bladder to 40 to 60 mmHg. Action potential can 
spread throughout the detrusor muscle, from one muscle cell to the next to cause 
contraction to entire urinary bladder. When there is no urine in the urinary bladder, 
the intravesicular pressure is about zero, but by 30 to 50 ml of urine, the pressure rise 
to 5 to 10 cm of water. 200 to 300 ml of urine can be accumulated in the urinary 
bladder without large rise in the pressure. However, beyond 300 to 400ml, the 
pressure rises markedly. Accommodation of the bladder to increased volumes of 
urine is primarily a passive phenomenon that depends on internist properties of 
detrusor and quiescence of the parasympathetic (Chai et al 1996). The storage phase
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of urinary bladder can be switched to the voids phase either involuntarily or 
voluntarily.
Micturition is under voluntary control and depends on learned behaviour that 
develops during maturation of nervous system. Micturition is the process by which 
the urinary bladder empties when it becomes filled by urine. Micturition is a spinal 
reflex, which is facilitated and inhibited by higher neuronal centres and by voluntary 
control. Contracted smooth muscle of urinary bladder can increase the pressure in the 
bladder to 40 to 60 mmHg. The first desire to void is initiated at a bladder volume of 
about 150 ml and a marked sense of fullness at about 400 ml.
6.3.4. The Storage Reflexes
During bladder filling, activation of the storage reflexes causes low detrusor 
pressure, absence of involuntary contraction and maximal urethral pressure. The 
inhibition of micturition and bladder activity to allow the bladder to accommodate 
large volume of urine are due to:
(1) Viscoelastic properties of the bladder wall and electromechanical properties of 
smooth muscle.
(2) Inhibition of parasympathetic effects and activation of the sympathetic efferent 
and activation of the sympathetic and somatic effects (Chai & Steers 1996).
(3) Supraspinal centre in the dorsolateral pons (Griffiths et al 1990). Stimulation in 
the lateral pontine reticular formation causes an increase in sphincter tone and 
inhibition of bladder activities. Stimulation of primary micturition centre excites the 
bladder and inhibits sphincter tone.
(4) Visceral-visceral reflex. Activation of afferent nerves from the vagina and cervix 
inhibit the sacral pre-ganglionics to the bladder and increase uretheral resistance (Fall 
et al. 1978).
(5) Somato-visceral reflex is evoked by cutaneous stimulation which inhibits 
micturition (Vodusek et al. 1986).
(6) Somatic efferent pathway to urethral sphincter. During bladder filling, pudendal 
motor neurones are activated by vesical afferent input whereas during micturiton, the 
motomeurones are suppressed.
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6.3.5.The Voiding Reflexes
Activation of the sacral parasympathetic efferent pathway to the bladder and 
inhibition of the somatic pathway to the uretheral sphincter mediate Micturition. As 
the bladder fills with urine, bladder afferent activity (through the mechanoceptive 
neurones) triggers a micturition reflex. The afferents synapse on the neurones in the 
sacral spinal cord. Second-order neurones project to the pons, which elicits a bladder 
contraction and inhibition of the external uretheral sphincter (Griffiths et al. 1990; 
Kruse et al. 1991). Parasympathetic pathways in the pelvic nerve are involved in 
relaxation of the bladder outlet and a fall in ureteral pressure occurs seconds before 
the increases in intravesical pressure (Van Waalwisk et al. 1991). Release of NO 
from uretheral nerves may cause relaxation of the urethra (Bennet et al. 1993).
6.4.Prostaglandins and Natural Effectors of the 
Urinary System
6.4.1. Prostaglandins
Prostaglandins comprise a diverse family of lipid autocoids derived from 
cycloxygenase (COX)-mediated metabolism of arachidonic acid , generating five 
primary bioactive prostanoids: PGE2, PGF2 alpha, PGD2, PG12 and TXA2 (Smith 
1992). The families of prostaglandins, Leukotriens and related compounds are called 
eicosanoids because they are derived from 20-carbon essential fatty acid that 
contains 3, 4 or 5 double bonds. Arachidonic acid is either derived from dietary 
linoleic acid or is ingested as a dietary constituent. Arachidonate is then esterified to 
the phospholipids of cell membrane. Phospholipase A2 liberates arachidonic acid 
from phospholipid in cell membranes under noxious stimuli. Arachidonic acid may 
be metabolised through three pathways (Willoughby et al. 2000) (Figures 7&8). 
Pathway 1 involves COX or PGH synthase (Regier et al. 1993). This enzyme has 
two distinct activities, an endoperoxide synthase activity that converts arachidonic 
acid into PGG: and a peroxidase activity which converts PGG into PGH COX has 
two isoforms, COX-1 and COX-2. COX-1 is a constitutively expressed form and its
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Figure 7 : Arachidonic acid metabolism. Open arrow indicates stimulation and 
slashed open arrow indicates inhibition of the enzyme. PG: prostaglandin, TX: 
thromboxane, All: angiotensin 11, NE: norepinephrine, VP: vasopressin, BK: 
Bradykinin, IIETE: hydroxyeicosatetraenoic acid, EET: epoxyeicosatrienoic 
acid, DHET: dihydroxyeicosatrienoic acid {From Wen, S.(1997), JFormos Med 
Assoc, 96,p.l58)
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Figure 8: Conversion of arachidonic acid to prostaglandin and 
thromboxane of series 2 and Leukotrienes of series 4. * Both of these 
activities are attributed to one enzyme-prostaglandin endoperoxide 
synthase. 1- Peroxidase, 2- Leukotrien A4 epoxide hydrolase, 3- 
Glutathione S-transferase, 4- Y-gluiamyltransferase, 5- Cysteinyl-glycine 
dipeptidase ( From: Mayers, P.(1985) Metabolisms of lipids: l-Fattj' 
Acids, In; Harpers Review of Biochemistry, Martin, D. et al.(eds), 20 1
edition, Lange Medical Publications, California, p. 227.
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concentration within a cell is constant once the cell is fully grown (Brannon et al. 
1994), but may be increased by 2 to 4 fold following a physiological stimulus (Wu et 
al. 1991). COX-2 is an inducible enzyme which is very low or undetectable in 
normal body tissues (Feng et al. 1993; Kam & See 2000). COX1 is responsible for 
formation of eicosanioids for normal physiological function while COX2 for 
increased biosynthesis of eicosanoid following an inflammatory response, stimulated 
cell growth or cell activity (Kam & See 2000).
Pathway 2 involves a group of Lipooxygenase enzymes. The 5-lipoxygenase 
is the most important enzymes which leads to the synthesis of the leukotrienes 
(Samuelsson et al. 1987).
Pathway 3, where arachidonate is metabolised by enzymes that contain 
cytochrome P450 to a variety of metabolites including HETE (epoxycicosatrienoic 
acids) and 19- or 20- hydroxyarachidonate (Fitzpatrick & Murphy 1989).
To date 10 groups of prostaglandins have been discovered. All of these have 
five members ring. Depending upon the substitution on cyclopentane ring, 
prostaglandins have been given alphabetical names which ranged from A to J. With 
exception of PG1, each group of prostaglandins has at least three members. Most of 
prostaglandins are inactivated during passage through the pulmonary circulation.
6.4.1.1. Prostaglandins and the Kidney
Prostaglandins play a critical role in regulating Na+ excretion, blood pressure 
and renal function (Table 1). In the cortex, major sites of prostaglandin synthesis 
include arteries and arterioles as well as the glomerulus to maintain blood flow and 
filtration (Bonvalet et al. 1987). Both the cortical and the medullary collecting 
tubules produce large amounts of prostaglandins (Schlondorff 1986). These 
prostaglandins act locally by specific heptahelical transmembrane G-Protein-coupled 
receptors, designated EP, FP, DP, IP and TP receptors (Narumiya et al 1999). 
Thromboxan A2 (TXA2) is a labile arachidonic acid metabolite that is a potent 
vasoconstrictor and a stimulant of platelet aggregation (Furel & Fitzgerald 1991). 
Evidences are accumulated suggesting that all four EP prostanoid receptors subtypes 
(EP1, EP2, EP3, and EP4) may be expressed in the kidney.
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The EP1 receptor was described as a smooth muscle constrictor. In the 
collecting tubule, activation of the EP2 receptor inhibits Na+ and water reabsorption 
suggesting that activation of the renal EP1 receptor might be responsible for the 
natriuretic and diuretic effects of PGE2. (Gugn et al.. 1998; Herbert et al. 1991). The 
EP3 receptor acts as a constrictor of smooth muscle and might contribute to fibril 
reaction (Coleman et al. 1994). PGF2 alpha regulates NaCl and Ca2+ absorption in 
the distal convoluted tubule, increases cell Ca2+ and inhibits water permeability in the 
cortical collecting tubules (Asboth et al. 1996, Fernande-Ligme et al. 1999).
PGI2 has been demonstrated to play an important vasodilator role in the 
glomerular microvasculature as well as regulating renin release (Jackson 1989; 
Bugge et al. 1990;Jenson et al. 1996).
Preglomerular function is under the control of PGI2, whereas postglomerular 
function is mediated by PGE2 (Frolich 1990). PGI2 induced a 15% elevation of 
urinary Na+ excretion by intrarenal infusion (Villa et al. 1997). PGE2 is the major 
prostanoid synthesised along the nephron (Bonvalet 1987) and regulates renal 
microcirculation and water and salt transport (Breyer & Badr 1996). It inhibits water 
and salt absorption in the thick ascending limb and collecting tubule directly (Herbert 
etal. 1991 & 1993 ).
PGE2 rapidly induced an increase in urine flow concomitantly with a decrease 
in urine osmolality and the water diuresis was mediated by an inhibition of 
vasopressin antiduretic effect (Herbert et al. 1991; Good & George 1996). PGE2 
increase intracellular Ca2+ in cortical ducts, which might contribute to PGE2- 
mediated inhibition of Na+ absorption (Takaichi & Kurokawa 1988). Prostaglandins 
increase calcium and magnesium excretion through diminished reabsorption in the 
loop (Mandon et al. 1993).
PGI2 increases distal tubule carbonate ion secretion (Good & George 1996; 
Wesson 1996). Medullary prostaglandins antagonise effects of different vaso­
constrictors such as angiotensin II, norepinephrine, and vasopressin (Mene & Dunn
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1992). PGE2 antagonises the action of antidiuretic hormone on collecting tubule 
water permeability by activation of aquaprin-2 retrieval (Zelenina et al. 2000). 
Prostaglandins lower aldosterone secretion and the diuretic effect of prostaglandin 
demonstrated after surgery could be mediated by inhibition of the action of 
antidiuretic hormone (Enzan et al. 1994). Atrial natriuretic peptide increases the 
synthesis of prostaglandin, which might be responsible for diuretic effect of atrial 
natriuretic peptide (Benzoni et al. 1989; Salzar et al. 1988).
6.4.I.2. Prostaglandin and Renal Pelvis and Ureter
There was a significant quantitative predominance of the smooth muscle 
constrictor PGF2 alpha and TXA2 over the dilatory PGE2 in renal pelvis, ureter and 
bladder (Zwergel et al. 1991).
The majority of the afferent renal sensory nerves are located in the renal 
pelvic wall (Liu & Barajas 1993; Zheng & Lawson 1997). Activation of these nerves 
by increasing renal pelvic pressure results in an increase in afferent renal activity 
(Kopp et al. 1994). Prostaglandins are importantly involved in the activation of renal 
sensory nerves by increased renal pelvic pressure and bradykinin (Kopp et al. 1994 
& 1996). Activation of renal sensory neurones by these stimuli increases the release 
of PGE2 into the renal pelvic efferent (Kopp et al 1994 & 1996). Substance P is 
important mediator of the afferent renal nerve activity response to increased renal 
pelvic pressure and bradykinin (Kopp & Smith 1993).
PGE2 increases the release of substance P from renal pelvic sensory nerves 
by a calcium-dependent mechanism that requires influx of calcium via N-type 
calcium channels (Andersson 1993; Kopp & Cicha. 1999). Substance P is a known 
mediator of pain, which not only activates the inhibitory renorenal reflexes, but also 
increases pelvic and ureteral peristalsis. Acetylcholine stimulates the endothelial 
release of prostaglandins, which mediates Ach-induced increase in renal blood flow 
and urine volume (Kopp & Smith 1993).
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Increases in ureteral pressure due to renal stone or clots, distend the renal 
pelvis and activate renal mechanoreceptors with a resultant increase in ipsilateral 
afferent renal nerve activity (Kopp et al. 1984 & 1995). Ureteral obstruction is 
associated with increased renal PGE2 synthesis (Kekomaki et al. 1989). Increased 
ureteral pressure results in a renal pelvic release of PGE, which facilitates the release 
of substance P and activation of renal pelvic mechano- receptor (Kopp et al. 1996). 
Both PGE2 and substance P have been shown to increase renal pelvic contraction. 
(Kopp et al. 1996).
Prostaglandins of the E and F series produce excitatory effects on the motility 
of the ureter or renal pelvis (Thulesius et al. 1986). The rhythmic contractile activity 
of the ureter is dependent on the local synthesis of prostaglandins (Angelo-Kattar et 
al. 1985; Angelo-Kattar et al. 1989).
6.4.1.3.Prostaglandins and the Urinary Bladder and Urethra
Prostaglandins are synthesised locally in both bladder muscle and mucus 
(Gotoh et al. 1986; Pairet & Engelhard 1996). The synthesis initiated by nerve 
stimulation, ATP, bradykinin, stretching of the detrusor muscle, and injury to the 
vesicle mucosa (Maggi 1992). PGE1, PGE2, TXA2 and PGF2 alpha contract 
detrusor muscle, whereas PGE1 and PE2 relax the urethra (Palea et al. 1998). 
Prostaglandins may effect the excitation —contraction coupling in the bladder smooth 
muscle in two ways directly by effect on smooth muscle and / or indirectly via 
effects on neurotransmission (Andersson & Sjogren 1983; Maggi 1992). PGE2 and 
PGF2 alpha enhance Ca2+ induced detrusor contraction and spontaneous activity 
(Santicili & Maggi 1998). The human detrusor may contain prejunctional 
prostaglandin (FP and TXA2) receptor potentiating Ach release from cholinergic 
nerve terminals (Palea et al. 1998). Capsaicin-sensitive afferent in the bladder is 
chemosensitive and can be activated by prostaglandins to increase the afferent input 
produced by given degree of bladder filling (Meggi 1992). Distension of the bladder 
wall can increase the synthesis of prostaglandins (Meggi 1992). Neurones are 
capable of synthesising and releasing prostaglandins (Franco-cereceda 1989). 
Endogenous prostaglandins enhance voiding efficiency through an action, direct or
indirect, on sensory nerves (Meggi 1992). Intravesical PGE2 increased micturition
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and basal pressure and decreased bladder capacity and micturition volume (Pandita et 
al. 1997). Prostaglandins inhibit GABA, which has inhibitory effect on excitatory 
neurotransmission in human detrusor muscles (Chen et a l 1994; Ibrahim et al. 1999).
Prostaglandins can induce bladder overactivity due to release of tackykinins 
from nerves, a lowering of the threshold for afferent firing and a direct contract effect 
on the detrusor (Ishizuka et al. 1995). PGF2 alpha production increases in conditions 
associated with oxidative stress such as ageing. In the aged bladder, it was observed 
that there is super sensitive response to ATP and serotonin (Saito et al. 1990). The 
contractile response to norepinephrine, adenosine 5 triphosphate and serotonin 
increased with age (Saito et al. 1993).
Detrusor instability increases in men from 23.4% (40 to 60 years) to 46.7% 
(more than 80 years) (Madersbacher et al. 1998). PGE1 and PGE2 relaxed contracted 
urethra induced by noradrenaline and adrenaline (Andersson et a l 1988). PGE2 
produced a reduction of intra-urethral pressure (Khalaf et al. 1981). PGE and PGE2 
reduced urethral contraction in a dose dependent manner which is mediated by 
cAMP (Morita et al. 1994).
ATP, VIP, NO and PGE2 elicited concentration dependent relaxation on the 
proximal urethra (Pinna et al. 1996; Ho et al. 1998). Prostaglandins caused a strong 
sensation resulting in reduced bladder capacity and leading to bladder instability 
(Schussler 1990). The reduction of urethral resistance was most significant with 
PGE2. Micturition was most provoked by i.v. administration of PGE1 (Kondo et al 
1983). Summary of actions of prostaglandins on the urinary system is shown in the 
table 1.
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Action References
Inhibit Na+ reabsorption Gugn e t al. 1998
Inhibit Na+ reabsorption Herbert Qt al. 1991
Natriuresis & diuresis Herbert et al. 1998
Inhibit antiduretic hormone. Good & George 1996
Glomerular vasodilatation. Bugge e t al. 1990
Decrease aldosterone secretion. Enzan Qt al. 1994
Increase HC03 secretion. Wesson 1996
Increase calcium & magnesium secretion. Mandon e t al. 1993
Increase renin secretion. Jemsen et al. 1996
Increase renal pelvic contraction. Kopp et al. 996
Increase substance P Kopp et al. 1999
Increase motility o f renal pelvis & ureter Thulesius et al. 1986
Increase ureteric contraction. Cole et al. 1988
Contract detrusor muscles & relax urethra Palea e t al. 1998
Increase acetyle choline from nerves. Palea e t al. 1998
Activate capsaicin-sensitive afferent in Maggi 1992
urinary bladder.
Enhance voiding efficiency Maggi 1992
Release tackykinines & cause micturition Ishizukia e t al. 1995
Relax contracted urethra Andersson e t al. 1983
Reduce intraurethral pressure. Andersson et al. 1981
Cause bladder instability Schussler 1990
Provoke micturition Konda et al. 1983
Increase intracellular calcium Takaichi & kurokawa 1988
Release calcium from internal stores Seniro et al. 1992
Increase calcium influx Shimizu et al. 1998
Cause oedema and hyperalgesia Whelan et al. 1991
Increase IL-6 production. Portanova Qt al. 1996
Inhibit GABA Ibrahim e t al. 1999
Cause inflammatory pain Bley et al. 1998
Table 1: The main actions of prostaglandins on urinary system
38
6.4.1.4. Prostaglandin and inflammation
The inflammatory process is a nonspecific complex, coordinated response of 
tissue to injury. This process involves vascular permeability, active migration of 
blood cells and passage of plasma constituents into the injuries tissues. The 
emigration cells initiate the complex reactions that are controlled by a multitude of 
intracellular messengers called mediators. Prostaglandin E2 plays a major role in 
tissue oedema, hyperalgesia and IL-6 production at site of inflammation (Portanova 
etal. 1996).
Prostaglandin and nitric oxide are important mediators of inflammation. Upon 
stimulation of cells, prostaglandins synthesis increased in the cells by direct 
interaction between nitric oxide and PGHS (Goodwin et al. 1999).
Nitric oxide production is increased in inflammatory reaction (Stichtenoth et al.
1994). Prostaglandin are generated in response to injury and inflammation and can 
sensitise or directly activate sensory nerve endings of nociceptions ( Smith et al. 
1998).
Prostaglandin productions
Many conditions in the urinary system could increase production of 
prostaglandins which might contribute to pathopysiology of the diseases (Table 2).
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6.4.2. Nitric oxide
NO regulates Na+/K+ ATPase, Na+/H+-exchange and para-cellular 
permeability of proximal tubular cells (Liang & Knox 2000). NO has important role 
in inhibition of Na+ reabsorption (Hagnes et al. 1997). It mediates pressure 
natriuresis and diuresis (Noonan & Banks 1999). NO decreases antidiuretic hormone 
stimulated water and Na+ ion transport in the cortical collecting duct and it has a 
direct effect on cortical collecting duct which may explain its natriuretic and diuretic 
effects (Garcia et al. 1996). The occurrence of relaxant activities in the detrusor 
attributable to NO seems to be controversial. The detrusor muscle has a low 
sensitivity to NO and agents acting by the cGMP system (Andersson & Persson
1995). Sodium nitroprusside fails to produce any relaxation (Wheeler et al. 1997). In 
the human bladder, sodium niroprusside was even found to produce contraction 
(Moon et al. 1997). Sodium nitroprusside as well as exogenous NO increased 
neurogenic detrusor contraction (Lin & Li-shian 1997). NO-mediated relaxation in 
response to nerve stimulation, which was clear in the trigone and urethra but not in 
the detrusor (Andersson et al. 1992). Nitroprusside and NO are effective in relaxing 
urethral muscle (Persson & Andersson 1998). Therefore, L-arginine / NO pathway 
may be one of several possible mechanisms contributing to the decrease in 
intraurethral pressure preceding micturition. NO stimulates uterine contractions by 
increasing COX products ( Franchi et al. 1994). Sodium nitroprusside was able to 
induce myometrial contractions by stimulating prostaglandin synthesis (Franchi et al. 
1994). Endogenous NO stimulates the synthesis of PGE & PGF2 alpha in uterine and 
ovarian tissue (Motta et al. 1997). Some of effects of NO on the urinary system are 
shown in the table 3.
Neuropeptide Y (NPY) and Bradykinin
NPY is a co-transmitter of the sympathetic nervous system. Systemic and 
intrarenal NPY administration lower renal blood flow, and causes diuresis and 
natriuresis (Bischoff et al. 1996; Bischoff et al. 1998). Bradykinin causes renal 
vasodilitaion, natriuresis and diuresis, smooth muscle contractions, inflammatory 
reactions, and increases prostaglandin and NO productions (Matsumura et al. 1999: 
Couture at al. 2001; Rodriguez et al.2001).
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Conditions Sites References
Diabetes, smoking, aging Bladder Tarean et al. 2000
Bladder nerve stimulation Bladder Tarean et al 2000
ESWL Urinary tract Hasanoglu et al. 1994
Increased ureteral pressure Renal pelvis Kopp et al 1996
Ureteral obstruction Glomeruli Yanagisawa et al. 1991
Nephrotics Kidney Ruilope et al 1983
Acetyl chorine Plasma Garin & Richard 1984
Activation of renal sensory 
neurons.
Kidney & bladder Salom et al. 1991
Bradykinin Kidney Kopp et al 1996
Nitric oxide Kidney Salvenmini et al. 1994
Stretching of detrusor & nerve 
stimulation
Bladder Maggi 1992
Vesicoureteral reflex Urinary bladder Walker & Garin 1990
Table 2: Conditions and factors stimulate production of prostaglandins 
at different parts of urinary system.
Actions References
Increases renal blood flow & glomerular 
filtration rat
Campo et al. 1996
Inhibits sodium reabsorption Hagnes et al 1997
Natriuresis & diuresis Noonan & Banks 1999
Inhibits fluid reabsorption Liang & Knox 2000
Decreases antiduretic hormone Garcia et al. 1996
Increases neurogenic detrusor contraction Lin & Lim 1997
Relaxation of trigone & urethra Andersson et al. 1992
Stimulates prostaglandin synthesis Motta et al 1997
Enhances nocicephors and causes pain Anbar & Gratt 1997
Urethral relaxation Garacia-Pascula et al. 1996
Mediates inflammation Salvermini et al 1994
Increases in ureteric obstruction Moridaira et al 2000
Table 3 : Some effects of nitric oxide on the urinary system
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6.5. Diseases of the Urinary System
6.5.1. Enuresis and nocturnal Frequency of Micturition
Detrusor instability commonly is associated with ageing and bladder outlet 
obstruction (Elbadawi 1995). Age-matched healthy men have an incidence of 
detrusor instability of 25 to 63%. Frequency, nocturia and urgency increased with 
age almost equally in men and women, and bladder capacity declined equally in both 
aged sexes. Aging causes increased lower urinary tract symptoms due to a smaller 
bladder capacity, increased detrusor instability, nocturnal polyuria and a less 
contractile bladder (Hald & Horn 1998). Nocturnal polyuria is defined as increased 
urine output during the night (Asplund 1995). The diurnal pattern of antidiuretic 
hormone secretion has been changed in the elderly, and plasma levels are often 
undetectable during night in the elderly with nocturia (Weiss & Blaivas 2000). Many 
patients with nocturia are found to have a combination of nocturnal polyuria and low 
nocturnal bladder capacity (Weiss & Blaivas 2000). Recently, other study showed 
that nocturnal urinary volume and nocturnal capacity were the significant 
determinants of nocturnal frequency in healthy older men (Kawanchi et a l 2000).
Enuresis is a common challenging problem. Conflicting data still exist 
regarding its aetiology and pathogenesis. Bladder dysfunction may play a role in 
enuresis. Enuretic children exhibited more frequent and more intense spontaneous 
evoked contractions of the detrusor muscle and also experienced greater bladder 
pressure (Scharf et al. 1987). Functional bladder capacity in enuresis may be less 
than 50% of the normal children (McLorie & Husmann 1987). Small functional 
bladder capacity results from inadequate cortical inhibition development delay or 
may be part of an allergic reaction in which the bladder is maintained in spasm which 
prevents it from accommodation large amounts of urine (Doleys & Dolce 1982).
Children with enuresis have been described as a deep sleepers (Wille 1994 ). 
Anatomical abnormalities were not usually found in cases of enuresis, but functional
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bladder capacity may be reduced in-patient with enuresis (Mayo & Bums 1990; 
Weerasinghe & Molane 1993). Children with enuresis did not show a normal rise in 
nocturnal secretion of antidiuretic hormone (Norgaad et a l 1985; Ritting et al. 1989). 
Some studies showed a lower nocturnal secretion of antidiuretic hormone with 
nocturnal enuresis (Fefferman 1994; Eggert & Kuhn 1995). Enuretic children need 
significant higher antidiuretic hormone plasma levels to maintain constant plasma 
osmolality (Eggert et a l 1999). Na+ and Mg2+ excretion is elevated not only during 
the night but also through out a 24-hour period in enuresis (Vurgun et al. 1998).
Children with enuresis have higher nocturnal Na+ excretion but not higher 
nocturnal free-water clearance (Vurgun et al. 1998; Yuri et al. 1999). There is a 
decrease in the ion reabsorption in the thick ascending LOH (Kuzentsova et a l
1996). It has been suggested that there might be a difference in the mechanism of 
reabsorption of Na+ and K+ between enuretic and nonenuretic (Vurgun et al. 1998). 
There was markedly high nocturnal urine production on wet night (Hansen & 
Jorgensen 1997). Neurophysiological study of enuresis showed hypoexcitability of 
sphincter nuclei (Podnar et al. 1999).
6.5.2. Renal Colic and Urinary Obstruction
Renal colic typically caused by acute obstruction of the ureter by a calculus 
or by the passage of crystalline precipitate from the renal pelvis through the ureter. 
The renal colic, typically sudden and severe, manifests as waxing and waning pain in 
the flank, abdomen, and / or groin and genitalia.
Since the 1970s the role of prostaglandins in ureteral colic has been elucidated 
(Sjodin 1981; Holmlund 1983). Obstmction of the urinary tract is associated with an 
increase in pelvic pressure and decrease in renal blood flow, which is associated with 
increased TXA2 synthesis (Sheehan et al. 1994). A greater production of PGE2 and 
TXB2 was noted by glomemli from the kidneys with unilateral obstmction 
(Fukuzaki et al 1993). Increased ureteral pressure results in an increase in afferent 
renal nerve activity and release of substance P, which is facilitated by renal pelvic
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release of PGE (Kopp et al. 1996). The production of PGE2, PGF1 alpha and TXB2 
by cortical and medullary tubules was significantly high in bilateral ureteric 
obstruction (Fukazaki et al. 1993). PGE2 may participate in calcium stone formation 
by regulating the renal tubular handling of calcium (Hirayama et al. 1988).
Patients with recurrent idiopathic urolithiasis had high level of urinary PGE2, 
which showed a positive correlation with urinary calcium excretion (Hirayama et al. 
1988). Pain of acute renal colic might be related to higher pressure in the collecting 
system proximal to the stone (Holmlund & Sjodin 1978). Stones causing ureteric 
obstruction are a potent stimulus for renal blood flow and diuresis (Olsen et al. 1965). 
In ureteral calculus causing uro-epithelial damage, urine can penetrate subepithelially 
and induced degranulation of mast cells with release of histamine and prostaglandins 
causing forceful peristaltic contraction (Ugaily & Thulesius 1988). The 
pathophysiology of renal colic is related to tension exerted on the excretory cavities 
by an obstruction, generally a stone, causing secretion of prostaglandin, which, in 
turn, increases the renal blood flow and glomerular filtration rate. NO is associated 
with an alteration in glomerular hemodynamics seen after the induction of ureteral 
ligation.
The expression of NO synthase was significantly greater in glomeruli with 
unilateral ureteric obstruction in both obstructed kidney and in contralateral non- 
obstructed kidney (Moridaira et al. 2000). Bradykinin stimulates PGE2 release in 
ureteral obstructed hydronephrotic kidney which is attenuated by NO inhibition 
(Salvenmini et al. 1994). Bradykinin causes renal vasodilitation, natriuresis and 
diuresis by NO and prostaglandin production (Matsumura et al. 1999; Tadano et 
al.2001). Inhibition of NO and prostaglandin abolished renal effects of bradykinin 
(Rodriguez et al.2001). In addition, bradykinin causes smooth muscle contractions 
which depends on calcium and prostaglandin (Oriordan et a/.2001). Bradykinin 
causes pain and inflammation (Couture et al. 2001). Endogenous release of NO in the 
contralateral kidney and in the obstructed kidney results in increased release of 
prostaglandins (Salvenmini et al. 1994). Events occuring in the ureteric obstruction 
are illustrated in figure 9.
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Figure 9 : Events Occuring in Ureteric Obstruction 
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6.6 Pain
6.6.1 Types and Pathophysiology
Pain is unpleasant sensory and emotional experience associated with actual 
or potential tissue damage or described in terms of such damage, according to 
definition by the International Association for the Study of Pain (IASP, 1986). Pain 
is multifactorial. 15-20% of population have acute pain and between 25-30% suffer 
from chronic pain (Aghabeigi 1992).
There are two types of pain:
1- Acute pain
It is associated with trauma or diseases and has a well defined 
location, character, and timing. It accompanied by symptoms of autonomic 
hyperactivity such as sweating, hypertension, tackycardia and mydriasis.
2- Chronic pain
This is lasting more than few months. There is no signs of autonomic 
hyperactivity and the patients experience physical, social, psychological, and 
functional deterioration. It is not necessarily associated with trauma or 
diseases and its location, character and timing are vague.
Another classification of pain showed that pain may be divided into:
1- Pathological pain associated with underlying diseases and arises from 
inflammatory response following tissue damage or direct damage of nervous 
tissue. It may divided into inflammatory and neuropathic pain (Woolf 1989)
2- Psychological pain which may be delusional or may be due to 
psychologically induced chronic psychological changes.
Physiologically pain may be divided into:
1- Nociceptive pain
It follows activation of nociceptores by noxious stimuli but is not associated 
with injury to the peripheral nerves or the CNS.
Nociceptors are specific pain receptors that have numerous different receptors 
such as GABA, bradykinin, histamine, serotonin and capsaicin receptors. The 
most fascinating aspect of pain perception in the periphery is that normally 
most of nociceptors lie dormant. Inflammation sensitizes nociceptors. This 
pain may be divide into:-
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1- Somatic pain which is usually well localized pain and may be described as 
deeply located sharp or dull, stabbing, throbbing or pressure like.
2- Visceral pain which is not evoked by all viscera, is not liked to visceral 
injury, is referred to other location, is diffuse and poorly located and is 
accompanied by motor and autonomic reflex. Visceral pain is a prominent 
symptoms in the clinical setting and one of the main reason for patients 
seeking medical care. The pain is described as deeply located, aching, 
cramping or pressing, and may be accompanied nausea and vomiting. 
Nociceptive pain usually responds to treatment with analgesic.
3- Neuropathic pain
It is resulted from damage or dysfunction of peripheral nerves/receptors or of 
the CNS. The pain covers deafferentation pain, sympathetically maintained 
pain including causalgia and reflex sympathetic dystrophy, painful conditions 
such as postherpetic and trigeminal neurologia, and diabetes’ neuropathy. It 
responds poorly to analgesia.
There are two types of peripheral nociceptors:
1- Mechanical receptors have high stimulation threshold and respond to intense 
noxious stimuli. They are associated with rapidly conducting small 
myelinated A fibers and their stimulation result in sharp localized pain that 
serves to activate withdrawal reflexes.
2- Polmodal nociceptors respond to mechanical, chemical or thermal stimuli. 
They are also activated by cellular mediators that are released following 
tissue damage. They are associated with slowly conducting unmyelinated C 
types fibers and produce dull, aching and poorly localized pain.
Nerve fibers from nociceptors terminate in the dorsal root of spinal cord
before transmission by ascending pathways to the brain. The main types of
nociceptor nerve fibers are :
1- C- Fibers. They mediate second pain which is dull, itching or burning 
sensation. They form majority of sensory nerves (Ran et al. 1991)
2- A delta fibers mediate first pain which is sharp sensation. These fibers react 
to chemical stimuli like bradykinin (Cambell et al. 1989).
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Primary hyperalgesia is characterized by a reduced pain threshold in damaged 
tissues to even non-noxious stimuli in which there are changes in the pain 
threshold within the area of injury, and it is due to sensitization of primary 
neurons (Ferreria 1981, Raja and Meyer 1988, Raja et al. 1988). However, 
secondary hyperalgesia is due to changes in the surrounding uninjured tissues and 
is considered to result from activation of NMAD receptors in the dorsal horn of 
the spinal cord (Woolf 1989, Woolf 1991).
6.6.2. Pain pathway
The following components are included in pain pathway
1- Peripheral receptors.
There are two response to a painful stimulus: a first pain which is well- 
localized and brief and second pain which is more diffuse. Visceral pain can 
be referred to a region of the body surface (Cervero 1994).
2- Neural pathway
Important fibers coming from the periphery into the dorsal horn includes
1- Unmyelinated C-fibers
2- Myelinated A delta fibers
3- A beta fibers that carry information about vibration and position sense.
3- Spinal pathway
There are two main pathways
1- Spino-reticulo-diencephalic tract pass to thalamus and from thalamus 
informations pass to cortex, mainly in the frontal lobe.
2- Neospinothalamic tract that passes to lateral thalamus and then 
informations pass to postcentral gyrus. GABA, CCK and NPY may play a 
role in pain transmission
4- Descending pathways
This originated from cortex, thalamus and brainstem. There are 
serotoninergic-based pathways and noreadrenergic-based pathways that 
inhibit incoming painful impulses.
6.6.3. Mediators of pain with specific references to prostaglandin 
and nitric oxide
Inflammatory mediators may exert their effects on nociceptive neurons 
either by direct coupling to membrane receptors (H+, K+, ATP, Serotonin) or by
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indirect action mediated by intracellular second messengers (Prostaglandins, 
Bradykinin, Histamine). Many inflammatory cells express receptors for 
neuropeptide that are released from peripheral nerve terminals (Substance P and 
CGRP) (Besson et al. 1987). Stimulation of peripheral nociceptors increases the 
release of excitatory amino acid such as glutamate which acts at the NMDA 
receptors ( Davis and Lodage 1987).
The nociceptive response to acute tissue injury can be divide into:
1- Release of sensitizing mediators. This includes K+ , H+, which activates the 
release of substance P, bradykinin, histamine and serotonin (Krishtal & 
Pidoplichko 1980). These mediators increase prostaglandin productions and 
lipoxygenase pathway products (Rang et al 1991).
2- Peripheral sensitization of nociceptors by released chemical mediators causing 
primary hyperalgesia. The inflammatory mediators also stimulate release of 
stored neuropeptide from the peripheral nociceptors terminals like substance P 
and calcitonin gene-related peptide and thereby cause vasodilatation, increased 
vasopermeability, and extravasations of plasma protein and inflammatory cells 
including mast cells, neutrophils and macrophages (Levine et al. 1988).
3- Central sensitization. The synaptic transduction properties of the neurons in 
the dorsal horn of the spinal cord and other central neurons result in the release of 
NMDA (Kuraishi et al. 1989). The reflux of substance P and excitatory amino 
acid at the dorsal horn not only causes changes in the neurons with which Ca­
libers have a common synapse but also in the surrounding receptive field, which 
is the main reason for the development of secondary hyperalgesia (Woolf 1989).
4- Recovery of normal nociception.
Pain is experienced predominantly during the second and third stage 
of nociceptive response.
It has been demonstrated that prostaglandins, substance P, VIP, 
calcitonin gene-related peptide, histamine, serotonin, bradykinin, K+, H+ and 
ATP are important mediators either as neurotransmitters or senitizers of pain 
receptors (Helme 1990). Neurogenic inflammation leads to stimulation of C- 
fibers causing vasodilatation and increased capillary permeability. This is due to 
local release of substance P. K+, H+, histamine, and bradykinine which in turn 
cause prostaglandins and interleukienes productions. It has been found that
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nerve growth factors, bradykinin and cannabinoids are responsible for primary 
hyperalgesia (Rice 1998). Nerve growth factor has a key role not only in the 
development of sensory and autonomic nerves but also in the presence of 
nociception (McMakon and Bennett 1997).
In general, neurotransmitters can be divided into;
1-Excitatory
This includes glutamate and tackykinin that act at the various neurotinin 
receptors as substance P. Other mediators that transmit pain impulse from 
incoming nerves in the dorsal horn including VIP, somatostatin and calcitonin 
gene-related peptide.
2- Inhibitory. Such as GABA.
3- Neurotransmitters involved in descending pain regulation which includes 
noradrenaline and serotonin.
Consequence of glutamate receptors activation include production of c-fos 
and spinal production of prostaglandin and NO (Herdegen and Leak 1998). 
Central C-fos expression correlates externally with painful stimulation. Noxious 
peripheral stimulation not only causes fos to appear in the spinal cord but also the 
inducible transcription factor that control mammalian gene expression.
Regarding prostaglandins and NO, there are abundant data indicating that 
inducible isofroms, COX-2, is important in inflammation and pain. The 
constituent isoforms, COX-1 has also been suggested to play a role in the pain 
and inflammation (Smith et al. 1998). Prostaglandins exert central as well as a 
peripheral hyperalgesic action (Ferreira et al 1973, Van 1971, Ferreira e/ al 
1978, Yaksh 1982). Prostaglandins did not activate directly but sensitize 
nociceptors to both mechanical stimuli and other chemical mediators of 
nociceptors such as bradykinin and histamine (Ferreira 1980, Higgs 1980). 
Prostaglandin acts with other mediators to sensitize receptors to affect nerve 
ending to produce inflammatory pain (Vane and Botting 1990).
Sensitizing effects of endogenous prostaglandins have been demonstrated on 
different indicator of sensory neuron function, including ion channel activation, 
neuropeptide release and second messenger level (Nicel et al 1997). IP receptors
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plays a major role in the sensitization of sensory neurones (Jacqueline et al. 
1998). Prostaglandins activate different second messenger pathway through 
intervals with several G-protein coupled receptors (Coleman et al 1994, Pierce et 
al. 1995). Prostaglandins sensitize the peripheral terminals of primary afferent 
nociceptors (Ferreira et al. 1974, Willis and Corelsen 1973). Prostaglandins 
contribute to the peripheral mechanism underlying hyperalgesia following nerve 
injury (Syriatowiz et al. 1999).
Peripheral irritation triggers the release of prostaglandin which in turn 
produces a release of CGRP from primary sensory afferent (Fries et al. 1997). 
Prostaglandin E2 potentiated bradykinin-induced hyperalgesia and prostaglandin 
D2 potentiate oedema (Whelan et al. 1991). Acute and chronic peripheral 
inflammation, interleukienes and spinal nerve injury increase the expression of 
COX-2 and release of prostaglandin. Prostaglandins decrease firing threshold, 
increase firing rate and release of excitatory amino acid, substance P and CGRP 
(Vagegas and Schaible 2001).
It has been found that prostaglandins sensitize or activate nociceptors 
and elicit spontaneous pain and hyperalgesia when injected peripherally (Hong & 
Abbott 1994). Prostaglandins contribute to neuropathic hypralgesia (Syriatowicz 
et al. 1999). Nerve growth factor and mast cells were shown to contribute to 
hyperalgesia following nerve injury and nerve growth factor induces synthesis of 
prostaglandins by mast cells (Marshall et a l 1999; Ro et al. 1999). 
Prostaglandins act on mylinated and unmyelinated afferents (Patermoichelakis 
and Rood 1982; Birrell et al. 1991). Intradermal prostaglandin E2 produces 
hyperalgesia by descending the threshold of primary afferent nociceptors (Yaksh 
1982,Yetunde et al. 1985).
Prostaglandin may also play a role in sensitization of central neurons ( 
Willinale et al. 1997). After C-fiber stimulation prostaglandin may contribute to 
nociceptive processing in the spinal cord (Willingale et al. 1997). Substance P 
and neurokinin cause release of prostaglandin (Thorboll et al. 1998). Spinal 
substance P-induced thermal hyperalgesia is mediated by an increase in spinal 
PGE2 via activation of the neurokinin 1 receptors (Han et al. 1999). 
Prostaglandins act on a G-protein-coupled binding site on dissociated dorsal root
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ganglion cells to induce a Ca2+ -dependent release of substance P (White 1996). 
Following peripheral injury and inflammation, NMD A, substance P and 
capsaicin significantly increase spinal prostaglandin E2 release in spinal cord and 
spinal prostaglandin E2 and NK-1 receptors activation play a role in development 
of hyperalgesia (Dirig and Yaksh 1999). Intrathecal administration of 
prostaglandin E produces hyperalgesia (Ferreira et a l 1978). Prostaglandin F2 
alpha also produces hyperalgesia when injected into the spinal subarachnoid 
space (Yaksh 1982).
Prostaglandins and NO have been shown to be a key mediators involved in 
the induction and facilitation of spinal nociceptive transmission and central 
sensitization after peripheral tissue injury and inflammation. NO may act as a 
retrograde transmitters in the spinal cord (Vetter et al 2001). In addition, NO 
may be involved in the generation and processing of pain signals (Stegmann et 
al 2001). It has been shown that low level of NO facilitates cAMP-dependent 
prostaglandin E2-induced hyperalgesia, whereas higher level of NO produces a 
cGMP-dependent hyperalgesia (Aley et al 1998). Skin hypothermia caused by 
regional vasodilatation is induced by extravascular NO. NO enhances the 
sensitivity of peripheral nociceptros (Aubar and Gratt 1997).
6.6.4. Pain in the Kidney and Ureter
Kidneys are insensitive to all forms of stimulation so that no sensation can 
be evoked by even the most damaging stimuli. Ureters are very sensitive to 
distension of lumen or inflammation of mucosa (Cervero 1994). Pain sensation 
in ureter can be evoked by irritation of the mucosa, ischemia of the organ, 
overdistension and enhanced motor activity (Cervero 1994). Pain is only 
sensation that can be evoked from ureter and the kidneys. Picking, cutting 
heating or cooling the outer surface and parenchyma of the kidneys did not elicit 
any sensation, whereas distension of the kidney, renal pelvis and ureter evoked 
server pain (Cervero 1994). Electrical stimulation of the organ evoked intense 
pain ( McLellan and Goodell 1943).
Uretral pain in human is usually referred ipsilaterally to a location that 
follows approximately the lateral edge of the rectus muscle of the abdomen. If
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the pain is due to the passage of kidney stone, the area of referral extends 
progressively toward the supra public region and can reach the scrotal or labial 
skin and even the medial thigh (Bonica 1990). The most common form of renal 
and ureteric pain is that produced by acute urinary obstruction due to passage of 
renal stones. Inflammatory or ischemia of the kidney and subcapsular haematoma 
can also evoke pain.
Basically two types of renal sensory receptors are recognized:
1 -Mechanoreceptors
The activities of these receptors are to trigger regulatory reflexes 
concerned with the control of the renal blood follow and body fluid (Dibona 
1982, Stella and Zanchetti 1991). Some of these can be activated by large 
pressure increase in the kidney and pelvis (Beacham and Kunze 1969). 
2-Chemoreceptors
These are sensitive to chemicals released by the hypoxic kidney and may 
play a role in renal pain (Moss 1989). They trigger regulatory reflexes to the 
control of body fluid.
Regarding the ureter, the sympathetic and parasympathetic innervations 
of the kidneys extend to the tope of the ureter. The bottom half received its own 
innervations from the hypogastric nerves and its parasympathetic innervations 
from the pelvic plexus and nerves (Semeneko and Cervero 1992). There are 
mechanoreceptors at either end of the ureter. They respond to increase in ureteral 
pressure and may be involved in the pain from pelvis and ureter. 
Mechanosensitive unites are classified into U-l contain only 9% of the unites 
and U-2 contained the vast majority of the unit. The U-2 units could mediate the 
intensive pain sensation.
6.6.5. Assessment of the pain
Pain is subjective experience which can not be simultaneously shared by 
others. It is clinically important to accept the subjects description of the pain 
experience. However, pain is not only subjective but it also something that can be 
documented in objective fashion particularly after the discovery of gene C-fos 
which is rapidly expressed in the spinal cord in response to painful peripheral
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stimulation (Cross 1994). Though there is no doubt about the physical component 
of pain, the psychological and social aspect should not be ignored particularly in 
the case of the chronic pain.
Each year emergency departments see millions of patients with moderate 
to sever pain. The use of valid, language-sensitive pain assessment method is a 
critical prerequisite to selection and evaluation of pain treatment. The nature of 
the patient’s pain is one predictor of the response to treatment. It is mainly 
characterized by its location, intensity, extent, timing and types as well as 
patterns of radiation, onset of duration and alleviating and aggravating factors. 
Pain assessment could be multidimensional process and emphasis is on the 
patients self-report as the major indictor of pain. The multiple components of the 
pain experiences include:
1- Physiological component. This includes the organic aetiology of the pain
2- Sensory component. How the pain actually feels to the individual who has it ( 
intensity, location, and quality of pain) (Melzack and Wall 1965).
3- Affective component. This is related to how the pain makes the patients fell. 
Pain has effects on mood, emotional states, and sense of well-being. This 
component include anxiety, depression and fear.
4- Cognitive component. This includes the manner in which the pain effects 
person thoughts.
5- Behavioral component. This includes physical activity, medication and 
treatment (Fordyce 1986)
6- Sociocultural dimension of pain (Snelling 1990; Greenwald 1991)
However, using a variety of instruments allowing the patients to select one 
that is most meaningful. Despite the growing interest of developing 
multidimensional scales, the use of uni-dimensional scales in assessing clinical 
pain is popular for its simplicity, efficiency and ease of use. Pain intensity rating 
scale must be appropriate for the patients population. When it is not possible to 
take direct measurement, it is often possible to grade individual in some way. 
Patients may be asked to assess their degree of something unmeasurable like 
pain. As pain assessment is subjective, the scales and measurements are of most 
values when looking at changes within individuals, e.g. before and after 
intervention.
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A questionnaire can be regarded as an instrument in its own right. It may try 
to measure personal attributes such as level of pain. There are two major types of 
questions (Altman 1999)
1 - open question in which respondents are asked to reply in their won words 
2- Closed question in which the possible responses are given
More than 40 potential instruments or tools for pain assessment were used 
such as McGill- Pain Questionnaire (Melzack 1975), Wiscosin Brief Pain 
Questionnaire (Daut 1983), Memorial Pain Questionnaire ( Fishman et al 1987), 
Integrated Pain Score (Ventafridda et al. 1983), Pain assessment Maps and 
simple rating scales such as Verbal Rating Scales (VRS) or Visual Analogue 
Scales (VAS). The McGill Pain Questionnaire (MPQ) is used to specify 
subjective pain experience using affective, sensory and evaluating word 
descriptors. The MPQ was developed to indicate the extent of change in pain 
quality and intensity as a result of an intervention. Patients with acute pain 
displayed a greater use of sensory word groups while patients with chronic pain 
used affective and evaluative groups (Reading 1982). The MPQ takes 5-10 
minutes to administer. VAS and VRS are widely used and considered as a 
standardized tools exist for daily assessment of pain intensity (Altman 1999). It 
has been found that numerical rating scale and a word descriptive scale were 
equally preferred by patients whether they spoke English or Spanish. Patients in 
acute pain were able to use both ways of communicating their pain to doctors and 
thereafter patients could be offered their choices of either of these simple pain 
rating scales to evaluate pain and the effectiveness of pain-relieving interview ( 
Puntillo and Neighbor 1997). However, some patients have difficulty with 
expressing their pain by use of numbers. Adults patients are encourage to use the
0-10 scale and if they can not understand or are unwilling to use it, the VRS is 
used. VRS was found to improve measurement of pain intensity in cancer 
patients (Au 1994). It was found that a VRS has its value in the measurement of 
pain intensity with culture relevancy (Chung et al. 1999). In VAS, the patient is 
shown a straight line (often 10 cm long), the ends of which are labeled with no 
pain in one end and very severe pain in the other end. They are asked to mark the 
point on the line which represents their perception of pain. It has been found that 
no significant difference between the horizontal and the vertical VAS-values 
were found in the assessment of pain (Dreivik and Skoglund 1998). It has been
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demonstrated that a difference in VAS pain score of less than 20 mm is unlikely 
to be clinically meaningful when the patients with acute pain marked the level of 
their pain on 100 mm VAS and gave a verbal rating of their pain (Kelly 2001). 
However, in comparison of VAS and other tools of pain assessment, it was found 
that patients had some difficulty competing the paper and pencil VAS during the 
procedure (Jensen et al. 1998). Berthior et al. 1998 reported that in a hospital 
emergency department both scales were used successively for acute pain 
assessment in 290 patients. VAS and VRS were used to assess the pain intensity 
after injection of morphine and it was found that there was no significant 
difference between the assessment of pain using both tools and the results 
obtained for both instruments are similar (Billion et al. 1994). Moreover, in a 
series of 255 patients with acute pain, it has been found that pain scales such as 
VAS and VRS are used easily and convenient for the assessment of pain intensity 
(Ricard-Hibo et al. 1997). In other study, Soyannwo et al. 2000 found that VAS 
and VRS constitute useful tools for pain assessment in patients with acute pain.
Briggs and Closs 1999 studies 417 patients with postoperative pain. 
Fifty-nine patients (14.2%) did not complete VAS and two patients did not 
complete VRS (0.05%). It was found that the VRS was more suitable for use. 
The scores generated from VAS and VRS correlated well. In addition to pain, 
VAS and 4-point VRS were used for assessment of postoperative nausea ( 
Boogaerts et al. 2000). In acute pain , VAS or VRS were used in most of studies 
reporting the affects of intervention on the patients pain. MPQ may be useful 
during the initial evaluation and when the person s condition permits. However, 
in acute pain like severe acute renal colic, some patients are quite ill and only 
simplest description of pain intensity can be obtained from their evaluation. 
Moreover, repeated clinical measurements of acute pain must be short and 
concerns sensory component and pain intensity. In chronic pain , measurement of 
many component of pain like psychological functions , behavioral dimension, or 
sociocultural components of pain may be important in evaluation of patients.
6.6.5.I. Choice of pain assessment methods
In section 6.6 we saw that there were many methods for pain assessment.
However, recent a review stated that VRS and VAS represent useful tools for acute
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pain measurement. In acute renal colic, VS A and VRS were used widely for 
assessment of pain intensity (Jonsson et a l 1987; Cordell et a l 1996; Aybek et a l 
1998). They are easy for quick answering and suitable for patients with acute crisis. 
In earlier observations, I found that there were no differences in expressing of acute 
pain intensity using either of the scales (Al-Waili 2001). Prof. Melzack stressed that 
the VRS and VAS would be valid for our work on acute renal colic and they 
correlate very highly with other measures of MPQ (Personal communication). 
Therefore, using either VRS or VAS is valid and acceptable in our studies. We used 
VRS in four studies and VAS in one study. We selected VAS in one study because 
patients were able to express their pain intensity using such scale. In other studies 
most of the patients found some difficulty using the paper and pencil VAS during the 
attacks. This might be partly related to fact that most of these patients came from 
villages. Hence, we mainly depend on VRS to measure pain intensity though both 
scales are valid.
6.6.6. Management of pain
Several approaches to manage pain have been applied ( Justin 1993, Justines 
1994, Rouveix etal. 1999). These are:
1 - Inhibition of transmission of pain impulses to the brain.
1- Pain may be managed at a peripheral level as in the use of ice packs or 
NSAIDs to inhibit local response to trauma or prevent stimulation of 
nociceptors. Nerve blocks or cryoanalgesia can be used.
2- At spinal level, intervention of pain can be accomplished using 
stimulation techniques or spinal injections of opioids, local anesthetics. 
Opioids and psychotropic agents can alter centeral processing of pain 
impulses. In case of opioids-insensitive pain, many drugs can be used such 
as corticosteroids, antihistamine, antiemetics, muscles relaxant, anti 
psychotics phenothiazines and calcium regulatory agents. These are used in 
bone pain, nausea, vomiting, and pain due to increase intraocular pressure.
2- Physiotherapy, nervous system stimulation, surgery, acupuncture and 
radiation could be used for management of chronic pain.
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In general, analgesic drugs for treatment of pain can be divide into
1- Non-opioids analgesics included NSAIDs which are suitable for use in acute 
and chronic pain (APS, 1990).
2- Opioids analgesics like morphine which is strongest opioid of choice. It has 
short half-life with many side effects particularly respiratory depression and 
dependence.
6.6.7. NSAIDs analgesia
It has been shown that the most frequent prescribed treatment for pain is 
NSAIDs (Gurwitz et al. 1994). NSAIDs have been used widely for treatment 
of various types of pain such as musculoskeletal pain and visceral pain. In 
addition, they relieve pain in post-herpetic neurolgia, reflex sympathetic 
dystrophy, chronic neurogenic pain and mechanical hyperalgesia induced by 
capsaicin (King 1988, Farah 1993, Tharison and Bhattachrgi 1997). The 
increase use of NSAIDs to treat pain is due to:
1- Lack of unwanted affects of opioids on CNS like respiratory depression 
and addiction (Cohen 1980)
2- NSAIDs may desensitize the nociceptors indirectly by inhibition of 
prostaglandin synthesis or by a direct action on the nociceptors (Conory et 
al 1991).
3- NSAIDs have prophylactic effects of pain ( Mattila et a l 1983).
The analgesic and anti-inflammatory potencies of NSAIDs are not 
simply the reflection of a common mechanism, namely inhibition of 
peripheral prostaglandin synthesis but also through many other peripheral and 
central mechanisms of actions (Dahl and Kehlet 1993). NSAIDs decrease 
significantly substance P and NKA response (Thorboll et al 1998). Inhibition 
of COX-2 represents the most likely mechanism of action for NSAIDs- 
mediated analgesia and all NSAIDs inhibit neutrophil function such as cell 
aggregation (Ku et al. 1982, Minta and Williams 1985). NSAIDs inhibit 
phosphodiesterase, resulting in an increase in intracellular cAMP and 
reducing release of known mediators contributing to inflammatory response ( 
Dahl and Kehlet 1991).
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There is increasing evidences that NSAIDs have central mechanism of 
action that augments the peripheral mechanism which may be result of 
interference with formation of prostaglandin in CNS (Cashman 1996). 
NSAIDs prevent the rise in CSF prostaglandin after activation of the NMDA 
receptors (Bjorkman 1995). It has been found that spinally administered 
NSAIDs has antinociceptive effects (Wang et al 1995). NSAIDs inhibit 
prostaglandin synthesis in the CNS mainly in the thalamus (Abdel-halim et 
al. 1978, Attal et al. 1988). NSAIDs may suppress the synthesis of 
prostaglandin because they easily cross the blood-brain barrier (Bannwarth et 
al. 1990). In addition, NSAIDs reduce both brain stem and spinal cord 
serotonin levels and activate descending serotoninogenic pathways to elicit 
antinociception (McCormack 1994). Pretreatment with NSAIDs has been 
shown to reduce hyperalgesia induced by NMDA activation as well as 
antagonize the hyperalgesia induced by spinal substance P and glutamate 
receptors (Malmberg and Yaksh 1992, Bjorkman 1995). It has been found 
that spinal NMDA receptors activation resulted in enhanced biosynthesis of 
NO from arginine and the anticiptive effects of NSAIDs may in part 
attributed to interference with endogenous NO activity at spinal cord 
(Bjorkman 1995). Moreover, NSAIDs may ameliorate or even abolish 
excitatory amino acid-directed gene expression by reducing NMDA induction 
of C-fos messenger RNA (McCormack 1994). Steroselective interference of 
G-protein-induced signals transduction by some NSAIDs may from the basis 
of an analgesic mechanism unrelated to inhibition of prostaglandin synthesis 
(Brune et al. 1991).
In general, NSAIDs have the following actions regarding pain relief:-
1- They have antipyretic, analgesic and anti-inflammatory actions.
2- NSAIDs have antinociceptive action and anti-inflammatory effects ( 
Huskaar et al. 1986)
3- The anti-inflammatory action is peripheral while the antinociceptive action 
is also centrally mediated (Malmberg and Yaksh 1992)
4- NSAIDs inhibit release of noradrenaline from sympathetic nerves ending 
and may inhibit the development of sympathetic pain (Hedqvist and 
Brundin 1969).
5- NDAIDs increase beta-endorphines (Martini et al. 1982)
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6.7. Pharmacokinetics and Pharmacodynamics of Prostaglandin 
Synthesis Inhibitors
6.7.1. Basic Pharmacology
Pharmacokinetic is the study of what the body does to a drug. 
Pharmacodynamic is the study of what a drug does to the body. A constant fraction 
of the drug in the body is eliminated per unit time. The rate of elimination is 
proportional to the amount of drug in the body. The volume of distribution (Vd) is 
the amount of drug in the body divided by concentration in the blood. The Clearance 
(CL) of a drug is the volume of plasma from which the drug is completely removed 
per unit time. Elimination half-life (tl/2) is the time taken for plasma concentration 
to reduce by 50%. After 4 half, elimination is 94% complete. The rate of elimination 
is the clearance times the concentration in the plasma. Bioavailability is the fraction 
of the administered doses that reaches the systemic circulation. Thus one plot plasma 
concentration against time, and the bioavailability is the area under the curve. The 
maintenance dose is equal to the rate of elimination at steady state (at steady state: 
rate of elimination=rate of administration). Many drugs are metabolized by the liver. 
The rate of elimination depends on
1- The liver ability to metabolize the drug
2- The amount of drug presented to the liver for metabolism
The drugs administered orally are delivered from the gut to the portal vein to the 
liver. Higher dose is needed when drug was delivered orally than intravenously.
Drug distribution depends on blood flow and protein binding. More highly bound 
drugs have a longer duration of action and a lower volume of distribution. An 
unbound drug is generally considered responsible for pharmacological effects.
6.7.2. Types of the investigated drugs
Drugs investigated in the thesis are listed in the figure 10. The drugs have 
inhibitory effects on prostaglandin synthesis and activities. In addition, they have 
effects on NO and neuropeptide production, calcium influx, smooth muscle 
contraction, antidiuretic hormone activity and water metabolism besides their central 
effects. The importance of these properties are discussed in relation to their
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Types of Drugs
Potent PGSI, NSAIDs
Short acting 
NSAIDs 
Indomethacin 
Diclofenac sodium
Long acting 
NSAIDs 
Tenoxicam 
Piroxicam
Tested in:
1 — Acute renal colic
2 -  U rinary culculus
3 -  Recurrent renal colic
4 -  Effects on renal function test.
PGSI, Nifedipine(calcium 
antagonist)
Tested in:
1 -  Acute renal colic
2 -  U rinary culculus
3 -  Recurrent renal colic
4 -  Effects on renal function
test.
Figure 10; D ru g  tested  in ren a l colic a n d  urinary ca lcu lu s, P G IS :  
P rostaglandin  syn th esis inhibitor
Types of Drugs
Potent PGSI PGSI
(NSAIDs) Carbamazepine
Diclofenec sodium 
Indomethacin
Figure 11; D ru gs tested  in p r im a ry  enuresis a n d freq u ec y  o f  m icturition . 
P G S I: P rostag landin  Synthesis Inhibitor.
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therapeutic effects in primary enuresis, frequency of micturition, pain of renal colic, 
pain recurrence and urinary calculus.
6.7.3. NSAIDs
6.7.3.1 Classification of NSAIDs
The currently available NSAIDs can be grouped in six major chemical classes 
(Table 4). However, based on recent studies, it has now become possible to classify 
NSAIDs on the basis of their relative selectivity for two isoforms of COX enzyme. 
Older NSAIDs such as indomethacin, piroxicam, tenoxicam, mefenamic acid are 
non-selective inhibitors of COX enzyme. Recently, number of new agents have been 
discovered which selectively inhibit the activity and / or gene expression of COX-2. 
These agents include nemsulide, meloxicam, and celecoxib. Moreover, NSAIDs can 
be classified into long acting or short acting NSAIDs according to their half-life.
6.7.3.2. Phamacokinetics
NSAIDs are among the most frequently prescribed medication (Roth et a l 
1988). Among NSAIDs users, 40% to 60% are over 60 years of age (Gurwitz & 
Avorn 1991). Absorption of NSAIDs is generally complete after oral administration 
and they are absorbed via passive diffusion (Kean and Buchanan 1987). H2 
antagonist, antacids and proton pump inhibitors will elevate gastric pH, altering 
gastric absorption of NSAIDs. They are weakly acidic, lipophilic and bound 
extensively to plasma albumin. Most NSAIDs are metabolized by hepatic oxidation, 
hepatic conjugation or both. Their plasma elimination half-life varies widely from 
0.25 to 70 hr. No correlation has been found between NSAIDs adverse effects and 
half-life (Albengers et a l 1988). In case of short half-life NSAIDs, an increase in 
administration frequency could be expected. Some NSAIDs undergo enterohepatic 
re-circulation and some experimental evidence identifies biliary excretion as 
important in the pathogenesis of NSAIDs entropathy (Wax et a l 1970). A summary 
of pharmacokinetics of NSAIDs used in our studies is illustrated in the table 5.
62
Salicylic acids and esters :
Aspirin , salicylates , salicylamide , salsalate , d iflun isa l, benorylate.
Propionic acids:
Ibuprofen , fenoproten , naproxen , ketoprofen , piprofen , flubiprofen , oxaprozin, 
ca rp ro fen , suprofen.____________________________
Acetic acids:
Indomethacin , tolmetin , sulindac , diclofenac , etodolac , zomepirac
Fenamates:
M eclofenamate , mefenamic acid , flufenamic acid
Enolic acids:
Oxyphenbutazone , phenylbutazone , piroxicam , sudoxicam , isoxicam , tenoxicam , 
droxicam________________
Naphthylkanones, nonacidic compounds:
Nabum etone , proquazone , bufexamac
Table (4): Classification of NSAIDs.(Wen,S.( 1997) Nephrotoxicities ofnonsteriodal anti­
inflammatory drugs. J Formos Med Assoc, 96, 157-171).
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Drugs Bound in Plasma 
(% of plasma 
total)
t Y i B
<h)
Vd
(L/kg)
CL/F
(L/h/kg)
Renal 
exccretion 
(% unchanged)
Primary
metabolic
Pathways
Biliary excretion 
(% of total drug)
Diclofenac 99.7 1-2 0.12 0.22 < 1 Oxidation 10-20
Indomethacin >90 4.5-6 0.12 0.0024 60-70 Oxidation,
conjugation
Extensive
Tenoxicam 98.5 60 0.12 0.102/10kg Insignificant Oxidation 0
Piroxicam >99 30-86 0.12 0.0024 <5 Oxidation 0
Meloxicam 99 13-20 0.1-0.2 0.0072 <0.25 Oxidation Extensive
Carbamazepin 74 15 1.4 0.076 1 conjucation 0
Nifedipine 96 1.8 0.42 0.78 0 Oxidation 0
CL/F- oral clearance^ Vi B = elimination half-life ; Vd = volume of distribution.
Table 5: The pharmacokinetic properties of the drugs used in the study.
(Braterl988, Verbeeck 1988, Verbeeck 1990, Sorkin 1995, Holford and Benet 1998, Martindela 1998, Davies & Skjodt 2000).
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6.7.3.4. Pharm acodynam ics
1- Mode of Action
(1) All NSAIDs appear to inhibit prostaglandin synthesis by blocking COX activity,
both COX-1 and COX-2, by binding reversibly or irreversibly to the enzymes 
(Sharma & Sharma 1997).
(2) Part of the action of NSAIDs may be related to a decrease in the generation of 
superoxide and hydroxyl free radicals (Ikeda et al. 2001).
(3) NSAIDs are antihyperalgesic through a direct action on the spinal cord or 
inhibition of prostaglandin synthesis in CNS (Cashman 1996).
(4) Interference with G-protein-mediated signal transduction by NSAIDs may form 
the basis of an analgesic mechanism unrelated to inhibition of prostaglandin 
synthesis (Cashman 1996).
(5) Epidural application of NSAIDs affects hyperalgesia produced by NO and dose- 
dependently suppressed nitroglycerine-induced thermal hyperalgesia (Masue 1999).
(6) Inhibition of calcium influx is another mechanism of action of NSAIDs, which is 
not related to inhibition of prostaglandin synthesis (Kankaaranta 1996).
(7) Inhibition of neutrophil activation might represent another mechanism of action 
of NSAIDs (Altman 1990).
2- Anti-inflammatory effects
The cardinal signs of inflammation develops as an acute response to a local 
inflammatory mediators such as prostaglandins, NO, bradykinins, histamine and 
complement (Garrison 1990, Moncada et al 1991). Prostaglandin is produced during 
inflammatory responses, and increased levels of prostaglandins help mediate some of 
cardinal signs of inflammation such as pain, oedema, fever and erythemia (Coleman 
et al. 1994).
NSAIDs inhibit prostaglandin productions, interfere with chemical mediators of 
kallikrienes system, inhibit NO, inhibit granulocytes adherence to damaged vascular 
tissues, stabilize lysosomes and inhibit migration of leukocytes and macrophages into 
the site of inflammation (Katzung and Furst 1998). Therefore, NSAIDs possess 
strong anti-inflammatory properties. It has been shown that a selective COX-2
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inhibitor attenuated prostaglandin and thromboxane production in a skin 
inflammation (Smith et al. 1998).
3- Antipyretic effects
NSAIDs reduced elevated temperature. Elevated temperature is due to 
production of prostaglandin in the CNS, and effect of interleukiene-1 on the 
hypothalamus. NSAIDS inhibit interleukiene-1 and prostaglandins.
4- Analgesic effects
NSAIDs have a potent analgesic action in different types of pain. They have 
been used for treatment of acute and chronic pain, somatic and visceral pain. The 
mechanism of action was discussed in the section 9. More recently, it was suggested 
that the analgesic actions of NSAIDs in inflammatory pain, especially visceral 
stimuli, are mediated to a significant degree by inhibition of signaling through EP1 
receptors (Stock et al. 2001).
5- Platelet effects
NSAIDs, particularly aspirin, might affect homeostasis. Single dose of 
aspirin produces a slight prolonged bleeding time. This is due to inhibition of 
thromboxane synthesis (Katzung and Furst 1998).
6- NSAIDs Effects on Renal Functions
NSAIDs have many effects on the kidney functions (Table 4). NSAIDs may 
possess receptor-mediated mineral corticoid activity to account for their salt- 
retaining effect (Feldman & Couropmitree 1976). The most efficacious NSAIDs 
seem to inhibit renal prostaglandin synthesis by only 60 to 80%, a large amount of 
renal prostaglandin synthesis remains intact (Patrono & Pieruccii 1986). NSAIDs 
treatment reduces the hyperfiltration, hyperperfusion and vascular glomerular lesions 
associated with hypertension and diabetes mellitus (Zambraski 1995). NSAIDs were 
used successfully to reduce urinary protein excretion in proteinuric renal diseases 
(Ganservoor et al. 1992; Remuzzi & Remuzzi 1995). Inhibition of endogenous 
prostaglandin production by several COX inhibitors caused a reduction of inducible 
NO synthase (Minghetti et al. 1997).
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Prostaglandins mediate chronic inflammatory processes and increased 
synthesis of these compounds may contribute to the pathogenesis of the progressive 
nephropathy associated with renal mass reduction (Fujihara et al. 1998). Abnormal 
high synthesis of prostaglandins is seen in renal interstitial inflammation 
(Vriesendrop et a l 1986). Chronic treatment with specific thromboxane inhibitors 
ameliorates glomerular injury (Zoja et a l 1990). Chronic NSAIDs treatment may 
ameliorate progressive nephropathies, glomerular proteinuria and tubular defects 
such as Fanconi syndrome and Batters syndrome (Usberti et al 1985; Fujihara et a l 
1998). NSAIDs with short or long half-life do not decrease renal functions in 
individuals without renal impairment (Lang et al. 1991). They aided in amelioration 
of cyclosporin toxicity and in prevention of explanted kidneys being prepared for 
transplantation (Winchester 1996).
Aspirin has beneficial effects in treatment of some glomerulonephritis such as 
diabetic nephropathy, pregnancy-induced hypertension and renovascular 
hypertension and it ameliorates cyclosporin toxicity in transplanted kidney 
(Winchester 1996). NSAIDs reduce hyperfiltration, hyperperfusion and vascular 
glomerular lesions associated with the hypertensive state (Zambraski 1995). 
Thromboxan inhibitors decreased significantly macroalbuminuria in diabetic patients 
(Tajiri et al 1990). NSAIDs-nephropathy including acute nephritis, minimal change 
nephropathy, membranous glomerulonephritis, may be caused by hypersensitivity 
(Ravnskov 1999).
7- Other effects
In addition to the main uses of NSAIDs in musculoskeletal disorders, gout, 
rheumatic diseases, NSAIDs, particularly aspirin, are showing promise in the 
chemoprevention of colorectal and oesophageal cancer (Morgan 1999). Recently we 
demonstrated that tenoxicam is safe and effective to treat biliary colic and to prevent 
complications, particularly cholecystitis (Al-Waili 1998). In paediatrics, NSAIDs are 
used in the treatment of childhood rheumatic diseases and other chronic 
inflammatory conditions, symptomatic treatment of fever, or musculoskeletal pain, 
and in induction of patent ductus arteriosus (Lindsley 1993). We and others found 
that NSAIDs are useful in the treatment of menstrual disorders, migraine,
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postoperative pain, polyhydraminos, premature labour, chorionic carcinoma and skin 
cancer (Al-Waili et al 1985, Al-Waili and Subhi 1988, Al-Waili and Khalaf 1990, 
Al-Waili and Saloom 2000, Al-Waili 2001, Al-Waili 2001).
6.7.3.5. USES OF NSAIDs
1- Fever
2- Gout
3- Headache
4- Hypersensitivity such as conjunctivitis and rhinitis
5- Malignant disorders. Regular use of aspirin may reduce the risk of 
development of fatal cancer of the esophagus, stomach, colon or rectum 
(Thun 1993). We used NSAIDs to treat skin cancer and chorionic 
carcinoma ( Al-Waili et al. 1985, Al-Waili 1988)
6- Menstrual disorders such as dysmenorrhoea, menorrhagia, premenstrual 
syndrome. We have used NSAIDs to treat severe primary dysmenorrhoea 
(Al-Waili and Khalf 1990, Al-Waili 2001).
7- Migraine and menstrual migraine. We used NSAIDs to treat acute attacks 
of classical migraine or menstrual migraine (Al-Waili and Saloom 2000, 
Al-Jabouri and Al-Waili 2001,).
8- Orthostatic hypotension
9- Musculoskeletal and joints disorders.
10- Pain due to renal or biliary colic and postoperative pain. We used NSAIDs to 
treat acute biliary colic and postoperative pain (Al-Waili and Saloom 1998, Al- 
Waili 2001)
11- Kidney disorders
1- Use for control of proteinuria due to nephrotic syndrome. We used 
indomethacin to treat steroid-dependent nephrotic syndrome (Al- 
Waili 1988).
2- Use as anti-platelet aggregation agent in mesangiocapillary 
glomerulonephritis.
12- Attenuation of suxamethonium-induced myalgia (Naguib et al. 1987).
13- Partner drug for antibiotics to inhibit the inflammatory response to bacterial 
death caused by antibiotics (Qualiarello and Schield 1992)
14- Prophylaxis of thromboembolic complications (Schroder and Schror 1992).
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1- The most common side effects during treatment are gastrointestinal 
disturbances such as gastrointestinal ulcer and bleeding (Cryer and Feldman 
1992)
2- CNS-related side effects such as headache, dizziness, depression and 
insomnia.
3- Hypersensitivity reaction as rash, fever or asthma. The later may be due to
block of the lipo-oxygenase pathway and more leukotrienes released (Schror 
1984).
4- Haematological side effects such as anemia, thrombocytopenia or 
neutropenia.
5- Some NSAIDs cause nephrotoxicity mainly phenacetin. High doses of 
NSAIDs like indomethacin (10 mg/kg) decrease glomerular filtration rate and 
renal blood flow (Beilin and Bhattacharga 1975). However, the effect of 
inhibition on renal prostaglandins is slight in normal situation (Dunn 1984). 
In stress like hypovolaemia, hypotension or cardiac failure in which high 
concentration of catacholamines and angiotensin causes vasoconstriction, 
renal blood flow is dependent on prostaglandin (Dunn 1984). Patients with 
such stress are at risk from NSAIDs side effects in addition to patients with 
dehydration, cirrhosis or sepsis (Harris 1992, McDonald 1994). NSAIDs 
cause salt and water retention particularly when there is preexisting 
hypertension or sodium depletion (Harris 1992). NSAIDs may cause acute 
interstitial nephritis, perhaps involving an allergic response (Whelton and 
Hamilton 1991). General precautions to be obtained include administration to 
patients with acute peptic ulcer, asthma, history of hypersensitivity to 
NSAIDs, impaired renal, hepatic and cardiac functions. NSAIDs enhance the 
effects of oral anticoagulant and reduce the antihypertensive effects of bet- 
blockers and diuretics.
Some of the effects of NSAIDs on the urinary systems are demonstrated in 
the table 6.
6.7.3.6. Side effects of NSAIDS
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Decrease renal blood flow, glomerulr filtration 
rate, and sodium excretion
Tannenbanum et al. 1996
Decrease aldosterone Whelton & Hamilton 1991
Increase antidiuretic hormone. Whelton & Hamilton 1991
Increase chloride uptake by loop of Henle. Kirchner 1985
Inhibit calcium mobilization. Jermy et al. 1982
Inhibit spinal nitric oxide & reduce hyperalgesia Masue et al 1999
Decrease proteinuria Remuzzi & Remuzzi 1995
Decrease urinary stone recurrence Schlichter & brudig 1990
Inhibit nitric oxide. Sakitani et al 1997
Inhibit isoproterenol-induced bladder 
contraction
Bolle et al. 1994
Decrease urinary bladder response to Ach Meggi et al 1984
Cause smooth muscle relaxation Perez vallina et al 1995
Cause sodium retention Zambrski 1995
Table 6: Some actions of NSAIDs on urinary system.
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6.7.3.7. Nonselective Prostaglandin Synthesis Inhibitors
6.7.3.7.1. Short Acting NSAIDs
6.7.3.7.1.1. Indomethacin
Pharmacokinetics
Indomethacin, an indole acetic acid derivative (l-(p-chlorobenzoyl)-5-methoxy- 
2-methylinedole-3-acetic acid), is one of the strongest inhibitors of COX pathways 
like diclofenac sodium (Menasse et a l 1978). It inhibits COX in a competitive 
reversible manner (Stanford et a l 1977).
Indomethacin is a NS AID that was introduced into clinical practice in the early 
sixties. It is readily absorbed from the gastrointestinal tract in adults and the peak 
plasma concentration is reached a bout 2 hour after a dose. Absorption may be 
slowed by food or aluminum or magnesium containing antacids. The bioavailability 
of rectal suppositories in adult has been reported to be comparable with or slightly 
less than the bioavailability of indomethacin after oral dosage forms. The 
bioavailibility of indomethacin after oral or rectal use is about 80% (Martindale 
1996). The time until maximum concentration after oral or rectal application varies 
between 30 min and 4 hours (Turakka and Airaksinen 1974, Hellberg 1981, Moller 
and Grenabo 1985). The main terminal half-life of indomethacin is 5-7 hours after 
oral, i.v., i.m., or rectal administration (Hellberg 1981, Moller and Grenabo 1985). 
Plasma clearance of indomethacin is 1-2.5 ml/min (Helleberg 1981). Indomethacin is 
metabolized in the liver. Up to 100% of indomethacin is entrohepatically recycled 
(Helleberg 1981). Excretion of indomethacin and its metabolites is predominantly in 
the urine (60%) and in the faeces (40%) (Helleberg 1981). About one sixth of 
indomethacin is excreted into the urine in the unchanged form (Baber et a l 1979). 
About 99.7% of indomethacin is bound to plasma protein, especially albumin 
(Martindale 1996). Indomethacin is easily cross blood brain-barriers and can be 
detected in CSF 30 min after i.m injection (Bannwarth et al. 1990). It has been found 
that peak plasma concentrations of indomethacin occurred 20 min after 
administration of rectal solution, 40 min after intramuscular and 60 min after 
suppositories. The availability after the two rectal forms was found to be almost the 
same, 80% (Jensen and Grenabo 1985). Rectal administration is associated with
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earlier peak plasma concentration. Watanabe et al. 1993 found that plasma reached 
the maximum level at 30 min after rectal administration. No histological changes of 
the rectal mucosa were found with multiple treatment with indomethacin 
suppositories (Ogiso et al. 1984). The total daily combined dose by mouth or rectum 
should be not exceeding 200 mg.
Uses of Indomethacin
Indomethacin is used widely in musculoskeletal and joints diseases and in 
disease other than musculoskeletal disorders and pain. It is used in the treatment of 
fever, gout, headache, hypersensitivity, malignant neoplasm, othostatic hypotension, 
patent ductus arteriousus, eye disorders, polyhydraminos, premature labour (Searle 
1990, Johnson 1993, Murphy and Medlry 1993, Merchant and Sakhalkar 1994, Al- 
Waili and Khelood 2001, Al-Waili and Al-Jabouri 2001). Others and we have found 
that indomethacin suppository is effective in inhibiting uterus contractions and 
delaying delivery in-patients in preterm labour (Johnsson 1993; Al-Waili 2001). We 
have used indomethacin to treat advance chorionic carcinoma and basal cell 
carcinoma (Al-Waili et al. 1984; Al-Waili 1989). Indomethacin has been used to 
treat patients with glomerulo-nephritis and the treatment proved effective in 65% of 
the patients (Doreskyi 1991). It has been shown that normotensive patients with 
chronic glomerulonephritis, but with preserved renal function, have no increased risk 
of acute deterioration of renal function during administration of indomethacin 
compared with healthy individuals (Nielsen et al. 1994). Improvement in diurnal and 
nocturnal frequency was obtained with use of indomethacin in patients with detrusor 
instability (Cardozo & Stanton et al. 1980). The use of indomethacin in children with 
daytime urinary frequency was associated with significant increase in urine 
osmolality and urine pH, and decrease in urine sodium and potassium levels (Luo 
1992). Indomethacin suppository is considered to be favorable agent in reducing 
polyuria in diabetes insipidus (Fujii et al. 1985).
Pharmacodynamic
Indomethacin is a non-specific COX1 / COX-2 inhibitor (Catella-Lawson et 
al. 1999). It reduces PGE2 urinary excretion (Stockes et al. 1997; Angnoli et al.
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1999). Indomethacin inhibits IL-1 and NO production (Du & Li 1999). This explains 
the beneficial effect of indomethacin on Alzheimer’s diseases.
Indomethacin prevents intrathecal PGF2 alpha—induced hyperalgesia (Taiwo 
& Levine 1986). In the kidney, indomethacin blocked the increase in afferent renal 
nerve activity and release of substance P and prostaglandin produced by increased 
ureteral pressure (Kopp et al 1996). Indomethacin stimulates circulating antidiuretic 
hormone levels and enhances peripheral antidiuretic hormone effects (Walker et al 
1994). It also inhibits renin release (Lijnen et al 1991; Olsen et al 1999). 
Indomethacin decreases mean urinary excretion of PGE2 by 73% and 80% and 
excretion of sodium (Prescott et al 1990).
Indomethacin reduces arterial natriuretic peptide-induced sodium excretion and 
creatinine clearance by 75% (Villarreal et al 1997). It decreases fractional Mg 2+ and 
calcium excretion (Dai et al 1998). Indomethacin completely abolishes NPY- 
induced diuresis and natriuresis (Bischoff et al 1998). It reduces the smooth muscle 
activity of human renal pelvis and upper urinary tract (Zwergel et al. 1990). 
Indomethacin stops spontaneous rhythmic human ureteric contraction that was 
reactivated by PGF2 alpha (Sahin 1993).
Indomethacin i.v. reduces renal pelvic pressure (Zwergel et al 1991). Motility 
of isolated ureteral preparation obtained from patients at surgery was dose- 
dependently inhibited with indomethacin (Angelo-Khattar et a l 1985). Indomethacin 
causes significant reduction of calcium excretion (Hirayma et a l 1988). 
Indomethacin decreased proteinuria, glomerular filtration rate, plasma renin activity 
and renal PGE2 excretion in nephrotic syndrome. The effects might be due to 
inhibition of renal prostaglandin synthesis and by lowering transcapillary glomerular 
hydraulic pressure (Vriescendorp et al 1986). Indomethacin potentiates the 
antiproteinuric effect of blocking angiotensin 11 without impairment of renal 
function (Perico et al 1998).
Some effects of indomethacin on the urinary systems are demonstrated in the 
table 7.
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Actions References
Inhibits COX-l/COX-2 Catella-Lawson et al. 1999
Decreases renal blood flow and angiotensin II. Frokiaer et al. 1993
Causes mesangial contraction. TerBor;? et al 1989
Decreases renal pelvic pressure. Zwergel et al. 1991
Decrease polyuria Fujii et al 198
Decreases frequency of micturition Luo 1992
Decreases proteinuria Vriescendrop et al. 1986
Decreases calcium & magnesium excretion Dai et al. 1998
Decreases sodium excretion Prescott et al. 1990
Inhibits rennin release Lijnen et al. 199
Decreases atrial natriuretic factor induced Villarreal et al. 1997
sodium excretion
Stimulates antidiuretic hormone Walker et al. 1994
Decreases urinary prostaglandin excretion Stockes et al. 1997
Inhibits NPY-diuresis & natriuresis Bischoff et al. 1998
Decreases renal pelvic pressure Zwergel et al. 1991
Decreases calcium excretion Buck et al. 198
Blocks release of substance P Kopp et al. 1996
Blocks ATP-bladder contraction Husted et al. 1980
Stops ureteric contraction Sahin 1993
Inhibits bradykinin & bladder contraction Nakahata et al. 1987
Decreases histamine release from ureter Nakata et al. 1998
Inhibits nitric oxide & IL-1 Du & Li 1999
Inhibits calcium channel Sawdy et al. 1998
Inhibits renal hypoxic damage. Kim et al. 2000
Table 7: Some effects of indomethacin on the urinary system
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Side effects
The main side effects of indomethacin are gastro-intestinal disturbances, 
headache, vertigo, drowsiness, tinnitus, skin rash, stomatitis, and rectal irritation. 
Renal and hepatic lesions have been reported in patients given indomethacin. Other 
side effects were occasionally reported such as pruritis, skin rash, alopecia, 
hypersensitivity reaction, syncope or psychiatric disorders (Boiskin 1987, Sheehan 
1989, Weir 1991).
6.7.3.7.I.2. Diclofenac Sodium
Pharmacokinetics
Diclofenac sodium (sodium (O-(2,6,-dichorophenol)-amin0)-phenyl)- 
acetate) is one of the strongest inhibitors of the COX pathway in clinical use. It is as 
potent as indomethacin and many times stronger than acetylsalicylic acid (Menasse 
et a/. 1978). Diclofenac is rapidly absorbed when given as an oral formula, i.m. 
injection or rectal suppository. 99% bound to plasma proteins. The terminal plasma 
half-life is about 1 to 2 hours. Peak plasma concentration is 3 h after oral 
administration as compared to 20-30 min after intramuscular injection of 75 mg. 
(Kurowski 1988). The peak plasma concentration is reached within 0.6 h after rectal 
administration (Landsdrop et al. 1990). Two hours after intramuscular of 75 mg of 
diclofenac sodium it could be detected in CSF (Zecca et al. 1991). After intravenous 
infusion, terminal half-life was 78 min (Willis et al. 1979). It is subjected to first pass 
metabolism after oral administration so that about 50 % of the drug reaches 
circulation in the unchanged form. The main metabolites of diclofenac sodium which 
account for 40% of all products of biotransformation, displays as antioedematous 
effect about 30 times less that that of the diclofenac sodium (Mensass et al 1978). 
Diclofenac sodium is excreted in the form of glucuronide and sulphate conjugate, 
mainly in the urine, about 65%, and also in the feces, about 35% (Fowler 1983). The 
mean clearance in children, 7.7 ml/kg/min, was twice as long as in adults (Korpela 
and Olkkola 1990).
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Pharmacodynamics and Uses
It inhibits prostaglandin synthetase competitively and irreversibly (Ku et al. 
1975). Diclofenac is used mainly as the sodium salt for the relief of pain and 
inflammation in various conditions, gout, eye diseases, fever, pain. We found that 
diclofenac sodium 75 mg intramuscularly could alleviate post-caesarean pain and 
reduce the use of opioids (Al-Waili 2001). In addition we have used diclofenac 
sodium to treat tonic clonic epilepsy (Al-Waili 1988). Diclofenac sodium has been 
used for treatment of renal and biliary colic (Grossi 1986, Lundstam 1987, 
Hetherington and Philp 1986; Sanahuja 1990). It is available in a number of 
administration forms, which can be given orally, rectally or intramuscularly.
Diclofenac sodium decreases the spontaneous phasic activity of renal 
pelvic smooth muscle (Lundstam et al. 1985). Diclofenac as indomethacin, abolish 
almost completely the contractile response of ureteric muscle to electrical field 
stimulation (Cole et al. 1988). Diclofenac sodium as well as indomethacin exerts a 
direct protective effect against the hypoxia/ re-oxygenation induced renal cell injury 
(Kim et al. 2000). The usual dose by month is 75 to 150 mg of diclofenac sodium 
daily in divided doses. It may be also given by deep i.m. injection into gluteal muscle 
in a dose of 75 mg once or twice daily. When administered intramuscularly it is at 
least comparable to, and frequently superior to, many narcotic and spasmolytic in 
conditions such as renal and biliary colic. It is suggested that i.m injectable 
diclofenac sodium provide fast drug liberation suitable for acute analgesic treatment 
(Kurowski 1988). It is well tolerated compared to other NSAIDs and rarely produced 
gastrointestinal ulceration or other serious side effects (Todd and Sorkin 1988). It has 
no effects on carbohydrate metabolism, insulin levels or tolbutamide metabolism. It 
does not affect the individual clotting factors (Fowler 1979).
Side effects
The most frequently reported adverse effects were gastrointestinal, 
CNS-related side effects, allergy or local reactions (Small 1989). Gastrointestinal 
side effects were reported in 7.6% of patients. CNS adverse effects were reported in 
0.7 %, and allergy or local reaction in 0.4% (Willkens 1985). The side effects of 
diclofenac sodium are usually mild and transient (Small 1989). At higher
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concentration, diclofenac sodium also reduces the formulation of products of 
lipoxygenase like leukotrienes (Ku et al 1986).
6.7.3.7.2. Long Acting NSAIDs
6.7.3.7.2.I. Tenoxicam
Pharmacokinetics
Tenoxicam is a thienothiazine derivative of the oxicam class of NS A TPs, 
which is a piroxicam analogue. It is a weak acid. It is entirely ionized at 
physiological pH, has minimal lipophilic properties, high plasma protein binding, 
and does not accumulate in fatty tissues and skin. Tenoxicam disposition is not 
influenced by age, sex or diseases (Guentert at al. 1987). The pharmacokinetic 
behaviour of tenoxicam after oral, i.m or i.v administration does not differ, with 
exception that higher plasma concentration was reached during the first 2 hours after 
the parental dose. After both i.m and i.v applications, tenoxicam showed a rapid 
onset of action and reliable improvement of pain states (Jenuet et al. 1989). It is well 
absorbed following oral administration and peak plasma concentrations occur in 1 to 
2 hours. The bioavailability of oral tenoxicam was 97% (Heinz et al. 1984). Intake of 
food delays absorption. It has been found that peak plasma concentration occurred in 
1 to 2 hrs in fasting patients and in 4 to 6 hrs when tenoxicam is given with food 
(Guentert 1994, Nilsen 1994). 98.5% of tenoxicam is protein bound. Plasma 
elimination half-life is about 60 to 75 hours. Tenoxicam is completely metabolised to 
inactive metabolites, which are excreted in the urine. The two main metabolites, the 
inactive 5-hydroxy and 6-0-glucumidated forms, are excreted in urine and bile 
respectively. Urinary and fecal excretion of unchanged form is less than 1% of the 
administered dose (Dell et al. 1984). No significant differences have been 
demonstrated in either single or multiple dose pharmacokinetics of tenoxicam in 
healthy individuals, patients with renal or hepatic failure, or elderly (Crevoisier et al. 
1989b, Al-Ghamdi et al. 1992). No dosage adjustments seem justified for those 
patients on basis of pharmacokinetics (Heintz 1995). Tenoxicam has a low potential 
to interact with diuretics, hypoglycaemic drugs, anticoagulants and H2-antagonist 
(Heintz and Gunter 1987). No clinical or pathological evidence of haematological 
impairment following intravenous administration of tenoxicam was recorded (Jones
2000). After intravenous of 20 mg, the plasma clearance was low with values from
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1.3 to 4.2/min and the volume of distribution was small averaging 20-40% of the 
total body weight. The median half-life of elimination from the body was 72 hrs 
(Heintz et al. 1984). Administration of 20 mg intravenously, intramuscularly or 
orally revealed no difference in the half-life of tenoxicam (Jeunet et al. 1989). 
Stebler and Guentert found that after i.m administration, tenoxicam was more rapidly 
absorbed compared to the oral dose while peak concentration was similar. It is 
completely absorbed after i.m administration and slowly eliminated (Scaglione et al 
1993).
Pharmacodynamic and Uses
Tenoxicam has anti-inflammatory, analgesic and antipyretic properties. It also 
inhibits platelet aggregation and neutrophil activation and may act as scavenger for 
active oxygen radicals at site of inflammation (Maffei-Facina et al. 1996). The 
principal pharmacodynamic effect of tenoxicam appears to be related to inhibition of 
COX and subsequent prostaglandin production (Bradshaw et al. 1984; Konig et al. 
1987). Tenoxicam inhibits a number of leukocyte functions including phagocytosis 
and histamine release and inhibits also leukotrienes B4 and C4 and PGE2 release 
(Konig et al. 1987; Todd & Clissold 1991).
It is indicated for musculo-skeletal disorders (Caughey & Waterworth 
1989; Marcolongoz & Fioravanti 1991). Recently, others and we found that parental 
tenoxicam is a potent for postoperative pain, acute biliary colic and prevention of 
acute cholecystitis (Elhakim and Nafie 1995; Al-Waili 1997; Al-Waili & Saloom 
1998).
Side effects
The majority of side effects of tenoxicam relates to gastrointestinal tract, nervous 
system or skin (Todd and Clissold 1991).
6.7.3.7.2.2. Piroxicam 
Pharmacokinetics
Piroxicam is well absorbed after oral administration, reaching levels with 
about 2-3 hours and 5-6 hours after a single rectal dose (Schaintarelli et al. 1981,
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Richardson et al. 1985). Food slows the rate of absorption after oral administration 
(Hobbs and Twomey 1979). Piroxicam has long half-life of 30 to 60 hours permitting 
administration once daily (Hobbs 1986). Piroxicam is highly bound to plasma 
protein, approximately 99% plasma protein bound, and has a volume of distribution 
of about 8 liters (Hobbs and Twomey 1979). Piroxicam is metabolized by 
hydroxylation and conjugation in the liver and no more that 5-10% of the dose is 
excreted as intact piroxicam in the urine (Hobbs 1993). Piroxicam levels are not 
elevated in patients with renal impairment and renal disease does not appear to alter 
pharmacokinetics of piroxicam (Woolf et al. 1983; Darragh et al 1985). In addition, 
the pharmacokinetic profile of piroxicam does not increase the risk of adverse 
reaction in the elderly (Hobbs 1986).
Pharmacodynamics and Uses
Piroxicam is prostaglandin synthesis inhibitors. Piroxicam is indicated for 
long-term use in the relief of signs and symptoms of the musculo-skeletal diseases. It 
is given in a usual dose of 20 mg by mouth daily as single dose and some patients 
require daily doses of 30 mg in single or divided doses (Martindale 1998). 40 mg of 
piroxicam was used for treatment of acute gout by oral, recta or i.m injection (Lee 
and Balfour 1994). Piroxicam can be used for treatment of dysmenorrhoea or 
postoperative pain (Saltveit 1985, Hutchison 1990). Piroxicam was reported to be 
superior to diclofenac and ketorolac to reduce post-operative pain following 
laporoscopy (O'Hanlon et al. 1996).
Side effects
Side effects are as for NSAIDs in general, and the most frequent adverse 
effects are gastro-intestinal. Piroxicam like diclofenac and indomethacin do not 
decrease renal function in individuals without renal impairment (Lang et al. 1991).
6.7.3.8. Selective COX-2 Inhibitor (Meloxicam)
Pharmacokinetics
Meloxicam is a new NS AID derived from enolic acid. Single and multiple 
dosing via oral, intravenous and rectal routs showed that meloxicam is almost
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completely absorbed and is bound to plasma protein by more than 99.5% (Turck et 
a l 1995). The highest concentration of meloxicam was seen in the kidneys and liver 
(Busch et al 1998). Elimination half-life is around 20 hrs, which is, reflected in a 
total plasma clearance of 7 to 8 ml/min. This indicates that meloxicam is suitable for 
once-daily administration (Turck et al. 1997). Intramuscular meloxicam have a more 
rapid onset of action than oral meloxicam in acute pain and local tolerance of i.m 
meloxicam was good and incidence of adverse effects was low (Euller-Zeigler et al
2001). Following i.m administration meloxicam was rapidly and completely 
absorbed while i.v administration resulted in higher plasma concentration than i.m 
injection (Najrjes et al 1996). Meloxicam is excreted in feces and urine and urinary 
excretion of unchanged is negligible (Schmid et al 1995). The metabolites detected 
in urine are biologically inactive (Poulsen Nautrup and Hortermann 1999). The 
pharmacokinetic of meloxicam was not substantially altered in patients with mild 
renal impairment (Boulton-Jones et al 1997). Neither renal adverse effects nor 
further deterioration in renal function test were reported (Boulton-Jones et al. 1997).
Dosage adjustment is not required in the elderly patients (Davis and Skjodt 1999).
Pharmacodynamics and Uses
Meloxicam has potent anti-inflammatory activity, together with good 
gastrointestinal and renal tolerability (Engelhardt et al 1996). Meloxicam is 
prostaglandin synthesis inhibitor and it causes selective COX-2 inhibition (Furst 
1997). COX-2 is the inducible isoenzyme implicated in the inflammatory response, 
whereas COX-1 has cytoprotective effects in the gastric mucosa. Meloxicam was 
well tolerated by patients with renal impairments (Boulton-Jones et a l 1997). 
Meloxicam has high anti-inflammatory potency and it inhibits swelling, bone and 
cartilage destruction and systemic signs of arthritis (Engelhardt 1996). It inhibits 
leucocytes migration and shows long-lasting anti-inflammatory and analgesic effect 
on inflammatory pain. Intramuscular meloxicam has rapid onset of analgesic action 
in arthritis, sciatica and lumbago (Euller-Ziegler et al 2001). Meloxicam was much 
better tolerated than diclofenac sodium in the treatment of acute pain associated with 
osteoarthritis (Valat et a l 2001). COX-2 inhibition reduced motility index 
(amplitude multiplied by frequency) in the upper urinary tract in a concentration- 
dependent manner (Davidson et al 2000).
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6.7.4. Carbamazepine
Pharmacokinetics
Carbamazepine is a complex drug that also possesses anticholinergic, 
antidiuretic, antiarrhythmic, muscle relaxant, antidepressant and neuromuscular- 
blocking proprieties. It administered orally. Absorption from gastro-intestinal tract is 
slow. Oral carbamazepine achieves therapeutic total carbamazepine level within 5 
hrs and was well tolerated by patients (Colen et al 1998). Mean maximum plasma 
concentration, time to reach maximum plasma concentration and half life for 
carbamazepine were 2.17 +/- 0.42 mcg/ml, 2.72 +/- 1.8 h and 11.67+/- 6.37 h 
respectively (Renaskar et al 1999). Estimation of plasma half-life of carbamazepine 
is 10-20 hr (Bertilsson and Tomson 1986). It is widely distributed throughout the 
body and is extensively bound to plasma protein (75%). Carbamazepine is 
metabolized in the liver. It is excreted in the urine in the form of its metabolites, 
carbamazepine 10,11-epoxide, 72% as unconjugated and only 3% as unchanged 
drug. The remainder is excreted in the feces. Carbamazepine appeared in beast milk, 
and is excreted in the urine and faeces and extensively bound to plasma protein. The 
mean half-life of carbamazepine on repeated administration is about 10 to 20 hr.
Pharmacodynamics and Uses
Carbamazepine is chemically similar to tricyclic antidepressants. By blocking 
postganglionic parasympathetic receptors, it exerts a potent anticholinergic effect on 
the detrusor muscles (Bissada et al 1979). Since carbamazepine is chemically 
similar to imipramine, it may increase bladder outlet resistance and enhance the tone 
of the internal urethral sphincter by blocking parasympathetic norepinephrine re­
uptake (Merrill and Markland 1972). In addition, it is a central nervous system 
depressant and can interfere with the spinal micturition reflex (Wein 1984). 
Carbamazepine promotes antidiuretic hormone secretion (Smith et al 1977). During 
carbamazepine treatment, the ability to excrete the oral water load was decreased, the 
urine / plasma osmolality ratio was higher, and free water clearance was lower 
(Soelberg & Hammer 1984). The use of carbamazepine was found to induce urinary 
retention in long-standing diabetes mellitus (Steiner & Bimanns 1993).
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Carbamazepme has water retaining propriety mediated by increased renal sensitivity 
to normal plasma concentration of arginine vasopressin and resetting of 
osmoreceptors (Stephens et al. 1978). Others reported that carbamazepine induced 
antidiuresis by release of antidiuretic hormone and impaired excretion of a water 
load (Perucca et al. 1978). Plasma osmolality and sodium concentrations were lower 
during carbamazepine administration (Soelberg, Sovemsen and Hammer 1984). 
Review states that although hyponatremia occurs in 10-15 % of patients taking
carbamazepine, it is seldom symptomatic or severe enough to cause fluid retention 
(Mucklow 1991)
Carbamazepine increased bladder capacity (Anders et al 1985). Because of 
its antidiuretic effect, carbamazepine has been used successfully to treat diabetes 
insipidus centralis. It caused considerable antidiuresis and altered sensitivity to serum 
osmolality by the hypothalamic osmoreceptors and increased sensitivity of renal 
tubules to circulating antidiuretic hormone (Rado et al. 1973; Vimla et al. 1983). In 
multiple scleroses, carbamazepine could suppress attack of urinary incontinence 
(Yoshimura et al. 1997). On the other hand, carbamazepine dose dependently 
reduces inflammatory exudates, substance P and PGE2 and it reduced hyperalgesia 
and oedema (Bianchi et al. 1995). In addition, it causes dose-dependent inhibition of 
both prostaglandin and NO (Matoth et «/.2000). It has been found that 
carbamazepine inhibited prostaglandin-induced hyperalgesia (Nakamura-Craig & 
Follenfant 1995). Carbamazepine induces hepatic microsomal enzymes and can 
accelerate its own metabolism or metabolism of other drugs. Drugs that can be 
potentially affected included prazequental, anticoagulants, corticosteroids, antifungal 
and cyclosporin (Hansan 1971, Bonay 1993, Quinn and Day 1995).
Carbamazepine is used in the management of epilepsy, neuralgia, manic 
depression, multiple sclerosis pain such as trigeminal neurologia, tinnitus, 
withdrawal syndromes, and psychiatric disorders (Murphy 1989; Guthrie 1989; 
Osterman 1976; Skelton 1988).
The suggested initial oral dose is 100 to 200 mg once or twice daily, 
gradually increased at weekly intervals. The usual oral dose in children is 10-20 mg 
per kg body-weight and suggested daily doses for children are: up to 5 to 10 years
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400 to 600 mg and 10 to 15 years: 600 mg to 1 gram daily (Martindale 1998). It has 
been used to promote ADH secretion (Seek 1989).
Side effects
The common side effects of carbamazepine are dizziness, drowsiness and 
ataxia. Gastro-intestinal side effects are less common which included dry mouth, 
nausea, vomiting, diarrhea and abdominal pain.
6.7.5. Nifedipine
Pharmacokinetics
Nifedipine is a dihydropyridine calcium-channel blocker with peripheral and 
coronary vasodilator properties. It is rapidly and almost completely absorbed from 
the gastro-intestinal tract after oral, rectal or sublingual administration (Kelly and 
Malley 1992). Following administration by mouth peak blood concentrations are 
reported to occur after 30 to 60 minutes with a half-life of 2 to 5 hours (Ruemsch and 
Sommer 1982). Peak plasma nifedipine concentrations were reduced when 
nifedipine capsules were given after a meal (Hirasawa 1985). 92 to 98% of 
nifedipine bound to plasma proteins and it goes extensive hepatic first-pass 
metabolism. Nifedipine undergoes complete hepatic oxidation to three 
pharmacologically inactive metabolites which are excreted in urine, and 30 to 40% of
the amount absorbed is metabolized during the first pass through the liver (Sorkin 
1985).
Bioavailability after oral administration is between 45 to 75 % and 70 to 
80 % of a dose is excreted in the urine almost entirely as inactive metabolites. During 
sublingual administration of nifedipine, the peak plasma concentration was larger 
than data obtained following swallowing administration (Palm-Aguirre et al 1989).
Pharmacodynamics and Uses
It has been found that calcium antagonists have inhibitory effects on 
phospholipase activity and prostaglandin synthesis (Danon et a l 1986). Nifedipine, a 
calcium antagonist, could inhibit phospholipase, prostaglandins and leukotrienes 
(Chang et al. 1987). It inhibited prostaglandin or leukotrienes in a dose-dependent
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manner (Levine 1983). In addition, nifedipine has anti-inflammatory properties and 
could attenuate inflammatory oedema and pain (Briukhanov et al. 1994; Sanchez et 
aLI " 8)- In renal tissues, it has been shown that prostaglandin synthesis in response 
to different stimuli is a calcium dependent process, which could be inhibited by 
nifedipine (Scharschmidt & Dunn 1983; Wuthrich & Vallotton 1986). Nifedipine 
exerted an antioxidant action and reduced blood serum PGF2 alpha in asthmatics 
(Amatum et al. 1992). Nifedipine decreased plasma TXB 2 and PG1 alpha 
concentrations in both smokers and non-smokers (Nakashima et al. 1990). Oral 
nifedipine attenuated development of inflammatory oedema in dose dependent 
manner (Briukhanov et al. 1994). Nifedipine suppressed carageenan-induced 
inflammation, an effect, which was potentiated when nifedipine was administered 
together with indomethacin (Madan et al. 1989). Nifedipine, verapamil and 
mdomethacin stop spontaneous rhythmic contractions of human isolated ureter 
(Sahin et al. 1993). The effect of a single 20 mg sublingual dose of nifedipine on 
function of proximal tubule of nephrone in patients with essential hypertension was 
studied. It induced an increase in diuresis, natriuresis and excretion of uric acid 
(Papek-Musialik 1994).
Nifedipine is a peripheral and coronary vasodilator and has little or no 
effect on cardiac conduction and negative inotropic effect is rarely seen. Its 
administration results in vasodilatation with reduced peripheral resistance, blood 
pressure and increased coronary blood flow, and a reflex increase in heart rate 
(Anonymous 1986). Nifedipine is usually given by mouth. Liquid-filled capsules 
with a rapid onset, but short duration of action have sometimes been used for 
sublingual or buccal administration (Storkin 1985). In the management of 
hypertension nifedipine may be given up to 20 to 100 mg once daily. In angina 
pectoris, nifedipine may be given in a dose of 10 to 40 mg twice daily or 30 to 60 mg 
once daily. The liquid-filled capsules may be given in an initial dose of 10 to 20 mg 
three times daily. The pharmacological effect of intranasal or sublingual was 
superior. For clinical usage, nifedipine capsules in which a hole is made with a 
needle, administered sublingually, can be effectively and safely used for rapid 
management of elevated blood pressure (Kubota et al. 2001). 20 mg of nifedipine 
sublingually was used for long time to treat patients with achalasia, 30-60 min before 
each meal (Bortolotti 1999). It has been found that sublingual nifedipine resulted in 
significant lowering of blood pressure without hypotension in pregnancy and it was
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concluded that sublingual nifedipine was effective, easy to administer and without 
serious complication (Gallery and Gyory 1997). Sublingual nifedipine was used to 
treat hypertension in children and found to be effective for rapid control of severe 
hypertension (Kumar 1996). Sublingual nifedipine was used in pediatric patients 
with renal diseases and acute severe hypertension. An initial and rapid response was 
evident as early as 3 min post administration. The greater hypertensive effect was 
seen during first 30 min (Marror Arroyo et al 1991). Moreover, 20 mg sublingual
nifedipine induced an acute improvement of left ventricular diastolic dysfunction 
(Grandi et al. 1996).
Basically, nifedipine is used in the management of hypertension, 
angina pectoris and Raynaud's syndrome. It has also been tried in numerous non- 
vascular disorders. It has been shown that nifedipine 10 mg sublingually has 
achieved a rapid reduction in blood pressure without causing dangerous hypotension 
(Angeli et al. 1991; Al-Waili & Hasan 1999). We found that sublingual nifedipine 
was effective in the treatment of severe essential hypertension and in pregnancy- 
induced hypertension (Al-Waili 2001). I have demonstrated that concurrent treatment 
with nifedipine permitted a significant reduction in corticosteroid intake without 
worsening asthma scores and to abort acute asthmatic attacks (Al-Waili 1988 & 
1999). Moreover, I have shown that nifedipine has a spasmolytic activity on 
intestinal muscles (Al-Waili 1990). Nifedipine has been used in the treatment of 
epilepsy, gastrointestinal spasm, dysmenorrhoea, cough, cramp, cardiomyopathies, 
hiccup, irritable bowel syndrome, migraine, myocardial infarction, esophageal 
disorders, myotonia, premature labour, phaeochromocytoma, and pulmonary 
hypertension (Rubin 1983, Read and Wellby 1986; Lenders 1985; Grigg and Wolfe 
1991; Gifford 1991; Fogari 1992).
Regarding renal disorders, nifedipine has a protective effect on renal 
function and has also been reported to protect against cyclosporin-induced 
nephrotoxicity in renal transplant patients (Epstein 1992). It has been found that 
nifedipine and ACE inhibitor had similar effects on urinary excretion of albumin in 
diabetics (Demarie & Bakrisl990). Nifedipine prevented increases in albuminuria in 
normotensive diabetic patients and decreased albuminuria in hypertensive diabetic 
patients (Melbourne Diabetic Nephropathy Study Group 1991). Improvement in 
renal function has been seen in patients with hypertension and moderate renal 
dysfunction given nifedipine
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(Reama 1991). Nifedipine 10 to 30 mg by mouth has ability to inhibit detrusor 
contractions in women with urge incontinence (Rude 1979).
Side Effects
The most common side effects of nifedipine are associated with its 
vasodilator action such as headache, dizziness, flushing, palpitation, and peripheral 
oedema. Other side effects such as nausea, vomiting, gastrointestinal disturbances, 
lethargy, eye pain, skin rash and mental depression have also been reported 
(Martindale 1998).
6.7.6. Drugs selected for the studies
Drugs used in the studies were selected according their pharmacokinetics and 
pharmacodynamic properties (Section 6.7). The main purposes of the studies were to 
investigate effects of prostaglandin synthesis inhibitors on pain intensity of acute 
urinary colic, enuretic episodes in patients with primary enuresis and frequency in 
patients with primary nocturnal frequency of mictrution, besides their effects on 
renal functions (Figure 12,13). Prostaglandin inhibitors belong to NSAIDs and to 
other groups were used. Nonselective prostaglandin inhibitors were used in acute 
renal colic, primary enuresis and frequency of micturition and COX-2 inhibitor was 
used in acute renal colic. Indomethacin and diclofenac sodium are nonselective short 
acting prostaglandin inhibitors belong to NSAIDs. They were used for treatment of 
acute renal colic, primary enuresis and frequency of micturition. Tenoxicam and 
piroxicam are nonselective long acting prostaglandin synthesis inhibitors used for 
treatment of acute renal colic (Figure 10,11). Meloxicam, a selective COX-2 
inhibitor, was used for treatment of acute renal colic. Nifedipine was selected for 
treatment of acute renal colic since it has prostaglandin inhibitory action as well as 
spasmolytic properties. Carbamazepine used for treatment of enuresis because it has 
antidiuretic action and it inhibits prostaglandin synthesis (Figure 11)
7. Hypotheses and purposes of studies
7.1 Prostaglandin and Primary Enuresis
It is clear that prostaglandins play an important role in the pathogenesis of 
many diseases of urinary tract, including; natriuresis and diuresis, inhibit antidiuretic
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hormone, lower aldosterone secretion, increase renal blood flow, urine output, 
arterial natriuretic peptide and micturition pressure, and decreased bladder capacity 
and micturition volume. In enuresis, there is a reduction of functional bladder 
capacity, typical unstable detrusor contraction or low compliance. In addition, 
urinary electrolyte excretions are elevated and there is high nocturnal urine 
production. Therefore, it is logical to hypothesize that prostaglandins may play a role 
in the pathogenesis of primary nocturnal enuresis.
In order to test this hypothesis, prostaglandin synthesis inhibitors, 
indomethacin, and sodium diclofenac (NSAIDs) were used to treat subjects with 
primary nocturnal enuresis. Carbamazepine, another prostaglandin synthesis 
inhibitor, was also tested in enuretic patients.
7.2 Prostaglandin and Nocturnal Frequency of Micturition
There are common suggested pathophysiological mechanisms for both 
primary enuresis and frequency of micturition (such as increased bladder irritability, 
nocturia, decreased bladder capacity and low level of nocturnal antidiuretic 
hormone). Therefore we hypothesised that nocturnal frequency of micturition, in 
otherwise normal individuals, might be due to over production of prostaglandins or 
the action of renal prostaglandins.
In order to test this hypothesis, indomethacin was used to manage healthy 
subjects with primary nocturnal frequency of micturition. Indomethacin was chosen 
because it is a potent prostaglandin synthesis inhibitor and it inhibits natriuresis, 
urinary flow rate, NPY, bradykinin-induced smooth muscle contraction, atrial 
natriuretic peptide-induced Na excretion and NO production and it stimulates 
antidiuretic hormone secretion.
7.3 Nitric oxide and enuresis
Similarly to prostaglandin, NO plays a role in the pathophysiology of urinary 
diseases, including; increases renal blood flow, glomerular filtration rate and causes 
diuresis and natriuresis. In addition, NO inhibits sodium and fluid reabsorption and 
decreases antidiuretic hormone secretion. Relaxation of trigone, bladder neck and 
urethra was mediated by NO during micturition. Therefore, we hypothesized that NO 
might play a role in the pathogenesis of enuresis and frequency of micturition besides
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prostaglandins. Urinary nitrite excretion was measured in enuretics and compared 
with normal control subjects. Indomethacin, which inhibits both prostaglandins and 
NO, was used to treat enuretics in whom nitrite excretion was measured before and 
after treatment.
7.4 Prostaglandin and Urinary Calculus
Prostaglandins cause inflammation and oedema, which may possibly 
contribute to stone impact. Therefore, I hypothesised that inflammation and oedema 
around the stone might impact the stone in the urinary tract. Therefore, prostaglandin 
synthesis inhibition by NSAIDs and the calcium antagonist, nifedipine, might 
facilitate passage of urinary calculus by inhibition of inflammation and oedema 
around the stone and also cause relaxation of urinary smooth muscle. In order to test 
this hypothesis, indomethacin was used in patients with renal or ureteric calculi 
awaiting surgical removal. Nifedipine was used for long-term management of 
recurrent renal pain and urinary calculus.
7.5 COX-2 and Renal colic
It has been suggested that renal prostaglandin production in normal kidneys is 
driven by the activity of constitutive COX-1, while at sites of inflammation, such as 
hydronephrotic kidney, there is induction of COX-2 (Seibert et al. 1996). Urinary 
calculus stimulates the synthesis of prostaglandin that contributes to increases intra- 
renal pressure and local inflammation, increases peristalsis and activation of renal 
sensory nerves. I hypothesised that renal COX-2 may be increased during ureteric 
obstruction and renal colic due to urinary calculus, which causes increased 
production of prostaglandin.
7.6 Purposes of the Studies
The objectives of the present studies are to highlight the following topics and 
questions: 1
1- Do NSAIDs reduce nocturnal frequency of micturition in otherwise healthy 
individuals?
2- Do prostaglandin synthesis inhibitors given through oral or rectal routs 
reduce bedwetting in children not responding to antispasmodics, imipramine
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or fluid restriction? And do enuretic patients not responding to NSAIDs 
respond to higher doses of these drugs?
3- Does carbamazepine improve primary enuresis and can NSAIDs improve 
patients not responding to carbamazepine?
4- Does urinary nitrite excretion increased in primary enuresis?
5- Does indomethacin which inhibits both prostaglandins and NO affects urine 
volume, urine osmolality, urine electrolytes, serum osmolality, serum 
electrolytes, clearance of free water, fractional sodium excretion, filtered 
sodium, creatinine clearance and 24 hrs urinary protein in patients with 
primary enuresis in normal and small functioning bladder capacity.
6- Do short acting NSAIDs given through rectal or sublingual routs relieve acute 
renal colic and renal colic resistant to antispasmodic/analgesic interventions 
and facilitate urinary calculus expulsion?
7- Do long acting NSAIDs relieve acute renal colic or prevent pain recurrence?
8- Are there differences between long and short acting NSAIDs and between 
long acting NSAIDs and spasmolytic/analgesic in the treatment of acute renal 
colic concerning efficacy, pain recurrence, side effects and cost of the 
treatment?
9- Does COX-2 inhibitor relieve acute renal colic?
10- Does nifedipine relieve acute renal colic and possess prophylactic effect in 
recurrent renal colic and facilitate passage of urinary calculus?
11- Do NSAIDs, nifedpine or carbamazepine affect renal function tests?
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8. Trial Design
8.1 Steps and objectives of the studies
Two kinds of studies were conducted in relation to the urinary tract diseases 
concerned in the thesis.
8.1.1. Studies on primary nocturnal enuresis and frequency of micturition.
Primary nocturnal frequency of micturition and primary enuresis are common 
and controversy still exists regarding their aetiology and management. I suggested in 
my theories that there might be a correlation between prostaglandin and NO and 
pathogenesis of these challenging urological problems. This based on the effects of 
prostaglandins and NO on physiological functions of the kidney, urinary bladder, 
urethra and autonomic nervous system and on the pathophysiological changes 
occurred in enuresis and frequency of micturition such as reduced bladder capacity, 
irritable detrusor and nocturia. If this is true, inhibition of prostaglandin might reduce 
bedwetting and frequency of micturition. Therefore reduction of prostaglandin 
biosynthesis might help patients with frequency and enuresis. To test this hypothesis 
seven steps were followed:
• Inhibition of prostaglandin production was obtained firstly with use of potent 
prostaglandin synthesis inhibitor, indomethacin suppository, which was used in 
patients with nocturnal frequency of micturition. The patients were treated with 
100 mg of indomethacin suppositories administered before retiring. The patients 
were followed for number of micturition and any adverse effects. If the patients 
improved, we would move to the next step and applying same principle in the 
treatment of primary enuresis. •
• As I stated that there might be common pathogenesis for enuresis and frequency 
as both have been shown to have small functioning bladder capacity, nocturia, 
irritable detrusor or abnormal antidiuretic hormone secretion and response. 
Therefore, I tested the possible efficacy and safety of potent prostaglandin 
inhibitor, diclofenac sodium, in children with primary enuresis. The drug was 
compared with placebo. 50 mg of diclofenac sodium once daily was first tested 
and the response as well as adverse effects was monitored.
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If there were no response regarding number of night wet to the 50 mg diclofenac 
sodium, the dose would be increased to 75 mg to test whether the response is 
dose-related. When I got favorable response from second and third step, I would 
move to the next step.
This step is important since I tested another potent prostaglandin synthesis 
inhibitor, indomethacin suppository, in management of patients with resistant 
primary enuresis. The patients were selected randomly from large group of 
patients who showed no responses to fluid restriction, antispasmodics and 
imipramine. 50 mg/day of indomethacin was used firstly and the patients would 
be followed for number of night dry, adverse effects or development of nocturia.
If there was no response to 50 mg of indomethacin, it was decided to treat the 
patients with higher doses of indomethacin to explore whether the response was 
also dose-related.
In this step I tested whether another prostaglandin synthesis inhibitor drug, 
carbamazepine, could improve patients with primary enuresis. The patients were 
selected from large group of patients who showed no response to antispasmodics 
or imipramine. Carbamazepine belongs to different group, viz, not to NSAID 
group. In addition, carbamazepine was chosen since it possesses 
pharmacodynamic actions that made it suitable candidate for this study. It is 
chemically similar to imipramine and exerts a potent anticholinergic effect. In 
addition, it is a CNS depressant and promotes antidiuretic hormone secretion and 
inhibits prostaglandin and NO production.
Patients who showed no response to carbamazepine were treated with potent 
prostaglandin synthesis inhibitor, indomethacin suppository. This would disclose 
whether the patients not responding to carbamazepine might respond to potent 
prostaglandin inhibitor from NSAIDs group. According to similarity of actions of 
prostaglandins and NO and their interaction in many biological systems, we 
hypothesized that NO might play a role in the pathogenesis of primary enuresis 
and frequency of micturition. Hence, we conducted study, which is the 8th step.
Figure (12): Steps of studies on nocturnal frequancy of micturition and primary nocturnal 
enuresis. PGSI: Prostaglandin Synthesis Inhibitor, PNE : Primary Nocturnal Enuresis. *
(Bianchi et al 1995; Nakamura et al. 1995; Matoth et a/.2000)
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• Urinary nitrite excretion was measured in patients with primary enuresis and 
compared with normal control. The patients were treated with indomethacin and 
urinary nitrite was measured before and after treatment and its level was 
discussed with the responses of the patients. To investigate the mechanism of 
action of indomethacin on patients with enuresis, a 9th step was carried out.
• Enuretic subjects were treated with indomethacin suppositories. Urine volume, 
urine electrolytes and osmolality, clearance of free water, osmolar clearance, 
filtered sodium, fractional sodium excretion, creatinine clearance, 24 hrs urinary 
protein, serum electrolytes and osmolality and functional bladder capacity were 
measured before treatment and at day 15 during treatment.
8.1.2- Studies on the acute renal colic and urinary calculus.
According to the review of the literatures regarding pathophysiological role
of prostaglandins and NO in the urinary system and pain we could summarized that
the pain of renal colic may be attributed to:
• Local ischemia due to ureteric and pelvic wall distension, stone impacting and 
local oedema.
• Prostaglandins stimulate and facilitate calcium influx, which triggers smooth 
muscle contraction, and increases peristalsis.
• Ureteric obstruction stimulates increases in renal blood flow, diuresis and high 
atrial natriuretic peptide and prostaglandin production, which in turn contributes 
to increased intra-renal pressure and activation of renal sensory nerve.
• Ureteral damage by stone causes release of histamine, bradykinin and 
prostaglandin which contribute to local inflammation and increase peristalsis.
• Prostaglandins facilitate release of substance P from renal pelvic sensory nerve 
by calcium-dependent mechanism.
• Prostaglandins sensitise nociceptors and elicit hyperalgesia.
• Production of NO in the obstructed kidney contributes markedly to increase 
prostaglandin release.
Prostaglandin synthesis inhibitors, NSAIDs and nifedipine, were used in eight
consecutive studies to treat acute renal colic and urinary calculus. Two types of
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NSAIDs were studied, short and long acting potent prostaglandin synthesis 
inhibitors, which are selective and nonselective COX inhibitors. In addition to their 
effects on prostaglandin biosynthesis, NS AIDs could inhibit NO production, 
significantly decrease substance P, desensitize nociceptors, inhibit release of 
noradrenaline from sympathetic nerve ending, increase beta-endorphins and have 
central and peripheral analgesic actions. They inhibited bradykinin-induced smooth 
muscle contraction. Calcium antagonist, nifedipine, inhibits prostaglandin 
production, attenuates development of inflammatory oedema and has anti­
inflammatory activity. It inhibited bradykinin-induced smooth muscle contraction. 
Nifedipine inhibit phospholipase A2, PGE2 and LTC4 (Chang et al 1987). 
Nifedipine has analgesic and antinoceptive action (Miranda et al. 1992). Previously 
we used nifedipine orally or sublingually to treat asthma, intestinal colic, post-partum 
hypertension, epilepsy, emergency hypertension and allergy (Al-Waili 1989, 1990, 
2000 & 2001; Al-Waili & Hasan 2000).
Eight steps (Figure 13) have been followed consequently to investigate safety 
and efficacy of short and long acting prostaglandin synthesis inhibitors, NS AIDs and 
calcium antagonist, nifedipine in acute renal colic and urinary calculus:
• Short acting NS AID, indomethacin suppository, a potent nonselective 
prostaglandin synthesis inhibitor, was investigated in patients with renal colic not 
responding to analgesic/antispasmodics. Indomethacin decreases urinary 
prostaglandin, reduces pelvic pressure, reduces calcium excretion, inhibits NO 
production, inhibits renin release, blocks the increase in afferent renal activity 
and release of substance P, and stops spontaneous rhythmic human ureteric 
contraction. The patients with resistant renal colic were treated with 100 mg of 
indomethacin and they were observed for pain relief, side effects and destination 
of their urinary calculus. When there was pain relief or passage of urinary 
calculus, the second step would be conducted. •
• Patients with urinary calculus awaiting surgical removal were entered for study. 
They were treated with 100 mg indomethacin suppositories twice daily and the 
patients were followed regarding expulsion of their urinary calculus and 
recurrence of renal pain. When there was pain relief and expulsion of urinary 
calculus it was decided to move to the next steps which involved using another 
prostaglandin synthesis inhibition, nifedipine, to treat acute renal colic and
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urinary calculus (steps 3 and 4), and testing efficacy and safety of long acting 
NSAIDs for treatment of acute renal colic (step 5).
• Patients with acute renal colic were treated with sublingual nifedipine and they 
were followed regarding pain relief and side effects. It was decided to investigate 
efficacy of potent prostaglandin synthesis inhibitor, indomethacin suppositories, 
in patients not responding to nifedipine. If the patients responded well, they 
would be entered for fourth step.
• The nifedipine-responded patients were treated with oral nifedipine for long 
period and they were followed for renal pain recurrence, possibility of expulsion 
of renal calculus, renal function test and appearance of any side effects.
• This step was conducted to investigate the possible efficacy of long acting non- 
selective NSAIDs in patients with acute renal colic. Tenoxicam and piroxicam 
were used in this step since they are long acting with long half-life, safe, potent 
prostaglandin synthesis inhibitors, and inexpensive. They could be delivered 
through i.m or i.v. routes. Their uses might reduce pain recurrence after initial 
responses. Recently, we have used i.m tenoxicam to treat visceral pain such as 
acute biliary colic and severe primary dysmenorrhoea (Al-Waili and Saloom 
1998; Al-Waili 2001). Tenoxicam and piroxicam were used for treatment of 
postoperative pain. Patients with acute renal colic were treated with 20mg i.m 
tenoxicam. The patients were observed for pain relief and any side effects. When 
there was no response the patients would be treated with pethidine. If the results 
of this trial were promising regarding the ability of tenoxicam to relief acute renal 
pain, another potent and long acting prostaglandin synthesis inhibitor would be 
investigated in acute renal colic to substantiate the results. A pilot study was 
conducted, showing that piroxicam 20-40 mg i.m was useful in patients with 
acute renal colic not responding to antispasmodics. After these encouraging 
results we moved to next steps, 6 and 7.
® Long acting NSAIDs and antispasmodics/analgesic were compared in patients 
with acute renal colic. Tenoxicam 20g i.v was used and compared with i.v. 
buscopan compositum (hyoscine butylbromide 20 mg and dipyrone 2.5 g). 
Patients with acute renal colic were treated blindly with one of either tested drug.
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The efficacy, safety, and onset of action of both drugs were monitored and 
compared. Frequency of pain recurrence during the next 24 hrs after injection of 
either drug would be recorded and compared. The cost of each treatment was 
accounted and compared with each other. After this study we moved to the next 
step.
• This step was important and was planned to compare between short and long 
acting NSAIDs in treatment of acute renal colic. Diclofenac sodium injection was 
used as short acting NSAIDs. Diclofenac sodium was chosen since it was being 
used widely for treatment of acute renal colic and many studies reported its safety 
and efficacy. In addition, I found that i.m diclofenac sodium was safe and 
effective for treatment of pain following caesarean section and had opioids- 
sparing effects (Al-Waili 2001). Long acting NSAID piroxicam i.m, 40 mg was 
used and compared with 75 mg i.m diclofenac sodium. The comparison between 
the two drugs were carried out concerning number of improved patients, 
requirement for pethidine-rescue treatment, pain relapse after initial response, 
onset of analgesia and pain score one hour after injection. After investigating 
nonselective short and long acting prostaglandin synthesis inhibitors, I moved to 
the next step concerning the effect of COX-2 inhibitor in acute renal colic. •
• I hypothesized that expression of COX-2 might be increased during ureteric 
obstruction and impacting of urinary calculus resulting in overproduction of 
prostaglandin that is played an important role in the cascade of renal colic 
pathogenesis. Accordingly, selective COX-2 inhibitor might be useful for 
treatment of acute renal colic. This is important regarding the adverse effects that 
might arise with use of nonselective NSAIDs. Meloxicam is prostaglandin 
inhibitor with highly selectivity for COX-2. It has high anti-inflammatory 
potency and it inhibits swelling, leukocytes migration and shows long lasting 
anti-inflammatory and analgesic effects and has long half life. Meloxicam is well 
tolerated in the treatment of acute pain. Different routs were used such as oral,
i.m and rectal with well analgesic action. In our trial, I used 15 mg meloxicam 
tablet delivered sublingually for patients with acute renal colic who were 
followed for pain intensity and adverse effects.
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Figure (13): Steps of studies on acute renal colic and urinary calculus.* (Levine 1983- Danon et 
al 1986; Chang et al 1987; el Din & Malik 1988), PGSIrProstaglandin synthesis inhibitor.
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8.2. Assessment of Acute Renal Pain
Our patients suffered from acute renal colic, which is one of the most 
common and aggressive pain experienced by humans. The pain is due to passage of 
kidney stone, which causes irritation of the mucosa, ischemia, over distension, acute 
urinary obstruction and elevation of intrarenal pressure, and enhances motor activity 
of renal pelvis and ureter. As for patients with acute pain, our patients were 
suggested to display a greater use of sensory pain component. There are many 
instruments applied for assessment of acute or chronic pain. During severe renal 
colic, after initial pain assessment repeated clinical measurements of pain must be
short and concerns with sensory component and pain intensity since the patients are 
quite ill.
Recent review stated that visual analogue scale (VAS) and verbal rating scale 
(VRS) constitute useful tools for acute pain measurement. In acute pain states, as 
renal colic, VAS or VRS were used for assessment of pain intensity in most of the 
studies reporting the effects of intervention on the acute renal colic (Jonsson et al 
1987, Cordell et al. 1994, Villoria-Muriel 1995, Cordell et al. 1996, Stein 1996, 
Supervia et al. 1998, Aybek et al. 1998). I found that there was no difference in 
expressing of acute pain intensity using VAS and VRS (Al-Waili 2001). However, 
patients with acute renal pain had some difficulty using the paper and pencil VAS 
during the attacks and some had difficulty with expressing the pain by use of 
numbers.
Many studies found that VRS was more suitable for use and could also be 
used for assessment of postoperative nausea. In our patients, we used VRS in four 
studies and VAS in one study. In discussing these measures with Prof. Melzack, the 
author of McGill Questionnaire, he said that the VRS and VAS would be valid for 
our studies and they correlate very highly with other measures of the MPQ (Personal 
communication). We observed that using VRS was easy and convenient for pain 
measurement. Self-assessment was made by asking the patients to indicate the 
occurrence and severity of their pain (no pain, mild pain, moderate pain, severe pain 
and very severe pain) and number was assigned for each grading. All the patients had 
severe to very severe pain and satisfactory pain relief was achieved when the pain 
became none or mild. In one study that compared between piroxicam and diclofenac 
sodium in treatment of renal colic, we used VAS. The patients were asked to mark 
point on horizontal line (10 cm) which represented the level of pain they are 
experiencing. The left-hand end of the line representing no pain, the right-hand end,
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unbearable pain. A cm rule has been used to measure the distance of the marked 
point from the left hand end.
In the initial assessment of pain, which was part of the diagnosis, beside pain 
intensity measurement other pain characters including, location, radiation, 
aggravating and relieving factors, timing, and type were also assessed.
8.3. Assessment of renal functions
8.3.1 Studies on acute renal colic and urinary calculus
8.3.1.1 Studies on acute renal colic.
After clinical examination and initial assessment of pain, renal function tests 
were performed. These included blood urea, serum creatinine, serum uric acid, serum 
sodium, serum potassium, serum chloride, general urine examination and urine 
culture. The same parameters were repeated 24 hrs after treatment.
8.3.1.2 Studies on urinary calculus and recurrent renal pain
We had two groups of patients:
1 Patients with urinary calculus awaiting surgical removal treated by 
indomethacin suppositories 100 mg twice daily for one month. Renal function 
tests were performed before the trial and at days 10, 20 and 30 during 
indomethacin treatment.
2 Patients with acute renal colic who showed response to nifedipine were 
entered long-term follow up with use of oral nifedipine. Renal function tests were 
performed before the trial and repeated during the treatment.
8.3.2 Studies on nocturnal frequency of micturition and primary enuresis
8.3.2.1 Study on frequency of micturition
Renal function tests were performed before the trial and repeated at after 15 
days of using indomethacin suppositories. Comparison between results was done 
before and after the treatment.
8.3.2.2 Studies on primary enuresis
• Studies using diclofenac sodium or indomethacin for treatment of primary 
enuresis. Renal function tests were performed before commencement of 
treatment and repeated 30 days during the treatment.
99
• Study using carbamazepine for treatment of enuresis. Renal function tests were 
performed before the trial and repeated at day 30 during therapy. In addition, 24 
hrs urinary protein and creatinine clearance test and measurement of urinary 
output were also performed. However, since all our patients wetted the bed each 
night, may be more than one attacks, it was difficult to obtain accurate collection 
of urine for 24 hrs. The parents were asked to awake the child each 3 hrs at night 
to pass voluntarily urine. However, out of 26 patients enrolled in the study, 9 
patients could collect 24 hr urinary output accurately. Therefore, the same tests 
were repeated for these nine patients after 30 days for comparison.
• In attempt to find out the mechanism of action of indomethacin suppositories in 
patients with primary enuresis, measurements of urine volume, urine osmolality, 
serum electrolytes and osmolality, filtered sodium, creatinine clearance, 24 hr 
urinary protein excretion, blood urea nitrogen and general urine examination 
were performed before treatment and at day 15 during the treatment.
8.4 Methods of Drug Administration
In basic pharmacology, there are various routs for drug administration. These 
include oral, i.v, i.m, subcutaneous, intradermal, sublingual, rectal and transdermal. 
Intravenous rout has most rapid onset of action. In oral rout the first pass effect may 
be significant which is less with rectal rout. The hepatic first-pass effect can be 
avoided to a great extent by use of sublingual rout and transdermal preparations and 
to a lesser extent by use of rectal suppository. Bioavailability, which is fraction of 
unchanged drug reaching systemic circulation after administration, is 100% for i.v 
while for i.m is equal or less than 100% and for other routs is less that 100% 
(Katzung and Furst 1998).
In our studies, we used oral diclofenac sodium and carbamazepine for 
primary enuresis, indomethacin suppository for primary enuresis, frequency of 
micturition and renal colic, i.m and i.v tenoxicam and piroxicam for acute renal colic 
and sublingual nifedipine and meloxicam for acute renal colic.
Regarding indomethacin suppository, it has been shown that indomethacin 
suppository was found to be well tolerated by patients with rheumatic diseases and 
dyspepsia, and it relieved joints pain and alleviated dyspepsia (Wright and Hopkins 
1979). Lauza ct cil. 1982 found that endoscopic evaluation of the gastric mucosa 
showed that indomethacin capsule caused significantly more gastric irritation than
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indomethacin suppositories. The maximum plasma indomethacin concentration after 
administration of suppository was found after one hour (Alvan et al. 1975, Jonkman 
etal. 1984).
More recently, Watanabe et al. 1993 found that plasma reached the maximum 
level at 30 min after rectal administration. No histological changes of the rectal 
mucosa were found with multiple treatment with indomethacin suppositories (Ogiso 
et al. 1984). In renal colic we used indomethacin suppository since nausea and 
vomiting are common association with acute renal colic. In addition rectal rout 
would eliminate the upper gastro-intestinal side effects frequently associated with 
NSAIDs and reduced hepatic first pass effect. Other advantage of suppository is that 
the patients appeared less scared to return home at an early stage since the pain could 
be adequately and rapidly alleviated at home. This is explained the importance of 
self-administration of indomethacin suppository to achieve rapid release of colicky 
pain prior to hospitalization. In addition, patients with suspected ureteral colic must 
have nothing by mouth until accurate diagnosis of the attack was settled. 
Indomethacin suppository can be used as outpatient treatment for pain relapse 
because most of patients with acute renal colic discharge home from emergency 
department.
We used i.m and i.v. tenoxicam and i.m piroxicam for treatment of acute 
renal colic. Review of 19 articles comparing parenteral NSAIDs with placebo or 
analgesic agents showed that parenteral NSAIDs are more effective than placebo and 
analgesic drugs in the treatment of renal colic (Labrecque et al. 1995). The use of 
parenteral piroxicam or tenoxicam was common in patients with musculoskeletal 
disorders and extra-articular diseases. We found that i.v tenoxicam was safe and 
effective to treat biliary colic (Al-Waili and Saloom 1998). In addition, i.v tenoxicam 
was well tolerated and effective for postoperative pain (Chin and Lin 1998; Roelofse 
et al. 1993, Eggers et al. 1999, Jones et al. 2000). It has been found that the extent of 
i.m administration was complete and tenoxicam was more rapidly absorbed 
compared to the oral dose (Scaglione et al. 1993; Stebler and Guentert 1993). After 
both i.m and i.v application, tenoxicam showed a rapid onset of action and reliable 
relief of acute pain states (Jenuet et al. 1989). Administration of tenoxicam i.m, i.v., 
or orally showed no difference in the half life (Jenuet et al. 1989). In our studies we 
firstly tested the possible therapeutic effects of i.m tenoxicam on renal colic then i.v. 
tenoxicam was compared with i.v buscopan compositum for pain relief, safety and 
prophylactic effect for recurrent pain.
101
Intramuscular piroxicam produced comparatively higher piroxicam plasma 
concentration up to 45 minutes after 40 mg dose than oral piroxicam (Fourtillan 
1987). Intramuscular piroxicam was compared with i.m diclofenac sodium to 
identify whether long acting NS AID relieved acute renal pain and prevent pain 
relapse. Diclofenac sodium was chosen for comparison because it is short acting 
NS AID and has been widely used for treatment of acute renal colic (Vignoni et cil. 
1983, el-Sherif et al 1995, Laervum et al 1996).
Nifedipine and meloxicam were used sublingually for treatment of acute renal 
colic. Sublingual administration of drugs has several advantages: (i) Sublingual 
mucosa is rich with mucosal network of systemic veins and lymphatics which give 
rises to quick absorption and rapid onset of action, (ii) This route is suitable in 
patients with swallowing difficulties, malabsorption or postoperative ileus, (iii) The 
drug will be absorbed to the systemic circulation and avoid first-pass hepatic or 
intestinal metabolism.
Nifedipine has been used increasingly by sublingual rout for the management of 
acute hypertension crisis and used for long-term treatment of achalasia (Motwani and 
Lipworth 1991, Bortolotti 1999). It has been found that sublingual nifedipine was 
effective, easy to administer and without serious side effects in patients with 
pregnancy-induced hypertension (Gallery and Gyory 1997). We have reported safety 
and efficacy of sublingual nifedipine in the treatment of hypertensive crisis and 
pregnancy-induced hypertension (Al-Waili and Hasan 1999, Al-Waili 2001). It has 
been demonstrated that sublingual, oral or rectal nifedipine is rapidly and almost 
completely absorbed (Kelly and Malley 1992). During sublingual rout, the peak 
plasma concentration was larger than that following oral administration (Palm- 
Aguirre et al. 1989). An initial and rapid response was seen after 3 minutes post­
administration in children with renal diseases and hypertension (Kumare 1996).
As for rectal route, we chosen studying the effectiveness of sublingual rout in the 
treatment of acute renal colic which is characterized by its recurrence, because this 
route is easy to use, could be self-administered and is useful when there is 
contraindications for oral rout or parenteral preparations were not available or there 
is no sophisticated monitoring with use of intravenous line. Self-administration is 
good advantage that make sublingual or rectal rout useful for patients familiars with 
their symptoms of acute renal colic and also in hospitals, general practice and busy 
emergency words.
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9- Papers on primary enuresis and primary nocturnal
frequency o f micturition with original data on renal
function tests
Pages 103-133
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Pages 104-133 have been removed due to copyright restriction. Provided below are 
the citations for those publications. 
Al-Waili, N.S. (1986) ‘Indomethacin suppositories: an alternative treatment for 
nocturnal frequency of micturition’, IRCS Journal of Medical Science, 14, pp. 
322-323.
Al-Waili, N.S. (1986) ‘Diclofenac sodium in the treatment of primary nocturnal 
enuresis: double-blind crossover study’, Clinical and Experimental Pharmacology 
&Physiology, 13, pp. 139-142.
Al-Waili, N.S. (1989) ‘Indomethacin suppository to treat primary nocturnal enuresis: 
double-blind study’, Journal of Urology, 142(5), pp. 1290-1292. 
Al-Waili, N.S. (2000) ‘Carbamazepine to treat primary nocturnal enuresis: double-
blind study’, European Journal of Medical Research, 5(1), pp. 40-44.
Al-Waili, N.S. (2002) ‘Increased urinary nitrite excretion in primary enuresis: effects 
of indomethacin treatment on urinary and serum osmolality and electrolytes, urinary 
volumes and nitrite excretion’, BJU International, 90(3), pp. 294-301. 
10. Brief Results of the linked studies on Frequency of micturition
and primary enuresis
Indomethacin suppository significantly reduced the frequency of micturition 
in all the 15 patients treated. Mean frequency was decreased from 71.4 +/- 23.6 to 
16.8+/-10.4 during a period of 15 days of the treatment. All the patients showed 
more than 60% reduction in the frequency of micturition.
Regarding primary enuresis, diclofenac sodium was used to treat primary 
enuresis. Out of 20 patients treated, 15 had more than 50% reduction in the wet 
nights. Three of the five non-responders showed better responses when the dose of 
the drug increased to 75 mg. The total number of responders to either dose was 18 
patients (90%). This revealed that the response is dose-dependent.
In resistant primary nocturnal enuresis, 14/19 patients had more than 18/30 
dry nights with use of 50 mg of indomethacin suppository, another potent 
prostaglandin inhibitor. The other five non-responders were re-treated with 100 mg 
of indomethacin and three of them showed better responses. This demonstrated that 
the response was dose-dependent. A total of 17 indomethacin-responders (89.4%) 
continued to take indomethacin for 2 more months, of them 6 maintained complete 
dryness and 11 wet minimally. After stopping treatment, 5 remained dry and 6 return 
to daily wetting during 2 months of follow-up.
With use of another prostaglandin inhibitor, carbamazepine, which belongs to 
different drug family, 20 out of 26 patients had more than 50% reduction in the 
episodes of bedwetting (76.9%). The other six patients were retreated with potent 
prostaglandin inhibitor, indomethacin suppositories, and four of them showed better 
responses.
In the other study, indomethacin suppository (50 mg) given daily to 10 
patients with primary enuresis caused a significant reduction in the frequency of bed­
wetting, from daily bed-wetting to 0-4 wet nights during a period of 15 days. Urinary 
nitrite, the end product of NO, was significantly elevated in the patients with enuresis 
and was reduced markedly at day 15 during indomethacin treatment.
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Renal function tests and side effects.
Treatment of patients with primary enuresis by prostaglandin inhibitors 
NSAIDs, diclofenac sodium or indomethacin, and carbamazepine did not cause 
significant changes or deterioration in the renal function tests regarding blood urea 
nitrogen, serum creatinine, serum uric acid and serum electrolytes (see details tables 
of the results in the sections 10, and 11). In addition, with use of carbamazepine, 24 
hr urine volume could be collected only from nine patients before treatment, of them 
six showed significant improvements and urine volume was measured at day 30 
during the treatment. Mean 24 hrs urine volume was 835+/-121 ml before treatment 
which was decreased to 492.8 +/- 228 ml during treatment (p< 0.05). Mean 24 hrs 
absolute urine sodium excretion was 82.9 +/- 49.2 mmol that was changed slightly to 
78.5+/- 55.9 mmol. Creatinin clearance was decreased from 105.6 +/- 28.5 to 85.9 
+/- 20.98. Blood osmolality decreased significantly from 283+/-3.44 mOsmol/kg to
277.2 +/-2.87 mOsmol./Kg. Mean blood sodium concentration slightly decreased 
from 142.8+/-1.47 mmol/1 to 140.2 +/-2.04 mmol/1. These results showed that 
carbamazepine reduced urine volume which might explain its effectiveness in 
primary enuresis. In addition, urinary excretion of nitrite was significantly increased 
in patients with enuresis which was decreased markedly by indomethacin treatment. 
This reduction was associated with significant reduction in frequency of wetting. 
Indomethacin caused reduction of urine volume by 41.3%. It decreased clearance of 
free water, osmolal clearance, filtered sodium, fractional sodium excretion, creatinine 
clearance, and urinary protein excretion. No significant change was seen in serum 
osmolality. Indomethacin decreased bed-wetting in normal and small functioning 
bladder capacity.
Summary
The results showed that inhibition of prostaglandin synthesis by NSAIDs, 
indomethacin rectal suppository and diclofenac sodium oral tablet, and by 
carbamazepine might widen therapeutic lines for treatment of primary enuresis and 
frequency of micturition. This indirectly supports the hypothesis that prostaglandin 
might play a role in the pathogenesis of primary enuresis or nocturnal frequency of 
micturition. Moreover, the result substantiate our hypothesis that in addition to 
prostaglandins, NO might have place in the pathogenesis of enuresis. Therefore, the
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results highlighted new concept for aetiology and pathogenesis of these urological 
problems in relation to prostaglandins and NO. The mode of action of indomethacin 
could be contributed to reduction of urine volume, clearance of free water, urine 
electrolytes, filtered sodium, and fractional sodium excretion.
Brief results of studies on primary nocturnal frequency and primary 
enuresis are illustrated in the tables 8. The subsequent sections include original 
papers discussing in details the results on frequency of micturition, episodes of bed­
wetting, side effects and renal function tests and the possible modem of action.
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Studies Diseases Drugs Doses mg/day Treatment 
Duration ( D ays)
Number o f Patients 
Studied
Responses
Number o f patients with 
significant response * %+
1 Primary nocturnal frequency 
of Micturition
Indomethacin
Suppositories 100 15 15 15 100
2 Primary Enuresis Diclofenac Sodium 50 -75 30 20 18 90
3 Primary Enuresis ( Resistant) Indomethacin
Suppositories 50-100 30 19 17 89.4
4 Primary Enuresis Carbamazepine 200 30 26 20 76.9
5 Primary Enuresis Indomethacin
Suppositories 50 15 10 10 100
Table 16 : Brief results of studies conducted on primary enuresis. * Number of patients who showed more than 50% night dryness with 
use of the treatment ( p<0.05). + Percent of responders out of treated patients.
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11.CRITICAL APPRAISAL OF THE PUBLISHED PAPERS ON
FREQUENCY OF MICTURITION AND PRIMARY ENURESIS
ll.l.Frequency of micturition
All the patients with primary nocturnal frequency of micturition showed 
considerable responses to indomethacin suppository. Although this is an open study, 
marked reduction in the number of nocturnal micturition was obtained with use of 
100 mg of indomethacin suppository given before retiring. The mode of action of 
indomethacin might be the result of inhibition of prostaglandin biosynthesis at renal, 
vesical, urethral and nervous system levels. The inhibition might cause reduction in 
urine output, increase in the threshold volume of micturition, lowering of intravesical 
pressure, elevation of urethral pressure and lowering of inhibitory action of 
prostaglandins on adrenergic transmission in the bladder and urethra.
Diseases of the cardiovascular and nervous systems and endocrine and 
metabolic disorders could cause nocturnal frequency of micturition. However, there 
is a group of patients having nocturia without any obvious causes as in our patients. 
The cornerstone of management of nocturnal frequency of micturition is the 
treatment of the underlining pathology, but this is not always possible or successful. 
It has been suggested that nocturnal polyuria might be due to low antidiuretic 
hormone (Asplund 1995; Weiss & Blaivas 2000). There is increase Na+ excretion in 
nocturnal frequency of micturition (Mathiesen et al. 1996). Decreased nocturnal 
bladder capacity was found in old patients with nocturnal frequency of micturition 
(Kawanchi et al. 2000). Therefore, antispasmodics, fluid restriction and antidiuretic 
preparations may be helpful (Hundballe et al. 1997; Weiss 2000). However, 
antidiuretics are expensive and may cause severe side effects. We found some 
similarity between despmopressin and indomethacin regarding reduction of urine 
output. Hence, indomethacin suppository could be a suitable alternative in the 
management of nocturnal frequency of micturition. On the other hand, it has been 
shown that patients with nocturnal polyuria and primary enuresis have higher 
nocturnal sodium excretion but no higher nocturnal free-water clearance and using 
vasopressin to induce water retention in elderly with nocturnal polyuria is illogical 
and potentially hazards (Mckeigue & Reynard 2000). Polyuria with nephrogenic 
diabetus insipidus is associated with elevated urinary PGE2 and 6-ketoPGFl
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(Hochberg et al 1998). Prostaglandin synthesis inhibitors are used to treat bladder 
overactivity and urinary incontinence and urgency and indomethacin was used to 
treat nephrogenic diabetus insipidus (Weinstock & Moses 1990; Dagues & Costa 
1995; Andersson 2000). Oral indomethacin was shown to improve daytime urinary 
frequency in children (Luo 1992). These studies support our hypothesis that 
prostaglandins might also be the cause for nocturnal frequency of micturition. 
Moreover, it was found that misoprostal induces urinary incontinence and a 
deficiency in urethral resistance (Bergman et al 1991).
11.2. PRIMARY ENURESIS
11.2.1. Prostaglandin and prostaglandin inhibition
Drugs used to inhibit prostaglandin biosynthesis in patients with primary 
enuresis are NSAIDs, diclofenac sodium or indomethacin suppositories, and 
carbamazepine. The results demonstrated that indomethacin, diclofenac sodium and 
carbamazepine reduced significantly nocturnal bedwetting. This suggests indirectly 
that prostaglandins may play a role in the pathogenesis of primary nocturnal enuresis. 
In addition to inhibition of prostaglandin biosynthesis these drugs have other 
biological effects that might contribute to their efficacy in the management of 
enuresis.
11.2.1.1. NSAIDs Effects
Human bladder mucosa produces large amounts of prostaglandin, which were 
shown to be liberated into the blood stream during vesical distension and after pelvic 
nerve stimulation (Gilmore & Vance 1971; Khalaf et al 1979). Indomethacin and 
diclofenac might cause depression of the smooth muscles of the bladder in enuretic 
children. Such effects might be ascribed to prostaglandin synthesis inhibition and its 
known calcium antagonistic responses (Jeremy 1982).
At the urethral level prostaglandins caused a significant urethral pressure 
decrease at basal condition and during micturition, and reduced urethral resistance 
Konda et al 1983; Schussler 1990). These effects might be a result of direct action of 
prostaglandins on the smooth muscle of the urethra or through inhibitory effects of 
prostaglandins on the adrenergic transmission (Andersson et al 1983).
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Prostaglandins are a potent inhibitor of noradrenaline release (Hedqvist 1977). 
Therefore, inhibition of prostaglandin with diclofenac sodium or indomethacin might 
result in elevation of urethral pressure and resistance and lowering of inhibitory 
action of prostaglandin on adrenergic transmission in the bladder and urethra. 
Generally, the frequency of bedwetting in enuretic patients could be reduced with use 
of indomethacin or diclofenac sodium by inhibition of prostaglandin biosynthesis 
and release at different sites of the urinary tract:
1- At renal level, results in reduction of diuretic and renal vascular
effects of prostaglandin and glomerular filtration rate
2- At bladder level, results in reduction of the maximum intravesical
pressure and increased threshold volume of micturition
3- At urethral level, results in elevation of urethral pressure and
resistance
4- At nervous system, results in reducing the inhibitory action of
prostaglandin on adrenergic transmission in the bladder and
urethra.
The inhibition of prostaglandin synthesis might cause decreased urine output, 
an increase in the effect of antidiuretic hormone, increased threshold volume of 
micturition, and decreased inhibitory action of prostaglandins on adrenergic 
transmission in the bladder and urethra. Other action of diclofenac sodium and 
indomethacin might help enuretic patients, such as analgesic effect, which may be 
responsible for more restful sleep.
Indomethacin inhibits not only COX but also the mobilization of Ca2+ linked 
prostaglandin synthesis in the urinary bladder (Jeremy et al 1982). It decreased 
plasma renin concentration, increased antidiuretic hormone and osmotic water 
permeability and abolished natriuresis (Lijnen et al. 1991; Walker et al. 1994; Rouch 
& Kudo 1997). Indomethacin reduced atrial natriuretic peptide-induced sodium 
excretion (Villarreal et al 1997). It inhibits sodium dependent adenosine transport in 
brush-border membrane (Gonzalez-Gastillo et al 1997) and completely eliminated 
neuropeptide induced diuresis and natriuresis (Bischoff et al 1998).
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To describe the possible mechanism of action of indomethacin, urine volume, 
urine electrolytes and osmolality, serum electrolytes and osmolality, creatinine 
clearance, urinary protein, fractional excretion of sodium and filtered sodium were 
measured before and during indomethacin suppository treatment. Indomethacin 
caused reduction in the total 24 hr urinary volume, night urine volume and day-time 
urine volume. Daytime urine volume decreased by 25.4% during indomethacin 
treatment. The reduction was significant at night (39.9%) and throughout 24 hour 
urinary volume (41.3%). Same results were obtained when urine was measured per 
min / kg. body weight . In addition, day to night urine volume ratio increased from 
0.982 +/- 0.395 to 1.521 +/- 1.1. Indomethacin decreased also clearance of free water 
by 46.4%. Indomethacin increased 24 hr urine osmolality by 54.89%, night urine 
osmolality by 86.2% and daytime urine osmolality by 29.25%. The absolute amount 
of calcium, phosphorus, magnesium, glucose, urea, and creatinine excreted in the 
urine decreased after indomethacin treatment. Indomethacin decreased osmolal 
clearance. No significant changes were seen in serum osmolality, serum glucose, 
blood urea nitrogen, creatinine, calcium, magnesium, and phosphorus concentrations 
during indomethacin treatment. Sixty percent of the patients had less than 70% 
predicted bladder capacity and the other patients had more than 70 %, up to 100%. 
However, maximum functional bladder capacity increased slightly from 200 +/- 52.4 
ml to 210 +/-73.4 ml at day 15 after commencement of indomethacin treatment. The 
absolute amount of sodium and chloride excreted in daytime urine, night urine and 
24 hr urine was decreased by indomethacin. Insignificant changes were seen in 
serum sodium or chloride after indomethacin treatment. Fractional excretion of 
sodium and filtered sodium also were decreased by indomethacin. In addition, 
fractional excretion of potassium and the absolute amount of potassium excreted in 
the urine collected at night, day or during 24 hrs were decreased by indomethacin 
though this change was statistically insignificant. Serum potassium concentration 
was not altered significantly by indomethacin. Indomethacin decreased creatinine 
clearance by 19.91% and 24 hr urinary protein excretion from by 47.25%.
The apparent action of indomethacin is mainly related to reduced urine 
output, fractional excretion of sodium, filtered sodium and electrolytes excretions. In 
addition, indomethacin could stimulate antidiuretic hormone, modulate tubular 
actions, suppress bladder contractility and increase urethral tone by inhibition of both 
NO and prostaglandin productions. Central effects of indomethacin on prostaglandin
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and NO productions in CNS might affect sleep pattern or central and neuronal 
control of bladder function. Moreover, it has been shown that neuropeptide Y caused 
diuresis and natriuresis and increased prostaglandin production in renal tissue (el Din 
& Malik 1988). Indomethacin could abolish neuropeptide Y-induced diuresis and 
natriuresis (Bischoff et al. 1998). Therefore, indomethacin might exert its effects by 
inhibition of prostaglandins, NO or neuropeptide Y. More investigations are needed.
11.2.1.2. Carbamazepine Effect
It has been found that carbamazepine dose dependently inhibited 
prostaglandin E2 activity and prostaglandin E2-induced hyperalgesia (Bianchi et 
al. 1995; Nakamura-Craig & Follenfant 1995; Matoth et a/.2000). The results showed 
that nocturnal bedwetting could be also reduced significantly with use of 
carbamazepine 200 mg tablet. Many studies reported other effects of carbamazepine 
such as its effects on antidiuretic hormone and water metabolism. Carbamazepine 
has water-retaining property mediated by increased renal sensitivity to normal 
plasma concentration of antidiuretic hormone and resetting of osmoreceptors (Jien et 
al. 1977). Others reported that carbamazepine induced antidiuresis by release of 
antidiuretic hormone and impaired excretion of water load (Perucca et al 1978; 
Soelberg et al. 1984). It decreases the ability to excrete water load and causes lower 
free water clearance and higher urine / plasma osmolality ratio (Soelberg et al. 1984).
Because of its antidiuretic effect, carbamazepine has been used successfully 
to treat diabetes insipidus centralis. It caused considerable antidiuresis and altered 
sensitivity to serum osmolality by the hypothalamic osmoreceptors and increased 
sensitivity of renal tubules to circulating antidiuretic hormone (Kimura et al. 1974; 
Stogmann 1975; Vimla et al. 1983; Yoshimura et al. 1997). Some studies reported 
increased plasma antidiuretic hormone by carbamazepine (Stephens et al. 1978). In 
combination with chlorpropamide, carbamazepine has been used to treat diabetes 
insipidus in childhood (Stogmann 1975).
The mechanism of action of carbamazepine is not clear, but it might be 
related to its antidiuretic effects, increased bladder capacity or reduction of 
prostaglandin-like activity. Recently, it was found that carbamazepine inhibited NO 
production (Matoth et al. 2000). Therefore, its possible inhibitory effects on NO
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production in the urinary system, as we suggested with NSAIDs, might play a role in 
the mechanism of action. This needs further investigations. However, the main first 
goal of our study was to find whether carbamazepine has any clinically therapeutic 
effects on patients with primary enuresis besides its possible effects on renal function 
tests. The patients wetted the bed each night once or more. To study the effects of 
carbamazepine on urine volume, we needed to collect urine at night and day, which 
would be used also to measure creatinine clearance. However, accurate collection of 
nocturnal urine production from children with daily enuresis is not an easy task. 
Invasive methods like transurethral catheterization or external catheter have been 
used to collect urine at night. Spontaneous voiding at 2-3 hrs interval by repeated 
waking patient also was used. Diapers has been used but could not absorb all the 
urine and the amount of urine at each enuretic episodes could not be determined as 
diapers could contain urine form more than one episodes. These measures could 
decrease patient’s compliance and it was decided that it was not necessary to stress 
on urine collection at that stage, viz before knowing the effect of carbamazepine on 
enuresis. However, we have asked the parents to a wake the child at night for 
spontaneous voiding. Accurate urine collection was obtained from nine patients. 
After treatment with carbamazepine, six patients showed dryness and urine collected 
from them at day 15 during treatment for comparison. Urine volume, urine 
osmolality, creatinine clearance, urine sodium and serum electrolytes were measured. 
The results demonstrated that carbamazepine significantly reduced urine volume and 
increased urine osmolality. It decreased blood osmolality to a lesser extent. Mild 
lowering of serum sodium was encountered. Though the number of the patients was 
small, it seems that the main action of carbamazepine is the marked reduction of 
urine volume. Further studies are needed to substantiate this possible mode of action.
11.2.2. Nitric oxide and enuresis
NO has an important role in the renal physiology and micturition (see 
Introduction). Renal vasoconstrictor and antinatriuretic effects of COX inhibitors are 
enhanced when NO synthesis is reduced (Gonzalez et al. 1998). It inhibits fluid and 
Na+ reabsorption by proximal tubules (Hagnes et al 1997; Liang & Knox 2000). 
Sodium nitroprusside and NO increased neurogenic detrusor contraction and they are 
effective in relaxing urethral muscle (Persson & Andersson 1994; Lin & Lin 1997). 
It has been demonstrated that inhibition of NO alone causes antidiuresis and
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antinatriuresis and decrease in renal blood flow and glomerular filtration rate (Sirajy 
et al. 1997). NSAIDs and carbamazepine inhibited NO production (Cirino et al 
1996; Du & Li 1999; Matoth et a/.2000). Indomethacin inhibits both the release of 
prostaglandin and NO and reduced COX-2 activity irreversibly (Du & Li 1999; 
Motta et al. 1999; Harback et al. 2001). Inhibition of endogenous prostaglandins by 
COX inhibition caused reduction of inducible NO synthesis (Minchetti et al 1997). 
Therefore, NSAIDs or carbamazepine might help patients with enuresis and 
frequency of micturition by inhibition of prostaglandins, and NO.
NO has been identified in nerve fibres of the detrusor, trigone and urethra. NO 
is the major neural inhibitory regulator of urethral tone and considered to be a 
mediator for the neurogenic dilator of the bladder neck and urethra during 
micturition reflex (Parlani et al 1993; Bennett et al. 1995). NO caused reflex urethral 
smooth muscle relaxation (Vizzard et al. 1994). A drop in urethral pressure 
immediately precedes an elevation in bladder pressure causing urethral relaxation as 
the first part of micturition (Low et al. 1989). It has been found that fluid passing 
through urethra could facilitate detrusor activity (Suk et al. 1999). Involuntary 
detrusor contractions were proceeded by a fall in urethral pressure (Low 1977). 
Moreover, urethral instability is a common finding in detrusor instability (Sorenson 
et al. 1986). Intraurethral administration of NO donors caused decreased urethral 
pressure (Suk et al. 1999). Inhibition of NO synthase blocked urethral relaxation to 
parasympathetic nerve stimulation (Fraser et al 1995).
It has been suggested that there is a major interaction between NO and 
prostaglandin in mediating renal response to various situations (Salazar et al. 1995). 
In addition to prostaglandin, NO production in the urinary system may be involved in 
the pathophysiology of enuresis. Over production of NO mainly at renal, bladder 
neck and urethral levels may increase urine production, solutes excretion and drop 
urethral pressure. The latter might allow passage of little urine in the urethra and 
initiate bladder contraction, which is exaggerated by high prostaglandin production 
encountered in enuresis. Therefore, we might hypothesize that both prostaglandin 
and NO are involved in the pathogenesis of enuresis. The present study presents for 
the first time the amount of nitrite in urine samples of enuretics, which was found to 
be significantly higher than normal control.
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NO and prostaglandin have similar action on renal water and electrolyte 
excretion and bladder neck and urethral contraction. Inhibition of NO and 
prostaglandin caused antidiuresis, antinatriuresis, decreased renal blood flow, 
glomerular filtration rate and bladder excitability and increased intra urethral 
pressure. NSAIDs and carbamazepine inhibit NO and prostaglandin production. 
Inhibition of prostaglandin itself resulted in reduction of inducible NO synthesis.
In enuresis, it was found that both urinary prostaglandin and NO concentrations 
increased, which might be the main reason for enuretic episodes. Therefore, 
inhibition of prostaglandin, NO or both might reverse their effects on renal, 
ureteral, vesicle or urethral level and consequently improved frequency of 
bedwetting.
11.2.3, Supported studies
The differences between enuretic patients suggest different aetiology, probably 
related to an increase prostaglandins and antagonistic mechanism of action of 
antidiuretic hormone or desmopressin (Medel et al 1998). Our results demonstrated 
that prostaglandin might be a possible cause for primary nocturnal enuresis and 
nocturnal frequency of micturition. This is either due to higher production of 
prostaglandins in the urinary tract, increased sensitivity of urinary tract tissues to 
prostaglandins or dominance of prostaglandin effects. Recently, subsequent studies 
by others confirmed our works and hypothesis. Natochin and Kuzenetsora (1997) 
found that the enuretic children had a high night diuresis and free water reabsorption 
and increased in nocturnal excretion of sodium, calcium and magnesium ions. 
Inhibition of prostaglandin leads to normalization of diuresis and natriuresis and 
elimination of nocturnal enuresis. The evidence has been obtained that nocturnal 
enuresis is accompanied by an increased production of autocoids in the thick 
ascending LOH which causes saluresis and diuresis. Study by Kuzenetsova et al 
(2000) suggested that change in the renal function in primary enuresis are due to 
dominance of prostaglandin effects as compared to other physiologically active 
substances that simultaneously act on the renal tubular cells, and there is a 
correlation between sodium ion and renal excretion of prostaglandin. In addition, it 
has been found that the mean serum and urine PGE2 concentration in enuretics were 
higher from control serum and urine PGE2 (Sener et al 1998). 100 mg of 
indomethacin was shown to be effective in the treatment of primary enuresis, which
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confirms our hypothesis (Sener et al. 1998). The study showed also that significant 
decrease in serum and urine PGE2 concentrations was seen after indomethacin 
treatment. Medel et al. (1998) found desmopressin non-responder enuretics had 
overnight mean PGE2 level greater than in normal subjects or desmopressin- 
responder. Diclofenac sodium was also found to be effective in the treatment of 
children with primary enuresis and it could restore ions and water transport in the 
kidney (Batislm et al. 1995; Natachin & Kuzenetsova 2000). In addition, other 
investigators showed that diclofenac sodium suppository was superior to placebo in 
the treatment of enuretic children (Metin & Agkel 1992). These results confirm our 
published findings and hypothesis. Moreover, prostaglandin synthesis inhibitors are 
useful to treat urinary incontinence and bladder instability (Wall 1990). These studies 
give further evidences for the validity of our hypothesis. Regarding the implication 
of NO in the aetiology of enuresis, our findings reported elevation of NO production 
in primary enuresis also substantiates our hypothesis on possible relation between 
nitric oxide and enuresis.
In general, many theories on the aetiology of primary nocturnal enuresis have 
been suggested, including psychological and behavioural factors, a small capacity 
and unstable bladder, and anatomical abnormalities of the urinary tract (Ullom- 
Minnich 1996; Hansen & Jorgensen 1997). Management with psychotherapy, fluid 
restriction, antispasmodics, tricyclic antidepressants and antidiuretic preparations is 
used but is not always effective (Miller et al 1992; Chiozza et al. 1997). Our patients 
showed good response with use of prostaglandin synthesis inhibitors.
11.2.4. Pathogenesis of enuresis, indomethacin and desmopressin 
effects
Primary enuresis is a diseases of complex pathogenicity with accumulative of 
conflicting data. Most patients have either normal bladder function and capacity and 
large urine volume production at night or slightly increased micturition frequency 
during the day, and small bladder capacity at night-time (Djurhuus 1999). Rare 
enuresis subtypes included nighttime natriuresis with or without polyuria, calciuria 
and air way-induced enuresis.
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It has been found that in primary enuresis, patients nocturnal urine 
production was greater than that of the control subjects and less concentrated 
(Hunsballe et al. 1997). This result in increased urine production, which in turn 
exceeds bladder capacity (Steffens et al. 1993; Eggert et al. 1995). Patients with 
nocturia showed increase urine production associated with increase nocturnal sodium 
excretion (Matthiesen et al. 1996). Enuretic patients had significantly higher 
fractional excretion of sodium and fractional excretion of potassium values than 
normal (Vrgun et al. 1997). There are significant correlation between fractional 
excretion of sodium and fractional excretion of potassium and frequency of 
bedwetting among enuretic (Vrgun et al. 1997). It has been found that diuresis during 
the night was 58.7% higher and the solute excretion 48.8% higher in enuretics than 
in healthy children (Natachin and Kuzenetsova 1999). This was mainly due to 
increase sodium and magnesium ions. The excretion of these ions is elevated not 
only during night but also throughout a 24 hour period in children with enuresis 
(Natachin and Kuzenetsova 1999). In response to fluid restriction, enuretics had 
significantly higher increase in plasma antidiuretic hormones than in comparable 
control (Eggert et al. 1999). Therefore, enuretic children showed higher secretion of 
antidiuretic hormone and do not show an antidiuretic hormone deficiency (Eggert et 
al. 1999; Jonat 1999). There is a defect at the AVP receptor level rather than AVP 
deficiency that has to be supplemented. The success rate with desmopressin has been 
reported to range from 10% to 91% (Moffat et al 1998). The basis for using 
desmopressin is that a missing circadian rhythm of antidiuretic hormone secretion 
result in nocturnal hormone deficiency in enuretics (Ritting et al. 1998). On the 
contrary, it has been shown that patients with primary enuresis do not have an 
increased nocturnal urine production when compared with a control group (Eggert & 
Kuhn 1995). There were no differences between the two groups regarding plasma 
osmolality and rhythm of antidiuretic hormone secretion. Enuretic children need 
significantly higher antidiuretic hormone to maintain constant plasma osmolality 
(Eggert et al. 1999).
Other investigators showed that no difference between enuretics and normal 
control was found in the total diurnal urinary volume, osmolality or tubular capacity 
for reabsorption of water (Vurgun et at/. 1997). Moreover, no difference between 
enuretics and control were found for urine production, antidiuretic hormone levels 
during day and night or plasma osmolality (Eggert et #71995). Therefore,
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controversy is still existing regarding the aetiology of enuresis and the changes that 
might occur in the tubular function, water and electrolytes excretion and bladder 
capacity and physiology. According to the role of prostaglandins and NO in the 
physiology and pathophysiological events in the urinary system, we have 
hypothesized that primary enuresis and frequency of micturition might be a results of 
prostaglandins and NO interaction and accordingly we and others have confirmed 
that inhibition of prostaglandin and probably NO production in the urinary system 
could improve bedwetting.
With our studies, indomethacin provided marked reduction in the frequency 
of micturition in 100% of the patients treated, and it reduced significantly number of 
bedwetting in 100% of the patients with enuresis and in 89.4% in patients with 
resistant enuresis. Diclofenac sodium provided significant improvement in 90% of 
the cases. The responses were apparently dose-related. Carbamazepine provided 
improvement in 76.9% of the case and indomethacin could improve 66.6% of 
carbamazepine-non-responders. In addition, indomethacin improved patients with 
small and normal predicated functional bladder capacity. Seventeen patients were 
treated with indomethacin for 2 months, of them 29.4% returned to daily bed wetting 
after stopping the treatment.
Desmopressin is used widely to treat enuresis which caused a reduction in 
the number of wet nights and a decrease in nocturnal urine production, even though 
non of the children become totally dry during treatment with desmopressin (Hasen 
and Jorgensen 1997). It has been found that 61% response could be achieved with 
desmopressin and it was highly effective when used in combination with other 
treatments including alarm and oxybutinin (Hjalmas 1999). Some patients who 
showed resistant to desmopressin treatment responded well to anticholinergic drug 
(Neveus et al. 1999). Enuretics with elevated nocturnal urination and electrolytes 
excretion had 85% response with desmopressin (Natachin and Kuzenetsova 2000). 
The most likely to be permanently dry with desmopressin treatment are older 
children and who do not wet frequently and who had only wet episode during night 
(Kruse et al. 2001). Desmopressin led to a reduction of nocturnal enuresis and to a 
decrease in osmolar clearance and excretion of sodium (Natachin and Kuzenetsova 
2000). Lysine-8-vasopressin induced a significant reduction of creatinine clearance, 
urinary flow rate and of prostanoid excretion (Angnoli et al. 1989). Recently it has
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been found that desmopressin responder produced larger amount and less 
concentrated urine than other children, while desmopressin non-responders had 
smaller bladder capacity than others (Neveus et al. 2001). In our patients, 60% had 
small predicted functional bladder capacity (<70%) and showed marked 
improvement with indomethacin while other found that patients with functional 
bladder capacity more that 70% predicated bladder capacity were more likely to 
respond to desmopressin (Rushton et al. 1999). Desmopressin like diclofenac sodium 
recovered renal function in enuretics and caused decreases in diuresis, osmolar 
clearance and excretion of calcium, sodium and magnesium (Natachin and 
Kuzenetsova 2000). Desmopressin might cause nasal irritation and nose bleeds and 
there is risk of water intoxication (Glazener and Evans 2000).
The action of indomethacin might be similar to desmopressin. 
Desmopressin and indomethacin reduced prostaglandins in urine and plasma in 
enuretics (Sener et al. 1998). It has been demonstrated that desmopressin-non- 
responders patients have overnight mean prostaglandin E2 level greater than in 
normal subjects or desmopressin-responders (Medel et al. 1998). However, 
indomethacin not only reduced water excretion, but also reduced absolute sodium 
excretion and improved patients with normal as well as small functioning bladder 
capacity. In addition, some of our patients become totally dry during indomethacin 
treatment.
Reduction of urine volume alone as it has been proposed with use of 
desmopressin may not be enough to avoid bed-wetting or to achieve total dry. So we 
might suggest that reduction of urine output by indomethacin might not be the only 
mechanism of action in the treatment of enuresis. It could stimulate antidiuretic 
hormone, decreased filtered sodium, modulate tubular actions, suppress bladder 
contractility and increased urethral tone by inhibition of both NO and prostaglandin 
productions. Central effects of indomethacin on prostaglandin and NO productions in 
central nervous system might affect sleep pattern or central and neuronal control of 
bladder function (Murphy et al. 1994; Naito et al 1988). These need further 
investigations.
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Prostaglandin synthesis inhibition with indomethacin decreased episodes of 
bedwetting by reduction of urine volume and electrolytes excretion and decreased 
bladder contractility and excitability. This is clear in our patients who had small 
predicted functional bladder capacity and showed marked response with 
indomethacin. However, this is opposite to what has been found with desmopressin 
treatment which revealed no significant effects on patients with small bladder 
capacity. Henze, prostaglandin inhibition might have superiority to desmopressin 
which showed its effects mainly in patients who produced large amount of and less 
concentrated urine.
According to the similarity of some actions between indomethacin and 
desmopressin, we suggest that using a combination of both drugs in management of 
primary enuresis might have synergistic effects and might result in better 
improvement and reduction of doses, and ultimately side effects. Other controlled 
studies are needed to substantiate this possibility.
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12- Papers on renal colic and urinary calculus with original
data on renal function tests
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13. Brief results o f linked studies on renal colic and
urinary calculus
Renal colic
Fifty-five patients with resistant renal colic treated with short acting potent 
prostaglandin synthesis inhibitor, indomethacin suppository 100 mg. Of them, 47 got 
pain relief within 30 min and other eight patients within 60 min.
Other twenty patients with acute renal colic were treated with prostaglandin 
synthesis inhibitor and calcium antagonist, nifedipine. Sixteen patients (80%) 
responded to sublingual nifedipine within 2 hrs. No pain relapse occurred with use of 
20 mg of oral nifedipine six hourly. Four non-responders were treated with 
indomethacin suppositories, all showed marked improvement within one hour. The 
responded patients treated with 10 mg of nifedipine eight hourly. The patients 
showed no pain relapse with use of nifedipine.
Regarding the effects of long acting prostaglandin synthesis inhibitor, 24 out 
of 30 patients of acute renal colic (80%) treated with 20 mg i.m tenoxicam showed 
marked pain relief within one hour, 15 patients relieved within 30 min and nine 
patients within 60 min. Four patients showed pain relapse within 24 hrs. They were 
treated successfully with indomethacin suppositories.
In comparison between long acting prostaglandin synthesis inhibitor 
tenoxicam and antispasmodic/analgesic, buscopan compsoitum, twenty-five patients 
with acute renal colic were treated with 20 mg tenoxicam i.v., of them 20 patients 
(80%) showed significant responses. At 30 min, 16 patients got pain relief and at 60 
min another 4 patients got pain relief. No relapse was encountered during 24 hrs 
follow-up. Twenty-two patients were tread by buscopan compositum i.v, of them 10 
patients relived at 30 min and 6 patients relived at 60 min after injection, total 16 
patients (72.2%). Of the 16 patients, 10 developed pain relapse during next 24 hrs. 
Patients developed dryness of mouth and dizziness. It seems that tenoxicam is better 
than buscopan compositum regarding the onset of analgesia, frequency of pain 
relapse, cost of the treatment and the analgesic efficacy.
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In comparison between long acting and short acting prostaglandin 
synthesis inhibitors in renal colic, the results showed that complete pain relief was 
achieved within 30 min in 25/34 patients and within 60 min in seven patients (total 
32/34 patients, 94.1%) when the patients were treated with long acting piroxicam 40 
mg i.m. No pain relapse was seen within 24 hrs. Another comparable 30 patients 
with acute renal colic were treated with short acting prostaglandin inhibitor 
diclofenac sodium, of them 15 patients completely relieved at 30 min and 11 patients 
at 60 min, total 26 patients (86.6%). Nine patients showed pain relapse within 24 hrs 
which was relieved with use of another injection of diclofenac sodium.
Regarding COX-2 inhibitor, sublingual long acting and selective COX -2 
inhibitor, meloxicam was used in the treatment of three patients with acute renal 
colic. The patients showed complete pain relief within 60 min and no patient got pain 
relapse during the next 24 hrs.
Urinary calculus
Fifty-five patients with resistant renal colic and urinary calculus were treated 
with indomethacin suppositories 100 mg twice daily for one month after their initial 
pain relief of acute renal colic with use of indomethacin suppositories. Fifteen 
patients passed their stones and none showed pain relapse. Another 30 patients with 
sub-acute obstruction and small urinary calculus were treated with 200 mg of 
indomethacin suppositories per day, of them 21 passed their stones within one month 
and none showed pain relapse. Another ten patients having small urinary calculus 
were treated with prostaglandin synthesis inhibitor and calcium antagonist, 
nifedipine (10 mg three times daily) after their initial pain relief of acute renal colic 
with use of sublingual nifedipine. Three patients passed their stones within one week 
and no pain relapse was encountered with use of nifedipine.
Renal function tests and side effects
Treatment of renal colic and urinary calculus with NSAIDs or nefidipine did 
not deteriorate renal functions during short and long period of the treatment. All the 
treated patients had normal functioning kidneys before treatment.
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Sum m ary
Regarding renal colic and urinary calculus, the results demonstrated that short 
acting potent prostaglandin inhibitor, indomethacin, which belong to NSAIDs group 
could relive pain in patients with resistant renal colic, facilitated passage of urinary 
calculus and prevent pain relapse in sub-acute obstruction. In addition, the results 
showed that calcium antagonist nifedipine which has prostaglandin inhibitory action 
could relive pain in acute renal colic, facilitated passage of urinary calculus in 30 % 
and prevent pain relapse. Patients not responding to nifedipine responded well to 
indomethacin. A combination of both drugs might have better effect. It seems that 
long acting piroxicam has faster onset of action, better analgesic efficacy and 
absence of pain relapse when compared with short acting diclofenac sodium.
In general, Long and short acting NSAIDs have significant analgesic effects 
on pain of acute renal colic due to urinary calculus including resistant renal colic, and 
either no or fewer episodes of pain relapse were seen with long acting during 24 hrs. 
Long acting prostaglandin synthesis inhibitor has better effects regarding onset of 
analgesia, side effects, episodes of relapse and analgesic efficacy when compared 
with combination of dipyrone and spasmolytics. Both nifedipine, calcium antagonist 
and prostaglandin inhibitor, and indomethacin, a potent prostaglandin inhibitor, 
could facilitate passage of urinary calculus and had prophylactic effects against renal 
colic relapse in patients with urinary calculus. Selective COX-2 inhibitor has also 
therapeutic effect in relieving pain of acute renal colic without pain relapse. The 
reported effects were seen when drugs were delivered rectally, sublingually, 
intravenously or intramuscularly. In addition, none of these drugs caused 
deterioration in renal function tests.
Brief results of studies on acute renal colic and urinary calculus are illustrated 
in the tables 9. The subsequent sections include original papers discussing in details 
the results on pain score, pain relapse, side effects and renal function tests and the 
possible modem of action.
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Studies Diseases Drugs Doses Number of 
Patients
Responses*
Relapse Side Effects30 min 60 min Total %*+
1
Resistant acute 
renal colic
Indomethacin
Suppostories 100 - 200mg 55 47 8 55 100 No No
Urinary calculus & 
pain
Indomethacin
Suppostories 200 mg/day
30 ( had small 
stone) **
21 Patients passed stones with in one 
month and all had pain relief, and no 
pain relapse
70 No No
2 Acute renal colic
Sublingual
nifedipine 30 mg 20 3 5 16 * 80 No
Headache (7  
patients) and 
Dizziness 
(5  patients)
Urinary calculus 
and renal pain Nifedpine 10 mg / 8 hr
16(10 had small 
stones)**
Three patients passed stone within one 
weekand all had pain relief and no 
relapse.
30 No No
3 Acute renal colic Tenoxicam i.m 20 mg 30 15 9 24 80 4(16.6% ) No
4 Acute renal colic
Tenoxicam i.v 20 mg 25 16 4 20 80 No No
Buscopan 
Compositum i.v
1- Dipyrone
2- Hyocine -N  
Butyl bromide
2.5 g 
20 mg
22 10 6 16 72.2 10(62 .5% )
Dryness of 
mouth and 
Drowsiness in 
all the patients
5 Acute renal colic
Piroxicam i.m 40 mg 34 25 7 32 94.1 No No
Diclofenac Sodium 
i.m 75 mg 30 15 11 26 86.6 9 (34.6% ) No
6 Acute renal colic Meloxicam
Sublingual 15 mg 3 1 2 3 100 No No
Table 32 : Brief results of studies conducted on acute renal colic and urinary calculus .
( x ) : Another eight patients responded within 2 hours. (**): Small stones: size of the stone was one cm or less measured by 
radiography and ultrasound. (+): response (regarding pain of renal colic) when moderate, severe or very severe pain became none or 
mild (p<0.05). (*+): Percent of the responders out of the patients treated.
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14. Critical appraisal of the published papers on 
renal colic and urinary calculus
14.1. Short acting prostaglandin synthesis inhibitor, indomethacin.
14.1.1. Indomethacin and resistant renal colic
Regarding treatment of acute resistant renal colic by indomethacin, the 
results showed that indomethacin suppository might be an alternative analgesic of 
value for use in resistant renal colic not responding to spasmolytics / analgesics. This 
is the first study-proving efficacy of indomethacin suppository to treat resistant 
urinary colic. Indomethacin suppository has both a potent analgesic effect on acute 
urinary colic and a therapeutic value in the management of urinary calculus. 
However, the study was open since the design of a controlled study is difficult when 
rectal administration is being compared with standard analgesics, and it was thought 
unethical to use placebo because of the risk of possible complications. All the 
patients, who showed no response to analgesic/antispasmodics, responded to 
indomethacin suppository. No side effects were reported. 27% of the patients passed 
their stones within 30 days of using indomethacin. In addition, we used indomethacin 
suppositories to treat patients with acute renal colic who showed no response to 
sublingual nifedipine or tenoxicam. These patients showed better response to rescue 
indomethacin treatment after 1 h of using indomethacin. Therefore, indomethacin 
suppositories could relieve pain of acute renal colic resistant to 
spasmolytics/analgesics, calcium antagonist nifedipine and long acting prostaglandin 
synthesis inhibitor, tenoxicam.
Indomethacin stops human rhythmic ureteric contraction, which is reactivated 
by PGF2 alpha (Sahin et al. 1993). The mechanism of action of indomethacin in the 
relief of renal colic might be a result of inhibition of prostaglandin and NO synthesis 
since the pain may be related to elevated intrarenal pressure (see figure 9). 
Indomethacin may exert its effect not only as a result of inhibition of both renin 
activity and diuretic and renal effects of prostaglandins but by central analgesic
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effects as has been suggested with other NSAIDs (Ferreira et al. 1978). In addition, 
possible inhibition of NO or bradykinin actions in ureteric obstruction might help in 
relieving renal colic. Intravenous indomethacin was first shown to have an effect in 
biliary and ureteric colic (Thornell et al. 1979). Moreover, intravenous indomethacin 
100 mg is effective as intravenous pethidine in the treatment of acute renal colic (Al- 
Sahlawi & Tawfik 1996).
14.1.2. Indomethacin and urinary calculus
Of great interest is the apparent ability of indomethacin suppository to facilitate 
the passage of urinary stones in patients awaiting surgical removal. The mechanism 
facilitating the passage of stones needs to be investigated. Stones may cause urinary 
epithelial cell damage, which may result in the release of prostaglandin; these may 
increase vascular permeability and oedema around stones and cause pain with 
cumulative hyperalgesia (Moncada et al. 1973). Indomethacin might encourage the 
passage of stones by reducing the inflammatory reaction and oedema, particularly in 
the presence of urinary tract infections. In addition, indomethacin may dilate the 
urinary tract by inhibiting prostaglandin as prostaglandin may cause smooth muscle 
contraction in different organs (Nakano 1967).
14.1.3. Supported studies
Indomethacin suppositories were found effective to treat acute resistant renal 
colic, chronic renal pain, and urinary calculus in patients awaiting surgical removal, 
and they have a protective effect against recurrent renal colic due to urinary calculus. 
Recent studies confirming our findings showed that 73% of patients with urinary 
colic showed good pain relieve 30 min after receiving indomethacin rectally (Nissen 
et al. 1990). Rectal and intravenous indomethacin were also found effective to 
relieve pain of acute renal colic (Jonsson et al. 1987; Nelson et al. 1988). In addition, 
our findings regarding the efficacy of indomethacin in relieving resistant renal colic 
are also confirmed by recent study demonstrating that oral indomethacin is effective 
in the treatment of renal colic not responding to narcotics (Wolfson & Yealy 1991). 
Concerning urinary expulsion, our results are supported by other studies showing 
that NSAIDs could facilitate passage of ureteric stone (Friedman 1990; Ahmed et al. 
1991).
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The protective effect of indomethacin is confirmed by other study which 
showed that indomethacin suppository prevented recurrent ureteric colic and 
decrease use of narcotics in patients with ureteral stones (Kapoor et al. 1989). Other 
study showed that oral diclofenac sodium was used as prophylaxis for recurrent 
ureteric colic (Laerum et al. 1995).
14.2.Long acting prostaglandin inhibitor (NSAIDs) and 
antispasmodic/analgesic in acute renal colic
The results demonstrated that tenoxicam i.m or i.v was effective to alleviate 
acute renal colic. Tenoxicam i.v exhibits rapid onset of analgesia and prolong action 
as compared to buscopan compositum. Both i.v and i.m tenoxicam provided pain 
relief in 80% of cases of acute renal colic. 50% got relief within 30 min with use of 
i.m and 64% got pain relief within 30 min with use of i.v tenoxicam. 16.6% of 
patients showed pain relapse with i.m tenoxicam while no case of relapse was 
encountered with use of i.v tenoxicam. When comparable patients treated with 
buscopan compositum, 72.2% of the treated patients got pain relief, of them 62.5% 
showed pain relapse within 24 hrs. Within 30 min, 45.4% had complete pain relief. 
Therefore, it seems that tenoxicam i.v or i.m has faster onset of analgesia, better 
analgesic efficacy and no or fewer cases of pain relapse.
Tenoxicam is long acting NS AID and its half-life is 60 hrs. The results 
proved that long acting NSAID has rapid onset of action in cases of acute renal colic. 
Acute pain usually treated with short acting NSAIDs that have rapid onset of action, 
but they associated with high rate of pain relapse. In our study, long acting NSAIDs 
provided no or few cases of relapse.
Again the mechanism of action of tenoxicam might be due to its ability to 
inhibit prostaglandin synthesis. Other studies demonstrated that tenoxicam has both a 
good clinical effectiveness and a good bearing in long-term treatment and rarely 
causes gastrointestinal disturbances. It has fewer side effects than other anti­
inflammatory agents and it is safe and well tolerated (Taglier et al. 1992). There was 
high percentage of relapse in patients receiving buscopan compositum which 
contains both dipyrone and hyoscine butylbromide. This drug can cause many side
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effects such as dryness of mouth, thirst, tachycardia, urinary retention, mydriasis, 
constipation, dryness of skin, contact dermatitis, vomiting, drowsiness and psychosis 
(Gordon 1989).
The cost of single injection of tenoxicam is more than buscopan compositum. 
However, the number of patients responding to tenoxicam is higher than with 
buscopan compositum and the onset of analgesia is faster. Moreover, 67.2 % of 
patients who responded to buscopan compositum showed pain relapse and needed 
pethidine injection. Besides its side effects, pethidine is expensive in comparison to 
tenoxicam or buscopan compositum. Therefore, the overall cost of buscopan 
compositum therapy is higher than tenoxicam. We could conclude that long acting 
prostaglandin synthesis inhibitor i.v. and i.m tenoxicam will widen the alternative 
treatment for acute renal colic and also reduce the usage of opiates.
14.3. Long acting and short acting prostaglandin synthesis inhibitors 
(NSAIDs)
Two types of NSAIDs were compared in acute renal colic, which are short 
acting prostaglandin inhibitor, diclofenac sodium, and long acting prostaglandin 
inhibitor, piroxicam. Although there was no significant difference between piroxicam 
and diclofenac sodium regarding the number of the improved patients, piroxicam has 
rapid onset of analgesia as compared to diclofenac sodium and pain relapse was 
significantly higher with diclofenac sodium. Intramuscular piroxicam relieved pain 
of acute renal colic in 93.1% of the patients, of these 73.5% got relief within 30 min. 
86.6% of the patients used diclofenac sodium had complete pain relief, of these 50% 
got relief within first 30 min. Vignoni et al. 1993 found that diclofenac sodium i.m 
provided relief of pain 25 min after injection in 59% of cases, while Laerum et al. 
1996 demonstrated that significant reduction in pain intensity was achieved after 5 
mins of diclofenac i.m.
Piroxicam is long acting NS AID and its half-life is 30-86 hrs while half-life 
of diclofenac sodium, short acting NS AID, is 1-2 hrs. The study proved that long 
acting NS AID could quickly alleviated acute renal colic, similar to short acting 
NSAID, with an excellent advantage of lower rate of pain relapse.
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The mechanism of action of piroxicam in the relief of renal colic might be the 
result of inhibition of prostaglandin synthesis. Piroxicam may exert its effect not only 
as a result of inhibition of prostaglandins but by central analgesic effects as has been 
suggested with other NSAIDs. Piroxicam not only inhibits the synthesis of 
prostaglandin due to inhibition of COX enzyme, but also inhibits superoxide anion 
formation and release of lysosomal enzymes from polymorphonuclear leukocytes. 
Piroxicam was reported to be superior to diclofenac and ketorolac to reduce post­
operative pain following laporoscopy (O'Hanlon et al. 1996). Moreover, piroxicam 
has long half-life, which results in the maintenance of relatively stable concentration 
throughout the day. This may explain that none of our patients showed relapse over 
24 h. Although this study showed that diclofenac sodium has high therapeutic effect 
to overcome renal colic the rate of relapse is higher than piroxicam.
The advantages of using piroxicam over diclofenac are related to the findings 
that piroxicam has higher analgesic effect to reduce pain intensity, rapid onset of 
analgesia and prolonged effects with no relapse during 24 h following drug 
administration. In earlier observation we found that i.m. piroxicam 20 mg was 
effective to relieve acute renal colic and renal colic not responding to antispasmodics 
(Al-Waili 1997). More recently, 40 mg of sublingual piroxicam was found to be 
effective to treat acute renal colic and allover efficacy of treatment was 81% 
(Supervia et al. 1998).
14.4. Sublingual nifedipine in acute renal colic
Sublingual nifedipine, a calcium channel blocker and prostaglandin synthesis 
inhibitor, was used to treat acute renal colic. The results showed that nifedipine 
caused marked improvement in 16 out of 20 patients with acute urinary colic. The 
other four patients failed to respond to nifedipine and were successfully treated with 
indomethacin suppository. We found that sublingual nifedipine is effective to treat 
acute renal colic, prevents recurrent ureteric pain and facilitates passage of ureteric 
stone. These finding are in agreement with others who showed that nifedipine could 
relieve pain in acute renal colic in 44% of the cases (Lioret et al. 1986). More 
recently, Porpiglia et al. (2000) found that 30 mg of nifedipine daily caused stone 
expulsion in 79% of the patients and reduced pain recurrence due to ureteric stone.
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Nifedipine limited calcium phosphate stone formation and it facilitates ureteral stone 
passage (Strohmaier et al. 1994; Berghi et al. 1999).
We suggested that a combination of both calcium channel blocker and 
prostaglandin synthesis inhibitor might be more effective in the treatment of renal 
colic. This is recently confirmed by others who found that addition of nifedipine to 
NSAIDs combined with oxycodeine caused higher stone passage rate and fewer 
emergency visits and surgical intervention (Cooper et al. 200). Many studies showed 
safety and effectiveness of nifedipine in urinary diseases. Nifedipine plus 
methylprednisolone are effective in facilitating ureteral stone in 87% of cases 
(Borghi et al. 1994). Nifedipine exhibited a protective effect on high emergency 
shock wave induced renal damage (Li et al. 1995).
It has been found that prostaglandin synthesis in response to different stimuli 
in renal cortical tubular cells is a calcium dependent process (Wuthrich & Vallotton 
1986). Calcium antagonists enhance analgesic effects of analgesic drugs and 
antipyretics and have inhibitory effects on phospholipase activity and prostaglandin 
production (Danon et al. 1986; Hrisen 1995). It has been found that nifedipine 
abolish effect of neuropeptide Y to promote prostaglandin synthesis (el Din & Malik 
1988). Moreover, nifedipine could inhibit phospholipase A2 activity, prostaglandin 
and leukotrienes activity (Chang et al. 1987). Levine 1983 has found that nifedipine 
inhibited synthesis of prostaglandins, leukotrienes and 12-hydroxyeicosatetraenoic 
acid. Calcium channel blockers, including nifedipine, inhibit thromoxan A2 and have 
antithrombogenic activity (Onoda et al. 1984). Nifedipine blocked arginine 
vasopressin or angiotensin 11-stimulated prostaglandin production in the kidney 
(Scharshmidt & Dunn 1983). In addition, nifedipine could inhibit tumour cells to 
produce prostaglandins (Snoek & Levine 1983).
Recently, it was found that nifedipine has anti-inflammatory activity and 
attenuating the development of inflammatory oedema (Briukhanov et al. 1994). 
Sanchez et a. 1998 found that nifedipine has anti-inflammatory properties which are 
dose and time-dependent. Nifedipine has antinociceptive effect (Miranda et al. 1992; 
White & Consins 1998). It induced a dose-dependent analgesic action in mice and 
reduced oedema (Brinkhanor et al. 1994; Al-Hamayyd 1995). Nifedipine could 
enhance epidural morphine-induced postoperative pain relief (Pereria et al. 1993).
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Nifedipine decreases thromboxan A2 in the kidney, which is increased in patients 
with glomerulonephritis (Tsygin & Kucherenko 2000; Dzgoeva & Kutyrima 2000).
Nifedipine reduces both proteinuria and acute interstitial nephritis and 
calcium antagonist has potential beneficial effects on kidney functions (Martin et al 
2000). Calcium antagonists have nephrone protective affected by reducing blood 
pressure, intraglomerular hydrostatic pressure and proteinuria and attenuation of 
ischemic effects of cyclophosphomide on the transplanted kidney (Deray 1999).
Nifedipine may inhibit the effect of prostaglandin on the cells of the ureteral 
and vascular wall since prostaglandin stimulate and facilitate calcium influx and 
movement across cell membranes, triggering and controlling smooth muscle 
contraction (Eagling 1972). In addition, nifedipine has a direct stabilising effect on 
the smooth muscle cell preventing contraction and also has an indirect action by 
stabilizing leucocytes and preventing mediator release such as prostaglandin, 
histamine, leukotrienes and vasoactive amines (Barnes 1985). Nifedipine stops 
spontaneous rhythmic activity of human ureter suggesting that in addition to 
prostaglandin synthesis, an influx of calcium is responsible for ureteric contraction 
(Sahin et al. 1993). Moreover, nifedipine caused a significant lowering of blood 
pressure and elevation of heart rate. These might result in reduction of intrarenal 
pressure. Renal blood flow failed to decline as blood pressure fell, which may be due 
to increased cardiac output, plasma renin activity and noradrenaline observed 
following acute nifedipine administration. A rise in renal blood flow may overcome 
any local ischemia resulting from a lodged stone. We have demonstrated that oral 
nifedipine has spasmolytic activity and could relieve intestinal colic (Al-Waili 1990).
The effects of nifedipine on acute renal colic, recurrent renal colic and 
urinary calculus might be ascribed to its ability to inhibit prostaglandin production, 
its anti-inflammatory activity, and its calcium channel blocker activity.
14.5. COX-2 inhibitor-meloxicam in acute renal colic
We used non-selective COX inhibitors to treat acute renal colic and urinary 
calculus with promising results. However, it has been suggested that renal 
prostaglandin production in normal kidneys is driven by the activity of constitutive
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COX-1, while at sites of inflammation, such as hydronephrotic kidney, there is 
induction of COX-2 (Seibert et al. 1996). COX-2 inhibition reduced PGE2 excretion, 
urinary sodium excretion, urine flow rate and fractional lithium excretion (Rodriguez 
2000). COX-2 inhibition reduced motility index (amplitude multiplied by frequency) 
in the upper urinary tract in a concentration-dependent manner (Davidson et al. 
2000).
Meloxicam has selectivity for the inducible COX-2 (Furst 1997). It has 
greater in vitro and in vivo inhibitory action against the inducible isoform of COX-2. 
Meloxicam caused significant inhibition of oedema and exhibited systemic 
anticipative action (Santos et al. 1998). Meloxicam tablet, given sublingually, was 
used to treat acute renal colic in three patients. The patients showed pain relief 
without side effects.
Meloxicam might show its effect through prostaglandin synthesis inhibition. 
This is the first study to report the efficacy of sublingual COX-2 inhibitor meloxicam 
in relieving acute renal colic pain due to ureteric calculus. Meloxicam is long acting 
NS AID and its half-life is 13-20 hrs. This property of the drug prevented pain relapse 
after 24 hr of drug administration. In addition, the drug was quickly absorbed by 
sublingual mucosa, which provided rapid onset of analgesia. Using COX-2 inhibitor 
to treat acute renal colic is a step forward to treat safely this challenged problem. We 
believe that investigating the effects of COX-2 inhibitors in other renal problems 
might be useful.
14.6.NSAIDs and Possible Side Effects on the Kidney
In our studies we used NSAIDs to treat many urological diseases including 
acute renal colic, urinary calculus, primary enuresis, and nocturnal frequency of 
micturition. The drugs were found to be safe with minimal side effects. However, 
NSAIDs are capable of inducing a variety of renal function abnormalities, 
particularly in high-risk patients with decreased renal blood perfusion. Fluid 
retention is most common complication, which is reversible on discontinuation of the 
NSAIDs (Whelton & Hamilton 1991).
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The next most common complication is acute deterioration of renal functions, 
which is also reversible. Nephrotic syndrome and interstitial nephritis are rare and 
reversible complications. Papillary necrosis is the only permanent complication of 
NSAIDs and is very rare (Whelton & Hamilton 1991). Nevertheless, normotensive 
patients with biopsy verified chronic glomerulonephritis but with preserved renal 
functions and without nephritic syndrome have no increase risk of acute deterioration 
of renal function during administration of NSAIDs compared with healthy subjects 
(Nielsen et al. 1994). Our patients had preserved renal functions and no deterioration 
was encountered during or after treatment with NSAIDs.
It is well known that prostaglandins and NO are mediators of inflammations. 
NSAIDs inhibit prostaglandin, NO and calcium influx. Prostaglandins increased in 
glomerulonephritis and thromboxan A2 plays an important role as an exaggerating 
factor in the development of chronic glomerulonephritis that accompanying 
nephrotic syndrome (Niwa et al. 1987). In addition, patients with chronic 
glomerulonephritis, purpura nephritis and lupus nephritis have increased thromboxan 
A2 generation-capacity of platelet which may cause abnormal enhancement of 
platelet functions and conceivably constitute an aggravating factor of glomerular 
microvascular drugs (Nakano et al. 1988). Therefore, inhibition of prostaglandins in 
some circumstance might be useful. Purkerson et al. (1985) showed that inhibition 
of thromboxane synthesis could ameliorate renal diseases. More works must be 
conducted on COX-2 inhibitors to minimize possible complications.
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15. Conclusion and further works
15.1. Main findings of the Linked studies
All the steps of the studies have been carried out with original and linked 
results. Inhibition of prostaglandins with NSAIDs or carbamazepine caused 
significant improvement in patients with frequency of micturition, primary nocturnal 
enuresis or resistant enuresis. In addition these drugs inhibited NO, which as we 
hypothesized that, might be implicated in the pathogenesis of these diseases. Other 
effects of the drugs on antidiuretic hormones and water metabolism might be part of 
their action. In renal colic, the results showed that prostaglandin inhibition by long 
and short acting NSAIDs or calcium antagonist, nifedipine, provided significant 
analgesic effects on acute renal pain.
Short acting NSAIDs, indomethacin suppository, was found effective to 
treat resistant urinary colic. Long acting NSAIDs are better than short acting 
NSAIDs particularly in prevention of pain relapse. In addition, long acting NSAIDs 
are better than buscopan compositum regarding efficacy, pain relapse, onset of action 
and cost of the treatment. These make long acting NSAIDs more acceptable and 
appropriate for treatment of acute renal colic. On the other hand, the results showed 
for the first time that COX-2 inhibitor, meloxicam, has quick analgesic affect on 
acute renal colic and prevent pain relapse. In addition, indomethacin and nifedipine 
have prophylactic effects against pain due to urinary calculus. Both drugs were found 
for first time to facilitate passage of urinary calculus. All these results have been 
confirmed by others.
The effects of NSAIDs or nifedipine might be attributed to inhibition of 
prostaglandin synthesis. However, other inhibitory actions of the drugs on calcium 
influx, smooth muscle contractions, and neuropeptide Y or NO production during 
urinary obstructions, or their central effects or anti-inflammatory properties might 
involved in their therapeutic effects.
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15.2.Conclusion
All the issues mentioned in the purposes of studies included in the thesis are 
answered and achieved with the conduction of the eleven studies and 17 steps. 
According to our hypothesises and research findings and to the subsequent 
publications by others that substantiated our works, we could conclude that
1- Prostaglandins may have an important role in the aetiology and pathogenesis 
of primary nocturnal enuresis and nocturnal frequency of micturition, and the 
inhibition of prostaglandin with indomethacin, diclofenac sodium, and to 
lesser extent carbamazepine, are effective in the treatment of primary enuresis 
and nocturnal frequency of micturition. The responses are apparently dose- 
related.
2- The mechanism of action of indomethacin in primary enuresis is mainly 
related to the reduction of urine volume, urinary solutes excretion, free water 
clearance, filtered sodium and fractional sodium excretion brought about by 
indomethacin treatment. In addition, it might have effects on bladder 
capacity, urethral and bladder neck pressure and CNS.
3- Indomethacin reduced bedwetting in normal and small predicted functional 
bladder capacity.
4- Indomethacin could reduce bedwetting in resistant enuresis, not responding to 
imipramine, spasmolytics or fluid restriction.
5- Urinary concentration of nitrite, the end product of NO, is increased in 
primary enuresis, which was decreased significantly with indomethacin 
treatment. NO might be implicated in the pathogenesis of enuresis.
6- The effects of NSAIDs or carbamazepine on primary enuresis might be 
contributed to their inhibitory effects of prostaglandin and/or NO production.
7- Inhibition of prostaglandin by indomethacin, tenoxicam, piroxicam, and 
diclofenac sodium are effective in the treatment of acute renal colic.
8- Long acting NSAIDs piroxicam or tenoxicam, and short acting NSAIDs, 
indomethacin or diclofenac sodium, provided similar therapeutic effects on 
pain of acute renal colic.
9- Long acting NSAIDs are better than spasmolytics regarding efficacy, onset of 
action, cost of the treatment and the rate of pain relapse.
10- Long acting NSAIDs caused lower rate of the pain relapse than short acting 
NSAIDs.
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11- Inducible-COX-2 may be involved in the pathogenesis of urinary diseases. 
Meloxicam could possess a potential therapeutic effect in the treatment of 
acute renal colic and prevention of pain relapse.
12- Indomethacin suppositories are effective in the treatment of acute resistant 
renal colic, facilitate passage of urinary calculus and have prophylactic 
effects against pain recurrence due to calculus.
13- Nifedipine is effective to treat acute renal colic, facilitates passage of urinary 
calculus and could prevent pain recurrence.
14- Administration of the drugs tested through rectal, sublingual, i.m. or i.v. 
routes showed rapid onset of action, which is badly needed in cases of acute 
crisis and in patients with nausea and vomiting. Rectal and sublingual 
methods are easy and self-administered. This is important when there are 
limited health services and a lack of sophisticated measures available to 
patients.
15- Mild side effects were recorded with use of the tested drugs during short 
course or long course treatment.
16- NSAIDs, nifedipine or carbamazepine did not deteriorate renal functions in 
all our patients who had normal renal function tests before the treatment.
In summary of conclusion, the results of our studies showed that 
prostaglandin synthesis inhibition with NSAIDs, calcium antagonist, nifedipine, or 
carbamazepine, as part of their mechanism of actions, has a potent clinical 
application to treat many common challenging problems including frequency of 
micturition, primary nocturnal enuresis, acute and chronic obstructive renal colic, 
and urinary calculus. The drugs investigated were indomethacin (capsule and 
suppository), diclofenac sodium (tablet and i.m.), tenoxicam (i.m., i.v.), piroxicam 
(i.m.), meloxicam (sublingual), nifedipine (sublingual), and carbamazepine (tablet). 
These drugs were tolerated well by all the patients and only a few side effects were 
reported. Different routes of administration were used and our goals were to achieve 
rapid absorption, safe method of administration and easy or self-administration of 
drugs. In acute status, such as acute renal colic, i.v, i.m, rectal suppository or 
sublingual routes were used to achieve rapid onset of analgesia and to avoid oral 
route, which might be not suitable for patients with nausea and vomiting.
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15.3. Suggestions for Future Work
Our works raise a lot of questions and scientific matters that will be 
excellent fields for further researches. The effects of COX-2 inhibitors on the urinary 
diseases will be fruitful topic of research since these inhibitors have fewer side 
effects. Further studies investigating methods to facilitate passage of urinary 
calculus, as well as prevention of stone formation or recurrent urinary colic due to 
urinary calculus with use of NSAIDs and calcium antagonists are warranted. Using a 
combination of desmopressin and prostaglandin inhibitors might have better effects, 
which need further studies. Studies to investigate the effect of selective NO inhibitor 
in patients with primary enuresis or renal colic are warranted.
Our previous hypothesis and findings suggested that prostaglandin inhibition 
might be useful for treatment of carcinoma, and immunodeficiency and anemia 
associated with malignancies and chronic inflammatory conditions (Al-Waili et al. 
1980; Al-Waili et al. 1983, Al-Wail & Al-Azzawi. 1985; Al-Waili 1988). Therefore, 
further studies to investigate the possible effects of NSAIDs, particularly COX-2 
inhibitors, on the malignant and chronic inflammatory diseases of urological system 
will be of great value. In addition, further studies investigating their effects on renal 
functions during and after treatment of urinary diseases are extremely important.
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